var title_f9_29_9680="Cyberknife system";
var content_f9_29_9680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CyberKnife treatment delivery system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The components of the cyberknife treatment delivery system are shown: (1) ceiling-mounted diagnostic X-ray sources, (2) X-band linear accelerator mounted on a multijoint robotic manipulator, (3) amorphous silicon image detectors mounted on the floor, and (4) automatic patient positioning couch with multiple degrees of freedom.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. Copyright &copy; Accuray Incorporated.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9680=[""].join("\n");
var outline_f9_29_9680=null;
var title_f9_29_9681="Sonogram fetal abd circumferenc";
var content_f9_29_9681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Image of abdominal circumference",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jacques Abramowicz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9681=[""].join("\n");
var outline_f9_29_9681=null;
var title_f9_29_9682="Assessment and Rx of delirium";
var content_f9_29_9682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Assessment and management of patient with delirium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 571px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DSM-IV: Diagnostic and Statistical Manual, 4th edition; CAM: confusion assessment method; EEG: electroencephalogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9682=[""].join("\n");
var outline_f9_29_9682=null;
var title_f9_29_9683="Anatomy abdominal aortic aneurysm";
var content_f9_29_9683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy abdominal aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 591px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9683=[""].join("\n");
var outline_f9_29_9683=null;
var title_f9_29_9684="Skull sagittal section";
var content_f9_29_9684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Skull sagittal section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Co. Copyright &copy; 2009 Wolters Kluwer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9684=[""].join("\n");
var outline_f9_29_9684=null;
var title_f9_29_9685="Pityriasis lichenoides et varioliformis acuta";
var content_f9_29_9685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrL2SGGUtdyopPRerD8Kq3EgnjP2O2muW9hgfrUilLM7rPzZVbOZPKyx/E1WuZUb5PI1BpD0OcZNWgsc1rdtLAyvfoU3fdQHH/AOuobeG4uSwku/skK8jchAP0rpdPadTxp8LlckyXEhZiPb0qDxTrZtoZLYRokrKM9/KJ9PrWjqcuhMaTkzG1e9GgRpEL1r65IGwRzEDHX5vT6Vxd8st9cyXN6zNLI2WI459KmjjfznklUbmOQzenv71ZeLbIjEZ64H9aylUudMKBnG3EXKqC69AegpFtgE3SjLlug9K3I0iHLj5vepREikbV3tnIrJybOuFOK6GdFbpH1TLEAipRCu/YiB5T1z2qT5pXKp/rCfvdkqwPKsoTt5c9CTncalS7j9mlsVJrfyWDPgzMOAeg+ntUEVsJHDsCF/iYfxew9quQ2jysZ7mQDPJXPb/CpHPmEqjhY1++44Cj0HvQtRW7lSVIydgGwZ6dl/8Ar1Wkbe3k2mBEvDSjkn2FLqTxNGsfKW27qOWc1KgjWNY4xtUDoB/Ki9mHs3a7K7Eww7YMg9cHt7/WpLKJZI2nlzx1Zj3q2tvHDGZJ2/4B61DLCrgNNwh+7H/XFUmyXFWIdrXUhW1C+WB80jnp70QW8YcrHk92mb+lTQ264YE7Yc5wvQ/Wp38pgFTPH3VH8/pVc1tSeS5W8oIGYnaueo+83/1qTyULAT/dHIjJx+dSxRupLgs7Y59Kz72xuZ3ws2wk5wtQ5G0KN3Z6Fx41mIII2L0AHAqdiFRkzsHHJ6n6VDDbyIiRxNu2/ebsKsxhUACku3ckZFCkTKCWhA0OGyynHYHqfrTZ5SVO2MyP3XPFWFkZ5sAbR90Z5LUTruGxCocckY/nQ3ZDik2rmOltFcXMQuEVJD2XtW1b6fFHlQu4+/aoYNMVLtbifeAeea1xtChQ3B5JNRFHRVaT91kP2CMIN6jHYDrUaWyQtuCKT2Y/4VY8zaW2ybye5qOSYlGWJfmXqxHSqMeZoUoTHu5Hpn/CqZd1bjAT+83apSx8vltxA5rOvbl3dR8y44H1obCKuWEEasS7F39TxgU1ZDv2qAR0DY4/KokdJP3ZK+YD8xFTunyhg+0L6UClpuLJLLDjhQvfjOaiS9EkhIfbjjg1UuJN6jbKVPcA4zVLzArBYVznoccGlZvYOaKWpryXflOSz7sdutRNcySKdw2qfbmq1vAXbLkE5/H8KvIFiyFXjGSW5q7W3MnLm0SKUpZzhix9FB6/WlSM4G9W2jnb2q0xcxAxJj1OOtMFs8il5SVA7bqlvsWqPVkGN7qoJJJ4x2q0iGLeNjP6tT0McZDKyoByQByaq3F7vZhBu46+9JOw+TokRrJJL/rd20ZJGOhpBexFwiYAAxmpC0k1vsdWRTzz1NVU07yyJFY5GcL6fSpdzWKjYsTWyStgkM5/lTpLSCBAyqFIHU80Q8OrbQJMY4qdgu0klmYc8niqsYylZ2uVreUeYQ5Z89MdKlllcgggbc44pwTzQVXgdz3rMuxd/bYxEcxngjbn8aq9kCipse8QkYybsOOntUTiRlyxGw9Md6u+XEgG98nPIAxUVzAHjBViCDxuNJrsaQkk7MrLcFAwJK4HU1HA0Zc7V68n/GpHtllbYjZPUipoLWOKFsrI3qSaCmopaFDUGK/JbMAxPbrRbSykqjr83rWqkMTuhSME46Cs+/st827zGU5zhfShpoSakrExQSYABUL/ABVTmjMkn3j5YGDk4qxNOUQxnhT71HFCs+dx+UDHXvSbCMXHcs2sUMS/IOcetPdVWIogUk/wgVC29Auz5eMbSeKht7uVpRlBlTwP4frRfoJRb1JTZGZMbTjOevSkeLyEVOTxj5upq+LhnQbiFx1wKpSuGbcoJb86rlsHtHsyOyKpGx8pgcnkVMHlXlVxGexqtFJJkKVO0d/SrZkWNfmYufyxRFEzkmS+btKnLFfaiYs6Eqo+hPIqt5wKlsbR+v4U0TIG+diMDNX5GLdnceqyGMs6r7k8Ciq00zy5G47cdjRQorsHM31PoN/E32S2ZFFrcKv3Snf8Kz117VLgvLDpIEL4BkYYwPYda17V/D8cpnWB1kXjGzgU/WtWtYrQ3MDMqRthlZcbwRjir0j0OTkcnuc9rWp/YbdMqouSCNoOdp9fwribkNNJ50xLEnPJ5PvWjdmS5ZppWzuOVU9xWXdbnX5RuLdB6/X2rGUrnoUaSSKFxJlld16nCIO9TmKVbYnG6Y8n2HpSJDMtwDJkuRyccfhV+NMSBV+Y98+tQmdTpormFnhw0Z8wjCr/AI1atYdqGKLLyHq2eF9qsKnmFkjbrxI5/kKSaZbaPFupIPAwepoM3roQzBLOLJDNuOPcmqkNqVm+1XQJk6qmeE+tacMBA8+9ILY4XsKjllV0GRkE/Ko6tRYV0irKGmQkAiM857uajCF/LDR4jXpGO/uakDu87owzLgEY+6o9KdHCzHy4GLE8vL6ewo2Je5VlRDIVAXIHVui//XpiYgmTepdjyFA5b6+grVns4o1RIgHlHPJ4X3NY95KYARDlpD95+5plrVWFubhQfMnKtLnCRoOhqpEXZjJcNk9kFYmq3N1bufJiJ3febvirWlLLNbb5dwGe/GaXMU6OmptSXHAUr8p42qKljKqOFCL6A804WamMeYuBgEAHk/U1FHCiSts3HP3mY5A+lNMzcY20JFlEjhYwF55GenvVho0I+UYTozdSabiMhio+QdWx96o2ByHBKJn8CKZN2TZ2ptwFUdhx+tQSSLIC3CqvpxmlXbMpCqGz2PQfWqU5a2ZSzeZ9BgL9KLgo8w9ppUdmMO0Dpk8mm2M80ruZ44kj/hOeaWH5t7SZcYBGepqO6VyQNu1B271LLTjaz3NKe4UqQX6DrnJqOORZU4BWMevU1mJJMV2og2g+lX1KIq+aQz9lHSmtSJNIsISVJ6AdAap+YfMIck7jwR2pl8Z5FyHBx0QGiJJo2UykueyjgUN6jiSkO8uU3FB1Of6VKYEaI9SvXGf51C021tsnyk02WbIVN2E6cd6dyX3RG+1MvEoOOpH8qgEhljOd3zDn2p1xdRhgkQy2O/YVHbyxSZG4ZHLH0pKyCXNLWxE8QaPdHlgOue1UbOzv5LotIw8jPygDFbSQhCzB8g8gjvTlIeTgkDoO+aOYuMUlsEKGNAoAVAeuP5VoQ28bJlkPXd81RoRGATjjpntU4dZP4scZPNPczasOcBUIHOegqtNh1+YAe3alkxGGKn5uue9VxC90w3MQQegoGl3Mq7Z1d93Q8DjtVKya6e9MYiHlE9eldDcyQCXyCRvHGKQbYcsFVQe5qLeZ1KolG1iQkxoCeuOeKqyXG9iijew67eMUXF0jRkeZ+Q6/4VlohdyIiEPXNU5GEad9WawdI490uA2e1VXu3dsxoNinn6VWgLO5ViCy9yetX47NidyNknr6U1JvYh0kn7xSjuZp2JQMiL096JLuc/KsZGO+auEAS7Q3B46inNbKUbnBHp/Ok79DS0V0KNsAXIYlmPOD2q6IGZNxIz2qCyCGUhkOB0J9fWrsjEdMIByXNNPQias1YrrEyv1CepA5pl0ZIhtXa3fB/rSy3CEkRAu5OOaZAt0z/PGAmc4PWhMFCT95mfdXc0BYrCzcZyOKZaagbiIMImXPZ63JLUzEZJx16U1IBk7VUKPbpSszSNSn1RzN/YT3EwZSAwPAz1rX02yMLAsQcjB9c1rJAHUY609ViiVlVcg/eNCjrcc68XGyIJIYpIGX7w6E+lZ92YrS3AK4XOAAMn8TWjcyxwxMWCrgZxngVjpcw3khCfPg8kjiqZhC9vIVZzKAgI2f3RS7yFyoVQP4qk3xREsEyxH3sYx9KbIiyoGbPlgcAd6Fcmb102IzMuGOcnPAxVdm3Mflb6k1KscYcqoJc9wOKpahG8asVB3DgZPFVdJGfLJvQnEisdrMMDsBmo5WQrsTO49fXFZ9kJvK3TDb7Dk1oQgIxyCSR35NF0xODW5Dv4G3IXoCRRTrixeZg6zGNR096KOdrQnkT6n0vNpl/B5RubxYlyBsjjAXnsfrXG67cte3oX/l2hbbGg6O3c12XijV5pdDuVkjRZGASMA85z19q8/WN2RcfMwGCx/h+lTKTSNMPTTd0V3JSRlH7xm646U+O0wpcAbhzu9KvW9uFTlcDrk96qySyNIVBCQr3FZXOxLUzbmFppHKL0zls0QqzqCMLCOGYHkj0FWp4nuACp2W69B/E/8A9aqTrceYscTI5AxjHyrQXe466mPlhFPlx/3F6t7VLDGVAlkHz4+VTxtFPtYEgYtPmSU9SOi+1I5Ej4bOwdAf89KZLfYi2y3R4yYs/Mx4B9hUmzylZ1AJAwznont7mpRJtAVflT1HU/Sn9Cq4A9E7L9aexnZsoDdtMcIVVbBdznJqRpTEqQwEBiOcdvc069lQFo4tvmHueiis6NWOY4twJ+/J/hSvfQ0srXJZJHlc21plhnMj9jUskaLEI1wT1Jx0p9t5X+otc8j5m/xpsyXCzqkaLsxjlufrRclIqzWoUbUQMfeooUWKRvMj3ysegHA+laTPGissY3SdyegpI544FO0CSVjjcadkPnk1YZ5e1B5pwT/COtIdz4G3gdEHf61ZhidiWfHzdSaG2qpCggHqT3/+tTepl5FR8MpD4YjkIp+UVA25vml+WPt/9apQ0YLlQD2A6Ae9RyAsjSykqp4Ab+dMYhYCMiAbc9T61CJkVghZXI9Tmq9xvdWIZvL6emarWMXJVIwCTkNknFTzamig+W5oJu80thQvUMT0qWMb+md3ckUiRCLDPuc9lxVhg5iLEeUvf1NWjnbRXuPKVdrAsc/dWqdzP9jieYQEKv8ACOTWxbxRAfIgJI445qK5s1n/AHbsCp4KrSd2aU1C/vGdZyC5RZTk7uQT2q4GRiVWT5x29KnaKK1hVVGeMACokVc/Iihj1NLVaMJW3iUb1JDGWcDA43Nzn6U20xtyq5weCa0xaCXgk4+nFDJHGnlxqOfbGal76FRSasUbiGEkGRUV2/iBqGHTlh3MGXJ9BV6ayidAX3k+/WmvbLFFlWbOPlAOaRrzLa46FFdfLyGIHTp+dJBbxRN+7UFu5J+UU22hlAO9iwPXNXDb5AAchT2FUjCWjtciH73oAx/vY4FDmNBwnz9MgVaht1iyFJ2k5JPelmMaqVjRcnuRxTI0uUJLI3B8ySXBx0zTkjIXIG33pYWjJxvMhB6DoKniU7tx3FR2NG5o29mVpLVVRmGd55BxWPcQXDT/ADSKYx1X+I10M0kbEKeO22su8U7jtyfQCk0iqTbdmZ7Qxsu1mdQeoA6UfZhGoWOQnj+LtV3SrYmMCRnkcf3jk1Ya1CSncc57cYFSa8yTsVLC2jUgvwAfvkcVqY2oRGDj1NRSKWQD5QOyjpVS5lm+VN+xR121SdjFrmdyvdxMZGKsFH6U6FpZp1zKnlj7w9TRMhe3xyuO/rUdpDlvkb5CeBUa3Nb6F+SJjllVWCnAx1qtO73GUJwgOMjoaviPI2scY6gVDdwKIsxk7jztH86uwoSXUgjshEN0TAc88/41amXbF5jnaq9Dnk1TEqlt0owEGMn/AAqxbymZsODgjAUc0kEt7sfbTpPGrI3HoeDSeYGJCooUfkasLZwqd4IBHof51ExikkC8HbzgcCqTsYyUZfCVoRLJcMzZRBgZH8VWJcgbSdufSpAi4zJlV7D1qCWdEUtjCj1ql3ZLTb0RXuLZJFKt97+7UNtYhGDFPLXuo/nVy0mW4beu3C9Mdau7QVyADIT0NNWYpKUNDCkG6bG0rGOpP8VEYBkC5IHbHatK/s/tBA3Y47VVt7N2baD0OSTU3sP2akrlOWJzIvlY29896feWpaBVfb7j0ra8hAmWAHHUVn3KljgBcetOyJTfQpWtsAgL5POMkc0qWMCys46+/WriW7feYnnoBQbfALljn1qlZCneTujNlUbzjH4dqK0PsUX3juyedxNFO5PKz0/VJ31KaNmk3QwjaCBje3c4qNYooY955xyBU+I7e32RgL6A9hWZcTR20atK5OT0x1+lc0ndnTTjaNiOR5XB85isPoOpqB1YlfMXA6rGOij1NK94JX8yYBCv3U/u/X3qjO7zsDMGitxz1+Z/r/hQlY0abehZPmXLFYWAjC4aUdx6Cq7OtuBFENp64PU+9Tw3TPiOGMD+6P7oqtcsilmYZY/ekPf2FUJRd7EclyDII1bYD97Pb6mpF2swEIZowev98/4VVnjXAaRdka4IX+pq3DLHHEC2AvYEck1Oty3DQneApKCoDMB1PRfpUMrbEYq3H8Unr9Kc8rMqG4yIuoQdWHvUVxdR3UnlqBHF6AcU99ydnoZE115k7w2mMn73HOauadGYQDI37xjgn+lW0gRXAt4A0hGC1aW2OGMAoMgct/hQlYJSTKnlJA2YiNzDJ9j61DuMjhFbex6tnmn3ltkKwJxydingCo0iECDy34POTzn8abdiIq6MbWILy4GyzymTye9WtLtGtlH2mYySL3PUVtmKOZVKBt2OMUiWgB28M2cn0H1pW6mzre7ylXdLJtO3CjoPWnbSWG9lZh1x0FW5VIby0IJ6sfSmmHYVJ69qpGDVync224qeR3wRWbfxuQDyxByPSt3Zvycn1y38hVS6BJCzEIAflVen50Nl01rqcjd3N0/nuFjEcRC5PQn0xWtpLB0iV1Ibqyjsa0bfSFmcMIl3dMkZH/661rfT0t48cbjzuNZq9zpqOHLZFeNFGCVGf1qO5haRTv5wQcfSroRS+9ckAcZHBqFwxBMmAOwWtLnDydii8ig42EOf7vpULuQ3y8Ke+ae42bnyFXsO9c9qV5JHMFZieOMdBRz2N4YZzNxYgSXZsn09asJbeYAMFEHTFZOlX2WCnLMK2QXaQY4UdalO4p03TdmO8lkIVXIFRSL8zHjOM57GrM48uPcTtJ7GqKO8riKFcgjJbsKu6RnZsVePvg4I6CpUjBhOF2j1brU4jCgBmycdabO5P+rHIFIhauxRkJt8DPy9iafbzqQS/wB7sKoahGciSeTBJ/h/wqpcWNzJGslm5JHQE9RUqTN3RUkb6bifUnv2oZTtIYgCotPeSG2VJVJl2/MR0BolVm2vK3TsK0OZxcZWJYoIY1JRVAPJPqacWLAkHC9OapSXvlp+7VmNNVy21mDByc4PapbRfK3qyS6jJCiE/OOee9Z7LdCVTKAEPp1NavmMrBigJFVL6di4JwuOoNJo1h2sT2xCL8ow+PxqhfPIjfJw571YM4AJ24Oc/WoJAJgSGxg96AhGzuxlvPMw/exgL6+pqBS8kzMo3DoB6GtKOHMXyDHqGNR3EcawtGASxHbijyGmm9ilEPOLF+g4IHrSLFKJOQQB/D6Vctw9rCoaMKig54zmpEzcNkICG6gcUXRLv8iqJGZ9hLEjt61ZhDbSzrtUHGe5oji8nJ2jn8cVO53EBenqapEPyKpiinO9lKxnv6mkdXiwqYRW7jrV7ZGhztyR19BUN1KYoVMaFyx7DmjTcqPM9ERxuhXEaEAeveo95EwZlG0egq7AAyKWG1m5Ix0pl4ViOep4AI6VLY4xd7MgmO7535X0NUdQhNyoVc5PHy9DVsxfbEChiSDyF45q9Fb+VMF4Lt+lF7mihya9TO0TTfsalc8f7XWtHCo2Cpx696tSLtbONxPAo2Blz1J7VSWljGo+Z3ZEIlPzDv3oEYcEIML39alKhVKqdxb9KdtdRwPlxy2MUyLdinKnH3crnoKqsoZsELt6jHWrJeOWVkQ4YdRUvlBGBx82OD2pqwONmVFTLAMGC9frUht4+pyTjGB0q3HEV+YAEn1psgKnJHHQe9IVmVWiG5eNw/lRT5U2SebyAB60Url8h2cjJaRjf87qBhfU1lvK8r+ZLhpOgB6Rirk8TRu0gw8jdSei+1ULi8ht3CZBmPXA4Ssm7G0ddBBAixtJIolcjI+vrWPNa3FxOp3MI16knit8KiqNuSG5GByTTnK2yK8ibm6LGOxNJtlxly6FLbHaW5Mp2rxn1Y1DGguX+0SqFjj6K3b61YgiW4l8++bJUn5ey0y8RpxiM4g6KB39zRcaV2YmpapH9oWN2ReflB/mau2HlhxLJLvx6isTVdKtxcLNcoXjXlQWxk+p9awptaKX/wBnWEhSQEI6Gi/c6vZxtqeiXDpO2E+53OelZOoafNOIvs0jRRI2T71NpUbtaiVyRGcHBHetNS7xiVkIHbP9BQYJOEhNPK20Km4fGOgxy1OllYy7mUb2HGeiipXUnYxHz44X+tZGp215KgWNwisctzzTb0JhS55XfU1GZEXbFhiRySe/eo0tYY/3kwG7Oc03TdLaKDhmaVsZz2rSeFoYcuAzDn1xSTbJqQUNmVS7tIoiwqn8MCiSZAPLjbAHJboaeIfJA3rvnk/hHakjh2FmmG5j1J6CtF5mDSCzQqPlT5T1J6mhx++2RAtIevsKsFMspVse3f61G7rFMqxn524JA60m0VYdHGkcZDICx4Zj29qUWsM75Kg4HUfypRB9oHzZATj8akiTylwgA7ZNK4W0HLasigRsVx1NMdVUlR859Kc7uyhVJC9zSiMhiQeg64pXJ1IZIxj5uuc8UJD5mWZRt64HepYIzKenQ96nkjLBQPlHencPIyNSs1ljKRrtJ9Oa5u50RS4eRNwXqB3/AArsjFtZjnJ6U2OEI+4jLHnk1L1OmnVcEc3ZaWVQBYQg6jb6e9aMaLGT8+MdM9DWlLbyyAmLEa9z/QVj6tbTTWpSF9rjoyii9gv7WWoy+jNzG0Svhj39KsaTZiC3WMMz4HzHuaj0qykjt0WSQtIo+ZjWqsYSMs3CH06mqTvqZVZ8q5EZ9+6rAdmIlXqcVzdnq6Xd00MMhcqeQe9dXPbLLE28ZXstZ9ro8EDEQRBW7kd6LhTUOX3txn2YSRlSx5BwcdKZYWDQRhWkZgv8R5zV3yhEQu76ZNPSJlUk5Geh9KLkuUrWRXlV0IKqOeOaiaL5Cc7vU+lXWkQKVZgfVj1P0qOJC3AAC+h700yeS2rM5V+QSIcLnpipreCQqXA685Parxhw2SowOw7UFS/AyF6YosWmrWRi3M5hG3ln69KrJMZJDJJgKeB3BrQuoA7iNkIJOMe1KthBFGqKhIHQCp5jZQSRU8p5c7AAByAB1q19jBVSD83cY6VagUK+wKcdjV2K2JIwMf1p3Ik+UzZLaF9pLESegPapFiLEkqQMcGtB7eOMs743dqS3/ekF1wB0HrS2JeqK/wBnD7AUG319aeYVgOAo56ZFWijfxfIAe9MZQ4wMVfmZ2KflDeS4G0ZPSomtBIMsMY6VfeBjEAxyRyPakEZJ4Bx6E0Jj5bbFEw/KUA4HUmhLdmO9uQvQYrTSPfneMr9Kr3reWm3aWz90KKGOF27Iz5Y3LjB256mpDpwmkQyNlQPwNW0tG8sJ26571NEojO0AEfrSsmaczjsVI7VYJC0akZ/IUky7DvU8+/61deRnH7pRt9TVd4Wcg/dbsMUEX11MyeSWSN1RCSDjIq3ZRbIVDAgkfiKvwWohAYqBjqfU1NEgZixHB6Ac5oW4pNNWSKSRYbt7+9TeUjnDcN6ZqyYlKg4GR1NMjhLsxA4B4NUpdDPlKSafGrsyjluSf6U1ojwoAAHY1qKpPAH3etRTIA25uWPtTvYreWpUEDK4x36Zpk8LPEY1bYx6GtSKMn5mxgHrSSRfMMAMDxSbBbmI1gzRmJmLZHJoq/GSLiSPYyhSME9D9KKlSNHJx0ZrTtJHG0KEF8YJ9M/1rDRYJbho0GZB8z7xkitlZjGRGgy5+8x7VEltDA0kqja0nb+JzUblRtFO49CsKh4tzuTgDHJ/wpLW2LStLcPlvTsnsKt6fbmNWJyX7tn7vsKJ1M8ixQjKDue59TTsjO7Kl3cxs3lgbYx04qEmNY2kQgjGBTdS0hZrgO0xU5zuH5VetdNEdtlvljQD71SbNRik76nMajDJcoTKCS3CqOtZ0fhuJXjuZ4gJF5Bxzj0rvIrBQ4fHzN+lOurESggZCZGW/vewpM0VaxkadaLJEQ4ARfupnr7mnS2M7aiHeYmLGBCOBmtYWcNk2Vb96RwAfu/Smx7oiXm2q3ZfT/69DJ53q0N8gxO25VLd6qzWjyzox+7ngdgKvkyyDzFA29gTy3ualSPan7w73PQZ6U9GZpuLuMjgWKJViyWxuqtITudTnOOAOxqzGWTeAACSQSeooKFn8tF+YDPsPrVXM7tvUowqZAMEhjwQeoqSeIsvlhAM/dHrVlbVpGyrEkDknrUc8ZZSNxRR1OfvUg0M5VaBWdQCAuT6/So7W5M8w3Q7SOQ39K0DGvljDKYxyD60LG5UkKoz607j6CJmT5YxhjTzGwHzchTzTotynag6/eapxGyYyN4PShtMkrL++YCMcA8ntUowQFIwOhxU6xuchAEXv6U4RFBlyBUjIwsY4Ut6E1EwIXABx7+tWUYH5tgwuQKq3JLlRvwM/dFAJNsrJlZMMwDN19qnaBQCT93HLd6dHs8wBwCw6DHAqaTEqkDnjFC1HJlRXxF8rbgeB6VXCFyQFAPtV0Q/KEwFC9O1MRDywPHTA9arYm9thggVNuAcjsO9EkeF5wre1Wo0K8nhu5qOcGQ/Kode5zTvczsyqsSKpbJNRCJmflyoHQDvV6a1kmhCo6w8g8Hk0+KzWPJkffkfd9KGXHQz3sIfM82UHeOh705kDAFRkns3arjISWZh8nYDrTQ6/wDLIZYDrUGiTsY2pIfs5CJ0HLHrmsO2muRIA2PLxwe5P+FdlLEko+br6VnTWqpKu0/LjlcdaVtTohUVrNGXFJMkbl8bfUnmtCzPnqpQc+opPKSdtrxllXvVq2MduBFAnPc01fqYyV2KUViQ6gkVKbaJVyVAqWTaIwxA4ORxyaVB5ycgbe+e9VoRdlE23IkjwFBwTVhYyp+c4PrU4kJZUSMccHPajyzk7ido7mktGErvczry2aVPLikKnP3sUqDy8EAYHUmrV2nkoJIl+ZhjA71n2ZmndmlQoobG1umKt2RUbuJISZUyT/8Aqp0dvtG7dx29qu+WqgttLE9sdKjmlSJkRyvmP61NyUuyIhFuAzyp6k96lxHGvzgAnuBUczMWUDI44NOt1MrhpW49DwKGPlfUayYYEDI6gZ704J5a5YBjnOTVhVBdnUjC/dPbNQeZuO0D5M9+9ISVyvKzbAyqN2eeaUxAgfMTUrIFQE8ryKSL5toOGx1xVJ2G1daEYVTlyuR2FFun70kZIHAJq1cAhAB932HSnJEiqVUgnuarmMyGX5iVPQUQgrt4wlEiuCWHrjPep4LhJPlZhuA/OpuaW00I0VQzE8E9B6VLGgUErkg/zok8rsMetKgBjP8AdBpLchxuMZAq5J/EU3yuGZgWz0z2q1EADl/ugcZFIGB3MxP4CnclLWxXCDCkdB29TUyxAH1Y+nSlQjk7QQOMCp0BMYKj5fQUmy7WMq4gdH3N1P3faitNlWbbhicUVJom+o2VVES+aRuY5VR1JqCwtCbmSa4bcM7VC87fatCCAzymaYEdAOOgqS4Cq4igGGP6e9K9xppaFa5klZ/s8SqF/jYdqnhj8lDzktyxH8hUsVsAnlhmJ6k0seJOx2L3H8qEZvYhKCTEpG2NOnv+FErEwKcfulPC9z7mrBVm+Y8KOi+gqK4iDANKMDHCjoBRcSs9ysk2+HzCDz0FWISUzK55PCj1+gqrHbFQ9zMCUHCx5p7lyRNJnK/dXoBQactxLi2C5k3Ylbk98D2ql5TzTNliYh6/xGrYmDKZJXUj0rDn1yKa7NpakMyn8AaH5mkKc5bI6CMKF+bG4DAC9qkkaOBNzYLkcDvmqUB8iFcKfqf4qZdTEf6zaJmGcgfdHtRzGPs25WLMUjBSXUb25/3frTlbzCQpKr3b1FYr3gGIo3KnGdx5yfetmzJaAKRkgD8TRc0lR5VdkryDHlRsRkdutVby2aeIIMx+/U4q/JYv5sZBwx+8fX2ps6GQrFERnu1F2Sl2MabYrJCiNlecn0FTPcpbKCVZwTtyBk//AKqu3FlFOrK/ORyc4zS29gkZRdmYwOM1KbRt+7auQCcLsIXCtzg1I0oBBIAUHgEZqLUHMM5AwFT+HFPgXz4wzrhW5AxVX1sZumrcxaRw8eTjaegqO4AOCobPYHvTTveQeTgRqwBB4zVjBUAsMn9aZmtCHJ8ojHznp/8AXqm8cokHA2kYJPXNX52McQ8sZfq1Rq+9Q0g2jrRohxbVyNVVFwuMY5Y9qjhuIxlVLHnIA61NJbtIC+cAdqrWOnpaTtJubc/OCaL9hpRabkywT5gbiiKFVHBzj9KstCZj1bB7dKcYCvyDgDqwprzMtyMhHAQZyO56UOiqmEHJ4o25x5eRg8nrmpJdkIIU7jnvSciuQrKg3Z8zBHQUqnBJCZI6k0lqCfMbqM457U6XaCWB+b0zxSuw5dSOdlfGTj1FUjLEuQp+aql9cnYSSF/rWM+oww5LNl88809DojRbR0ay73KL6csajYFThPmI6nsKwE1wHBViB2rZsJ/PiBYjJ7jvR5ESpSjqSQQtuJZ+pyauiMBPlUY7HFEIBOGUEDnmrSFWOwDgDJNBk23sQJH8vIG2nmEZxnCnmp/JJ+YEDHakIC8tyKCSvIyRoz4HH61WWUznDDb354NPupo1JJIwOB9aqGE+dzkHIJOeMUGkY6FpF82UO5BQdBT3VC3QYHQCnRg5LFeAOMdqhMyK2Cp3njBockJRb1JH3EgIpzj5qa9uhbdIMnFTpH5aqzN71BqUqwwPNJlQoyMU0CTbsiAhfMATkL0HpTbq0Nx92XZnr/8Aqqjot7HdBvJBJ3d+TWwbfJLs2Mf5xS3NZRdKWokFittbpGrMwHfPLGpPLRRuK8jt61FFcM0nl7cVb4QDGCcemaDKXNfUqtApYr2+8QfeiOFFP7vAJqWTDyFAfmHJx3pDHsztBOOp60+pN7bCPGgB68GoTsiwccn1pplbedy7QOOtOlgLoFJyW5AJ5oZUYW3BtkoU7lGOCKhCqsvyMAfu9OfzqxFD5URUg4BySR0qrZf6X5hdTGucD1x6/jSNVCybWxJBDvBDg4JxwabNdJbTLEMfN3Jq/wDZ3UEIcjHBrFvbFJLmN58nZyozQ5WHThGb1NVVaXGASO9PQjf5ZU5PGabAwt4cSHJPI7VaEbZ38FcdD1zRdWIcLFVYjHLjblQe1XGBCsATwO1TLENhzjOO9MljZcqgxx+tBPxOxmNbyl/MRiqjsO9FXInfzdgXIHU0VNu5pzSJmkljQxtu8x+ijsPpVmCHylwTukYdSOgpkttIJt6kc8k55pZJNpwDkkfMfQUkS1cbJKRmOAHaRlmNMtx52ACfLTqR3NFxG86rHAxWIHLNjrUrnyFCxoQoxj/apikkkPDH7wXLHhF9PwqOaKaKBpp2BwcjFTJMqEFmHnNwMDp7CobmfEqxycqeSAep9KGKMWU4PMupEmYEIeQpP60zVfMC7oWIHTditAwNs352g8MB0A9KhvHt5ozGXO0DkDj8BR0LTTlc5608x7h0cDZ/nmpLXS7WG7N1HEqN/E2OtSXEXkkCFsbewOfpmpDKwh2swZiehOMUI65OT+HqW7hyxwhBx09BSLp0E0odzlh15/Sj+zWkhLxDLkcDPBq5YWMsbq5bLY544BpHNpHVPUWOwtYQdsY+Y8/4VZt41LkogXb29KfJAflAfMm7IX+7705lXbgnjPPqaFuZuTluxZCjsyxMSR940wQiIlzjA42+gqS2AjO85Bz8oHapColUvIP/AK9UJOxSOHcOSAewA6D1p8ciSfNkqo4Gf5mkktkdMAnb6d//ANVILNI0Jydzcn3qNS1y21IpreO63FkBj5wT1Y1BLCIShIJVf4M+3SrAuSgIKgKoxye3rUUX79S7HKA8D1/GmtBu/UfBmYZ24AH5e1TO3zhDg45NKV3KFUY7ccUSWW4AZO3vg4NUZR5b6kT2yEjAyp5Az0rFayvJNQLbgsYbjc3b6V00Fu0YAwWPfNK8ScOw2hTg85P0qHG5tCryXRSELbVVT8/UmmH5JcMRkDPPQ1YkaQSLsX5dv5UyaBXUZGDjIzVdDF26jFJPR8knqO3tVgRrsKgN06Cm2aFEHIYmnOpjXO7luCO9O/cVtdCJkAwFyFApI7eMMxOCW96lUAqCD25NNki5XrjHPNL1K8iORgqbRtCg9PWsXUbx1iIhQY9+wrdniLx/uxhxxkjr7YrmdXikU7F3hs8+gND8jahFSepyus3cjK5ZsDv2/OuUvJWWFZpJ9u48DBPFdJrtrMYWcxjPsenuax73Rhc27M5eFiod9/Qj1HpWsUdOK9pCH7palSzuQSpRt4J6jp9K7XS5jKEKsQBXOW+kg3FvbpGVXbuMpBG7Pce1dto2npHtVU38gZHTNKehUbuknUWpq27qQqgkOByD3q/bAJFhgR60z7CVIcjHGMDrVx4QVGTyP4fSslc4puPQEw8LPsOwfmabKqjIXIX1qdMpHiM4Y9zTNp3HceAeR6mrMGrsoNYLNtL8EH5R7VUe3mSchkPkjpjvW08mXVUHzdzUjdVUgDvk8UmrmkW47lWFf3YBzg9R/Skazi80zy4Z1HXPQVM20LnOAG/Oog4Z24yex7UkkJN9CpLITIwXqvb2rmtYjv8AUbyDypdsKtl1/vV2Jt1wMg4XsO9VobULO7cY6Hjp7UNG1GpGnd21KmmaXHaAsu4MDk4Hc1plAE2tj1x61NMqlQT8uP1NQKxaT5hz1/CmjOcpVHdkSwDzQRyevTpTzGgG7ByeKS5lIjZgPmH4cVFY3BuCR6HuKLiUJNXJfIVMMo+Y9ajERRu/J6Vc3IG2jk9zUhiDEN36U0Z6p6nI+JNUFjLFEYzuY9K1tPYTW0cig4YA5ParGo6bb3M0ZKAuvPzCnSRLaWhZGAVew9aR1uUHBRjuRXakrhQM+lVrZJIVZV289fY0+2na5BBTkckg1KsjBygjBTGc+lTe4KLjeLLaHbGO5Poaa9ss8artGAe4rM0t5Vu2+0OHIPC10CsvlgAFSeae5E4ukzHurH5wpLsgbPX9Kv2iOsYWU/N79BV5olMeVPzHgHGahEfl9WLDOMkd6WzBz5lYcSgjIHIHX3rMeWV2KoSMnbuPrWhdNFb24kmO0EgDj7xPaqt2XVUIGSecj09KTY6cfIlt9kahM/vD1wKKZZbkRpZgQwGCc96KtPQPZ3bNGVCCREVHqRVZ7XJVASS3LHP86tTlQoI78KoHJHvSx/6NuDZyRkk9Kkz1KrSiHehUeWvfHX/GnN8kQnnH71h8qZ6UMSWWVl+XHyqev1qz9nDDzZT8/wDCB0WgXmzNlCKwk4eQjB5ztGecU1njZvtDK21OEU9/erZhWSRYoVwoHzPjH1pl8Eht5N4O1VwD7Uyr30KU2olYd8oG3k7B0rlNS1SRWEvHzg/KOwq1dJdZdgd0fYdOKwNQjY7lLHfgsQO3oopLXc9OjQitSF9XuZGBUOUPT2H8q2NGvhM4WRs4/M/SsmKwY2qma4BfnLK3Cj/H2q9pNo5ud6RjG7auTyK0krII+8nzKx3drfKkSiPb0HvWkZXkeMQn96/T2+tZmnWiwKpIG9vurWk8ZgB2Esx+8R6+lZHm1eW/ukpSJE+ZwSD8xJ5ZqqXd1Fa+WWYGZz8q+lMaRFUsQpkIOATwtZU9zByZCDIpOCRTemwU6TbNy3eNiAGO7vmppXw4GF9/Yelc3p2p+cxVQSg6N3NbMJme5VvlERHQnOTQpMc6Tiy8igp5jAJgZJ9qzNSmu4ol8lDK7NgD0HrntWo+XCs6nYvUDv7U5MT4Z4wpzhVPpTZnTaTuzmhaPLceW0pk3/ex29q1VRYEWNEOEHXrir8lqgGyABZcfMwHAFRSRhI9uAzY4HrSirM0qVedWK0UhYYjBL+pHH1qwCdnDK8vrjpVPUjd+QIrEJHIerMOMd6RB5SD7RN2z8pqrmfs7q5djkHc5YnmnuTnLNkj0FZcUySSMsTcA9c5q4rGOXIG5iOhovYbhZiswMZBOCx4J9ap3MjQypuV3Mnyg4/WmFZpL9gNxUjnHQVrQxBB84zgck/yFJMlpRepGkeQNuOmartCxcncQO5q3u83GEOAeTVLUb1LeMFVMhLbcCmxw1dkWraMKuSeTwCf60sm7btIwB90+tSWkRaJdwYdOnek8l1lzk7gcg+1SHVkTv5SHbySMAmsa+YTOQq5x6DmtudQcqFPHP1qtbQR792DkZH1FDNKb5dTnbuxjJRtvU5298jvisi/sfMYqVJAYNtI6ntn/Cu6urRSyPGBs7gjj8Kgmso5MMOG64xximpM6I4pJXOUfTrieZRjAAwT1/8A1V0Wk2TW8eGbOPXkCrsVtiHaMAE8n/GkkwJPLXO0d89aTd9yJVnNaEm1nHYgU4Ju+Xrjk0kbZxtUADjOanRS2ey9vemjlkQSIEJIK5xwSelRLlyGbnHT396naINIQ3GOcelOjVNp2jtgU9xbEKgJlyvemsu8bX78nHarDIURmPYcDrVCGWbJAVeevFJysXGLepLKgC7i21egFEAC424YUrJvHzgMy8ACqd7ujZQu7IORjv7VHMUot6GgImdue5yaiuJI44wGwNxxmrts48gHHJHPtVDUbfz8lQBn9Ku5EY3lZlRNShuG8u2Achtpxzg1fjt183L7vcAdKoeHLEWLTPsyM5OR1NbqGTgsAFPJP9KS13Lq8sXaJy+szXcV4sUVs0lu5ChlHrWxZ2wjgUlcSHp61YmC+aDkDHIAqaJhIGYYJxgf40LfUdWreCSRRktDHLlCWZjU0arlvmwO+KsKfk4Pzd29KhaFgU2nHfGO1UZfFuQFWJZmyfQ1m3N6j5jZW4OCMVp3Mu1ckEHHQdzXO3NzBHcuXIGeu71qW2dVGlzampaxRs37tQvGSBTo4wgPPUkACs3T71ZG2xsucEcnpWvFImclh8owc0XQThJOxRntIraMmR8Z5D55FaVsV8veSWUjAPtVI+TqquFOVjOG+talvAsaCNjtRMA8YxQtxVHpZ7ksbF9zhQqgYXPWn28WcB87CCalCeYFCAHsPapChRCB97+lBzOXYz7hUaZUcbwp3c9jTJkLiQlgiL1YnpVm/aKysZbyXlI1LsFHJ9qz9RluW0NZ2sVZyhM9uZM4j7/U47UW0L9pYpau1xbaW4swZWI+QrzmitizhjmtYlg/1DIrIQOAuOBRVI66OJhTVmrliOMRRAsu6Vgdx/wpJ4d6A5YhOfrT7ncMBO4z/uimyTYi8uIHjqfWl6nFe5Xtkk2tLMwPZQKSa4UOVJ2ADLZ/hFWBIwiIABcjA46Vz99ZXF5MsQl2wZyxXqxqX5F04qcveNiK6jkTZC20N1bNQXiboygO7A7HlqZY2kUESCQlj0Ct396vLBHnduDEd8Y/yKEmwlywfunPwRThTGY8FTjJHWqjaVHM5RkO4HcWxzXVLG7y/u0Bb8s+9Ojg+833QeM+tGxssRbVHIW2kpkFh+7Gfl9RWpY2MdsNz/IpOQMdfart3ayHAswdinPPrVhGRf8AXlmk6BQO9NvQdStKS3JII2IWRSTIwwAf4RT5ECFm3Mcf+PGpGkWGEscg46D+EelZUt2ZHDgj2AP61Jzwg5alfUpTBFLNJHk9cevtXGXQvLyJrgx4iJ3hF7f/AF/auzuZRPEySsOnYVT8tZJUjYEW44+QAH6VSPRpWhG9tTJ0eObIRtwQjO8Hk+1drZMUiVCSx7msq004NMWjAEPXI7+grQMchkjCMqRL94MOp9qW7uY15qexfeRkYBOWI4x0UetWlBCg4IbGcnt6Gq0CAOcfPyBx0qe4kcW7DYxz09/f6Uzha6FO61BLfCEFpG/M1JFKrrvjJJJzk+vvWQdFmnvPtbSS7yMfe4UVrRWMkSYVsp2z396WpvVp04xVnqNm+WHLMxlP6e9efeIdYAuxaKzx7sgsBya9DnDGMjq/cgdR7Vzt9okdxOrMApfg/Sg0wsoRd5E3hy3dLSME+YfUcgn3roo408sfdLN3qlpluLGJYUHyj1OPyq4zI+IxtDH+EHkCmjGvLnk2hkahXCwEEg/Me5p8g2jBGOcZP605bfy8bflHuKglIY4Vjt7ZHem+5hFczLafOOQVRfTvUD2UTZaMfO/8J7e9PjJijXIJHYZ/WhJ1nK4ChGOOT1A60r6FJNO4oYpBsyRGPXqaSAhg3XA4AqvqsbXMIWN/LUEAsOCantGKxoi/MwGM+g9am9maOHu3Ri6hdXsUzGG0Z1x13c5+la8MRaJNwCjHI/CrmEUFguWHqM0wK+wBsY7VQTqRaslYqzZAKqMj0pnlGJeu5jVmUgBRnJHOarKWlk2HqetCMHsRiJiNxXLY4U9KrYJj5w2erGtx4Wyu04OOp4xVKWzGTuRSCc4HQUn5G1NpbkVjGpjAyCx5+gq2qiPexwVXt61LbrEIn2IN5GFC1BJlgqtjYOMf3jRcTXMyveOkMO5RyfmJzzVSO7GQuxst3FJf21xPIvlFfLI7Dk+9S6Xpb29x5ksjsCoyp5pXZsoQULsseTIq/KQC3r1qpGkiXAWVMgcgj+KtmYqrFjgYHUdKoysUO7nLcDnNK1zOMimF2MzBsMT+FNlhe5dBgbR1NWvK2je38PTFS2sDFWkyQO/+FFuhdyFVdv3SggYx9amWFYtoySfU1mXeoXCaj5LRvtOBkDpWjcABRyeCMmmKpBxtckuYw6ELwVOAB3NV33FxGrE+v171NGS8gYqxHNWo4VQqQuW6j61SsYu+xUe3T5QTl+v4elSwopg+UcAnAHamvIVbzXVRzyzDpU8UglUGMqF6DHc+tFybOxA0KiUYPB5bnrUrmM7AMDJJz6ipSqkNtAbnr70xIgc4xknLZHYdvzpFozb9FMTHpXn+o2clzdbIlJZicZ+v+Fei6oBHauxjZpCOFHpXMfY1aQzFmEm3JAP3c007Hp4SSSOa0m3ns710fPXIyf4a6i0geeYB5AAx4xx+tWrLS98qyTqx3L8pxnj0rcsbYRFX2JjOMYzxUvcdeuuglnZxWyDCBE+9n1PrVyKFZVdz909aluP3kYAGcGmK7bMhBheWwep7U0eZJuTuMWEq2EbjPP5dKVSQhDfeB5z2qpd30i5WMDjngdTTFv5Y7P8AfdByQRyaLq5Xs5WuWb+3SfTZra6YJDKpLnOML657VyJvY3ga0k8TQtabdrMtufMZfTd06d66LWPMu9FvIiJHlmiwFjGSe4GKojVrsQxo2gXiMFAwirjPtVpmM73sb+nfZ47SIowEQjAiUdxjiis190kcbFWTcBkHqD6fhRU8xqqcWilbXpY+WjHceSc9RV+BWduGC5PU84Ncbo9vfW10WmDFeykY4/rXcQyxrbqSgEsgPH92kdGIpqm7IJAOIoSV/vNjOB/iaqXpaNSEUCJP4umauwFjKdpGB97jqarXUKS27q5IQnketBhHc5q81IW7rM6ksxwq56D1rcsZ2ujHnOT90HiqS6Cklyk0xfj7gJ4+lbVnYCAANwzHPXoKDoqygo2W48ZU7lGXY9epxToy3lsCDhyam8rJ3Y2qowDnoKiFyAQBtKLnA9aZxpCOGRwFCknofSmtsTdJyzDpzyaZdFvJYqfm6n2qjYzXJiLTwqIwcL6saTZpCLauMa/eSZhMhVR0PY/WqV8WmtT5YC5BxtHJramEUjMZMFR6DGTTI3jSZNkbFVxwBmpVzphUjHZHJ6JaXoupPtLPtxhdw5rqotLSYBHY5AyccbvatGO0DyFmUKx+bPcCiMAAgtwCeO7VRNav7TVDYo9igrxGo+8B1PpSMi7Q20BVOT9aZNcu04hVjkYZiBwo/rUzzIo8vIz90L149aF2OeSkSxKHCPG4yfvDHH0qdm2Ru7ONoOATzmq8DxpGY4m4Axu/nUMO6aVTu+RSQF7cd/pQRoPubsQxlY+JJD1xnApouGREEjZDDhFPU+lV3gMkkhjY7jxuI/lUwsW8pAzN5jdDSuzRRja7JEmVzlsDb0xzVKKcSXkiIuXXgbj196lj0+VZHkTbg4Jzxk/4Urabvvo5vMKsowcDt3pJstxir6iySzJDnbls44qpawQ297JezMUlk+Tk9vT0rUkdpSoVPkwPmPenywRORv8Au9cY6VRkpWVu4GcSxHy2LHv6Ba43VLzVm1xBYo32ZcALt4+pNdusflICVwX9BTjCspDMoxGOpHehl0asae6uUYIJGjywGCBuOf0qVdqy/Ko3HqcdParMduJDt/jB4XNWfs8Um8M42r+BJ9BQZuVzIuJRKzZZg2cY4/P2qGwlQP5UR3lTn2FaLWihQqIoJBHI6Vn29mmnF5VwxkbJJPX8KXU2Ti4tdTSdm+ZdwBPB9PpUQc7gAMZ4xms67vHUZyuegPtVGXV0EqrnuBk9frTuKOHlJG8RhjvXp/KktMkvIR8pO0cc4qta3Ud0cL83OGPrWstu5g/drsQdSaDGUGnYX7qsV4BOarTOzShdu1cZJx37UgmdgfkIjHBz064HPYmpwjuTHhdqjk9s9qVx8rjuRNGvlmNTkj7xHQHuKWKFJMmVtqBflXHb3pyoIo8nG0Ef8CNSkP8AxKAoPPvQUvIgmUuW2kYUYAP8qhVZFBIzgDcQece2atGTduYH5VyQfU0cnyiMgMCTj0oC9lYqoBICXzsHzHipZYWnCtxsxjinCVMsMjLdB2x6VLA65KdAOvbmmTqQSRLvi3Jjt9anCgAlBhQDgeppxJeLzmAxyq+9Ml/dyCPORGB/30e1GnQWvUqyQxmT51BlznPvSTx7o/LyMDkkd6kdP4t+0g7jSlCVALYzyRQK9yCNBFIAVO48tjtVqXdHbtI6hNo4OetQeYEYMDy5+YjjB7ZqS7nSaIRxYcnOfalc05bsoRywX0I2sWAOOOhNX0hVIwsCgAfKD/Os6ILZ2Mzqu4RqxC/3z6fnUmh3Vxd6cJJ4fJm6bT60JlVKfu8y2J5OHEeCNvoeDR9oVJhEuPMK7yP9ntSzMIirSHIHQDuaoXFwIwXwd0nJUdAPSmiIxuS3OZG2kg5Gce1RrZxNJuAyVGW9jWNPqoinJkYBexz3HSr2m6ilzIcHLNxx3oOp05RjoaoTdIVyPLPGRxT0JSQqvoMVHJKqIQGy54Ax1pIZvJU5YBiPmz6UjC0mWJkEDBmO4gZ2j1pDkRKo5GdzduacJlmGSMEc8DpVaV/LRwxAC/MBTJim9BkkIlbJQFs8D+tSpbRMm9vmBPSorG7W6jDRrtXv9KuE4QnPQ4C0WVhScouz6GHeaYbq8LJf3lvwECQvhfr9aY2gk7mGsaoeMA+b2rXMe2VnY4HQc/maSaNzBJNbo0jhPlUHGfbPvRewSim9COKILCiM7OUGNzHJbHc+9FR2DzGPddw+Q684Dhx07e4ooDYI7YNKGlO0DnHWkmAaTIYZJwAeKv8AlhoiXzuJyw7f5FUy0QcNK44OB70AnzbkmJFg8uNQCf0p6ruQBj09etGCqgxbvm4qUxcpuOWPUjtTViG2hhGV3MecYFQRT+a53KBt4J9fb8KmlG/cqHOOMnt7/WqN1GsSKiNhvTuB6n3pMqGujJr24xC207j2HY+1ctpB1W41GZbvatsDhAvYetdDYus+4FgVQ7dxq7FbHdhcKO/vQdEZqknFoZHb7YSucg9D3NKbPexff8qj8qsMQOpBOOM0+MM0nOFA5x6n6UWObme6MK+VxKryEgRjKIKjtGQXWGOc4JHSt65gRpVzy2e9Zz2MSTyTxptHc9zU8prCaasabXIRAJFXfj5eeSf8KzZ0lbAgbax4DnuaigLRyMxXex6E+ntVuC5ZSqhMknaCRjHrxT5k9AjDk1EiheOIr8xf+8O1Mgt8CTOcltoz39TWiXSNAAc5OOO5qleyxRK0fWT1HSiwKTk7DnMIQQ2/LKMEgZx6ipVtmUqxbAAGFHpWCdUtLZgkTFpFOeP4j/WtayufNb9620HlVpjlScdbGjEFiTfJnB4Ucc0oJeMyPgAc4z09qAyOMspKKcKD3P8AhS3KBbdFIyzHJfP6Cgyvd6jIbnzT8g2kZ2j0qSUu7FUKqdu0nHbuaowAWsjyEsw7A/yqzDIeMH0LZ60loVKP8uw+WJWVcZVV9fX1qxHFuKkg4AyQwqBRzycA9B+PX6VZnZtioBnHU560zNjXwVaQnag4X3PrQpCRdMg8depPeo8B5QnXPCr2+tPZtuI15cc5FBPUmXcMhfmdxgDp+PtSOESRBg4Ucn+tZUN5dLqnkOg8nGTIOd3tV9VEhkwSu7sTk4pXNZQcdyq012L9cJ/o0gyrP1NF2oaEylVLE4APpVy6ZWt8EHzMAZP8OPSqEziV8kEKAAoFJXNLxdmjltZmEULfIzSs3ynOMDsK54W11c3MSCTM0pKhz93jr+FdlrOnzXK7I3zkYJUcrXLJa3drflUYosuF+U9RVwaW561Gacfd3NjwpKxbY5AVHIPPP4V2weQQsFfazrwuelc34ftY1YSLjIPJ6810sMQAJ6/3fpU7nmYuS9poQsr+SQ4/dRNkc9Wxin2u9IsNlufmA9T0FOmlBCE8Rgg49aejK0gbGc8cUGHNcRY1LjqSg/dj0b1p64kkVG6DrzwPemqTs3+X878Kvf60Q7lkckDA4zRsDG3caxSbdoVMfL249aqqxedyc4UYPYY7CotSuZNjOMttbauRk0y3n8q0HmhiWwXI5P0ApJl8nu3NQoGRQEBIG7gdD2pknG6KJCARtJHqetJDMIIG2qQ59TnFNnmWziDyuct19geufc0zOzJdgjjB6hAMfWmSsoG/blgcA9yao6jetb27GMb5BlsHoT6Vg+GbzUrySdr8OscZyvHemmaqhKUHNvY6Vo1J2y/Nk7ifUU/zFJB5xjPPb0FYcEepNqE32gAwtzHhudvpWslvK2SXwCuWz2obRHs0upBczM1woZfmHfNOtIHkdgc7VOctxu9ada2ZLje7MxJG9jyB9KtxjLEkfuwO/apfcpy0shPs29zEFAXOc9setP2eXD90AtlRk9feiO6A8xSCpbhR6/SoL11DIDuB6Aeg7mn5iSctGUL9XZQqluOQc9Pf6VmT3IS0Vs5DenbFbqxeaoOCylsLnr7Vj67CfImWPAL+npRE6Kdm7M5RLJ9RFw6n5YiSSOrH0A71DoLXSXDKgfKnJbPC+1MgiukkIjd0IbcpU8j6VtaRYysWZ12sTkA8hQOlayatY7m1GLuzo9Od3i3OgY449veqms280lxbSxNjaRuBHG30rZsbYJEBGTtIxz+tTm1yMkfMe/tWR5yqqEmyjAJEiyATGeo9akZRIDGeQSBwOpqwMebhOpGMdhUwiEEQGAWbnPoKZlKo0ysUjhGyMDAHJ96jUmKLfncT2Pas7XdNvLwR/ZZmiWM5yDjP19a0IDvtsghtg2jPUn1o0K5E4qTd7mTqupBLC+a3ZGuY4jtAGSvvj86zLmdblrhRq0v2LTbVStxHJgSzsMjOOD9K1FsINDivtWdTK6Idqf3mNNtvt9vFqVs0OmtJbRx3YiSHCDILMPc4GAaa2IxHIpWg7qxoQC5uLS1eRAssioXBHQkc/rRWtYyrfW9tcQgqkqK43dsjNFS1qSplN3kK+Wpz3JArMn0iS71CGdnYCHogOBz61qiQxw4G0uThTUhSRYVRmzu6kd6ornlTegeWIBgEFQMKc9T3NU7rUYbSNmk4c5A96umaPIUoQx4XuAKoajZx3UbA9TkHHakFNJtcxBZX8d0qrESSeSB1q5JbIsRZQCzHaM+tZmj6WlguYiXP3uW/zxWtGnmHzJSfQAdAPWh7DqqKl7j0GWtlFCMQgF8469T61O4CDBb5c/MQfzqVlAXMQ5Pb1oUhuG6jk+5oM229WQDBblfmIyo9qAHZtuQdvJYdzVhlUOoX/WnkexpwXp8h2p1xQJsqTT+U4+T5cc+5rMuLt1uwgjIUrkk9K3BGrzKzKdi9MfzNVJ4PObYcrj5snqRmkaQt1Q62iDIjYDdwR3+lRzRiO5OVJAHUdPoPerkC+XHnKnnHTtUd2yohPT+Lkd6b1FFu9jNvnZpQ4IKocbU7VWu03RkAMWYYAHYfWrlu8T7REcq3LEd6fIj79m0Mfbqo96SRvGVnY5O309IiGiXewZndnYcnsF9av2cF0bhEYEc9R1Fags+ronGdoLfw+/1q1Yow3BT838h3obOipV5kaCRhURQwG0ZYHniofOUlix3LnOR0ApZpQsQwp29SQcZPpXNnXIVuhCV2uDluMAn0FM44UXO9jelXzI8noV+X/Z96oaLYz2IkDTvMztkMx5Aq/bSQzw+a5G9j0JxUF5qEdv8AvFIYYxkdB+FJ2Ljz2cEaQkREO47kHy8/xGpyD5QdeVb8hVCF4p7XzFRtoGEUnr75qWSd/s8SKdw5YgDoKLmThrYmtjt3ygKxwdoPYdyahN4QSiAGRuST2FVxNI65K7RjBAP8Xas/Tba6gvWM8gYMc7z1PtRcpUVZts6FlG1I0UeYRk46AUsHzRyNNGV2cL702KUpMDGAxXGOP51YbDS7Wbcc7jg8CnYxuVjuSNmlTp075NVkWYRhmXknOSKkWQyTiQthWOEQdh0zVi4bIGPuKeD9KCleI3ylZAq9uvpk9fwrNn09TMJBwy8L9a1ocJbrvJLEZHsDVS5kDMkRyO4x3pFRm09CKys40+TaygHcx6VYBAkViWZT91R3PanRfLEUbKknaPYdzSYw+5Puj7oNBDbk7snZAoVMBpDyx7L6VDcKIx+6wpUbV292PWpGbCBWPLNzTHYY3KRlQcA+tCY0u42OQorMx5X5VOeAP/11HJIzW5Hzb29OgHrSxIpT52xjtT3U4wOcjoOwoZZSuLaImIybvl5BJ5+lWI1UEAgfMcFV6e1QNJ5kzSScJH029/anRz+axXbgE9fQd6QNuxNK5RC38Q7H+VZbl9QmAVdp3bsemOlbJVdvzDLYy2O3tVOF1t1mKx7ZGJ5POfpQ9R058q8yCOF7mN1kwQpOG9Sepqc4jZYVA2rhmJ9e1PjkXyXO0/KPmA4zxxTYh5kOPmZ2IY/X0prQlycnd7Fm2ZJGAkxv5LU8Puf+JhwB9KbJALUbWIMgHzMO3tT4WUDYxG/g8Dr6CiwrD1+UkADA5cZ6+1RwoZDJvXYuct259Pyp5LLjAQygk4POCaezLHGE3bgpyxPegViktwn2sfJ90fKrdzU20Sb2fDHGSKqy2ivMJVB8xR8uT0qzbMWLqT8wOWP9KDR2WqI44pYgcuAw5A9KpXsEYC7g3zck1orKDMecKchc9fc1HcujwtkkqpwCO5oWuwrtO5zsmmmWVZI/kyf09K3ba1iSEkjAHX1/CpoI41Vj1OOB/dH1p6xxuAWDBRx16miRUqrloEe5gVVMLjOMfw0suFiIBIc8delIsbiRRu5z82fTtippLdJWZskbR1z0H+NO5na2pkaPbSRzXD3ExdpHzgnhR6CtVh5j7wcL91R/WqyQ+TkZJZz29KtsgiB28h/lX1AoHVfM7iTIr26xRjcxO3j+dM2RIFjjULjhvalQ7CRuxJjnA+6Ka6hYgcjrjjqTSvcz8itqptF0+4+3YNqsZV1UE8H6Vx3m6Xvl87xDePbTosUg+zEGRV6KXx/+uur1SCW/0u8t7aQJI0ZCse7e/t2rK1C9u5tFksk0C6imki8shwvkpxjcG9O4qkyJRubtnqNnd2oj0t1eKICPaAVMfHGQeRRWRoaTyapNdPE6RQ20dqJX4Ny68lsen1opaFK/U2ljG0O4wuMKMdKUgqFdiR2+lE8u5JHX7qfqaRJkaPc2OONp7mi5STaIjIin5vvE5AFRvGrbBhjk5OOKncIGABHNKnmZaTgMeBz90GkmVshhh4WFBiQ9WFLcxsQqI55wOPQd6liUg/KwDN8vTmiXahYk4Xpk9gP/AK9Nkx0YbSYgufmbv6CiIFQSADjOBVdmkYkhsFvyAq51i2jAPf0pDfmNtoDIwJyC2Tnvj1qeSQOhjTJ57dqhiZlU54G3IPqKkjITbwcY4BH60Ct2Eux5MZAJOwAdO9c1r2uJZsHb2HHOa6GS6EykBgxYnJH8q53VNLjuZsdB/dH+NB04dQUvfJ9J1VbyOMqRkdM9KuX0D3UIjJIWQEAiqOk2a27lYlCxD2zmthfuhkwvZeenqaS1FVcVO8CjomnJZRsjks27ccjA+lXzsTeMYPX609A0kZZMhV6HHH1p+AVUPgAclm4qjnlNyldlKQs8RVFyq8f71M08NGHErEbiMKP4a0GQhThuoznHQVnyAwSDf977xyeMUjaMrqwXsqMGJwEHGScbveuev9Dj1WYS7MsAAGXgCti8szeW4c/dc/InvWhpsC2lsoY7j0AI/WhdjSNRUVeL1MIGWGBIih+ToAOvvV6wgS9+aeMqQc9PStSdBI6rnlwMcdqhZSreTAAFH3pCe1FrGTr3II2SCNmUbIxx7Ad6ak6mNnJA8wHg+nbFTXMSyttkACLwB6+30qO6CRov3SSMHPOKTBSUt9ySyLMAZSCzckY4B9qmuAA+cjgfex1NVzcQLGkcfEjY2jP8qrajdPDJDHskJLFRgdPXNNDlFt6Gjab85Y5cdx61G8riIsOXc/nSxyF02EkMcbiB+Z/KiSMMy7WKhD8uR1oZjFq+o+JSX3kBAQFBzwBTDdorOJW4J42jt7U91EcZViNxOAPbvWXIi/2gJyMsilVBPH5VLZrGKluaskvnJsUlWPOQOnsKFeP7rHLKeB71D5qxw+eQFJ4/GoI5MMqlNr5yB656mncjlZogKpHmEED5VI7+tRTXSxhwzqGYZUY7elRBuHC/dHyjHrXP6xdBZEBY4B4x1NG5rRpc7OiS437dwALDv2FTnnYi4GeeRXG2+oyRlXPzhyAWPY+gHpiuhs5MsZvM354AB6UNNGlWjyGk4Mr/AC4Cr0IHU1C5bzX3S7Tj5sjtVhG8uHAwP8ahlCSQFAu7fy3NM5LsrKR5TMF4H6mktMK3y/Mx/SpFXbEFABYH5Ae5pyIFZQSCp4Lep70WC5OH2hsD5uhPqahILvyMDp/iaQyKAzAjygcKc9aQSZ+YkMGGRz0phZsczxxpjA2A8n1NR6dOBLtAHyndxxinpIZFClcA/KDjrT2ijjOI+So+Y+gqHqy1ZKzHvMZpAynHdcjOPc0Rb4X3tyMHAI5+tEW5g7jGZDn6gdBUbyh22q4JJwKpiiSRygyIiEEjJLZpGYFhjoegPc+tRW0H7yUHoMY/2varKKo3M4+50Ge/pU7jeggVl2MRhz0HpS8EIicFjnI6n3pFbzCxkJwPmP8AhTWmHJQqDwqjpiqFqMmTLBjkJtwagbbEwMeCMdAO9Wrh0eFVUDqO9U7qJ441WHqeM+pPXFJWWxorvRjYLjzImjX5drfO1Xo3A91Xp/tGs9I9soD8KDyB/OrUbDI2DESnA9SaLicV0JcySSqQwGT07mrqt5YK8bV+/nu1VUcDEgHIztB9O5ohImdF3YRfmYn+KhESHlMN5oOCxxg+lODNIx2sAScA9QK5/wAW6hd2dor2MZkZm+YA9BVnR7yS4soWuBsllAymPu0ypUpcimXJYXMpYH5cgKAetSXETKCAcSdSD2qYupcvhdqDC+5qO52OgjBO9vmY980WM77GTrcs9toF7PbOyOkJw46j1IrlLyxgRruN9SuNn2Nbm2ka4JV+u4dec/pmus1+7GmaPcXHlCVYUJKdj/nvWEun6lcWVuslpo0sar+5VkYhM88Yo2G431Oo0iYXFjaMoEa+ShCddg296Kdb2rW9uhuCA7Aebt6H2HtRU3YtDLu76OArG0gXIyF/xpLW7H2jc0gYE5GOlc1rllcyuZrdyHII56Gr2h20kcUSyffABBPPFaJpnoOjGNO6Z00EkauzNkFz07CnLcIHVE+7/e9feqKI7RybslWODjjNWEtgI9vGCecfoKppI8yUmzTjIyXc4JGFA7CoZ03qd/CA4APeiMkAue3yge9Mu7d7m1ETSFSx52nkGoYQu3qPQhEKjoBz35qxEm2MBhlc7sHtUVrbNFGkbEkL3NDu+8FmZyDhR70ipbkkjlv3YwS3PpxWL4g15dJt2eTJ7YHpW8Y1VAznLHqT2rL1OxhvYWW4VSD1JHamy6Lip+/sZWmaiuopG8e5Q3A4xWi64j5YMpPUHlqWysUtYY44tqnoMDnFWmt3iBCHJ7jGABQVVlFyfLsVEVxGDGFyx+8DzVtLdyRGjgZGGbviqkmlzTX0VxHPtijHKdia1GiO7aBtdjxjvU2CVklZk3lRxQ7Q26PryeaRAZFzJja3QVABsfa5zj75J4+lTvKg5cAADHtTM7DDnevQP7dqrXVr5hZZMGQsFHPU96vhQygsBxyPU+1VSXBklfaSp2qB6+tG447kEAwSxbAX5UHYH1qdMtHvBBUA7QfSqskMhKKAd/fPSmyTfZl2MOD85+npQtSpwRdG6RQzYQduelOIKBkWMASD5fpjrVGx1GO7mUph4kGMKcitKT55AZuFPUL2X0oJdNx3Ksdu3k5btwPpUE8cRUljkDgD+8fetBmDqzcYJwqj0Hf61UltvNm3o3yddvak3oVTWt2Uo7QxSLIUBU8qPQ+1W1jByxBdz92po4skGUnI5Iz90VIwWNfMGMngewoQ5zbKhilPMfCH5eO9TRx7QGckg9BjpUyOCit2AwCKdvG4KoyEU8n1pmV7FPy99wQCBtAzn+VQXNuZ5kC8Y5+gqxcyraWcsxXc+MnAyW9qh0uVr1VnZTGeAAeKTLjdLmGywHaR96NTkk8c+1Uboy/a1khcgAcgjqtbbSKcp2U9aoHYcRkjnk4PJ5oSSKjUbY+EnyD/AHgC3pya5vUrNpYpHCkyN93B6V1OEyIwoGR8x6/Wqt6VSElSofGdvtT0tc0pTcZaHB2FkYtRVnZjtGDj1PSuxSU29mhCqJGOMDtWSlq7JwAxPzkiq+samsESKwI2jOfeluds06jSNwagDMI2JIOAPpWlAwxlBgD9M1w8Gogv5h2sBhVA65rqreUbEVGyTgkk09tzmr0eXY0DtIC9M8UyQGX5CRtXqahcE/vFBx91fzqbcApEpwx6n0oORR1KlyvkwBTyg9OgNTWcaC1RUO7c2PfFZOoXnkKVLZTtn09adpd0H5V8/Q9B6Ubs6nSfJdm3d3At1O5gMDA571BazqYxFuLSsdzHtUcka3OA/Qc/lVWOCX7ezR7ghXJXHFFncyXLy2e5pmYBmXcd4xsUVBb2L/bRcGZxHHn5OxPvSxZVzJsw4H3j/SrqPGUMf8eBkfWk10FzOPwjmdyEEYG5uAf60u5XCqjAIDjOfzqG8lyHCD58bU9BWdG7WwC3TAgDjjhz6UbBGHMi7PcbSUQkd8noBWbaazBPqs9tGHZowFBxx9auR7ZbhmduCvzL2pY7CGAs8caI78tjrii5rHkSaktSzJjcAuB2Gf1pV++jngYyuKybf+0JNZl83C2QUBfYCtJrhmuDGqcj7px2pEzhbQmSJSQrDI+8709UQDcuBkEDd2FVb+6+zIiIoDvyVPYetV7iSZrfzYgGOOB2AobIUWzQuJ0hiJJBcjt29KqQXaTIAjAn+LH8qqtbSi13Ssd7DoO9Y+hWN/DdyPcPmIduy0Js6IUYODbex0zIzoqHlc7iPX0FTpExQnADN0z29qS3VygJJDMc4HYUl1eJbAea2F9euKq5yNt6ImCEpjeQAcZHf2FOkGwMAFMxIzx+S05JBsWZQGB4QGo1y5JkYnJyQPX/AAoIabKOvo8eg3zxPHuWJsb8YJ6d+Pzrm9LstEFtCsfiG5VdoOBeBAvtgjitzVdTuo5ysOlR3dqwCktKFDH0warCS8Rcf8InaF37GSP/AApkyujcAUxRhJWkiVQPMzu3ccHPf60UQlI7ZVKCNwoLqDkKccqPp0oqWiro5KS7jMAd2XjgLVuG9haMFDy3XNcA8+2ZDPOERjgMeQB34rQ0q/VbkES7oicKT3HqRWqiz1qtGLTSeqO7tpS0gyQVXsPWrZdlRnAOSQcCsvTJ1lKiEgg961H3Ff8Aa7HtUSZ5zhy6EtvJ5alscjjB55q5HKE+eQcn+VUYW3fKQMDqfenSScM7Yx0FBk9y4XLuygkADNOBWJlPykgd/U1VgJULnqw5pJSWznK89aQ7dCdpFcZLANnt0xVG6kMjjAJ54x0rmtVub5dWgS2VjGepPSt20EiPuJDLj070viOiVH2cU77luJ/nBLncowPer0jEKF3MWbr7VnkGRxs+X1AqbzCrKcbsnnPaiOxzvfQusynaOFCnBI/maljkz+8yuQMLj0qsQpBxySOaaxWPIzhT0HqaZNtRHYghFAb1Pc06FFL9W2DqvvUTfK4Cgg+vpUsCnBYDCjv60i29NCxc/uo/MYfMB8oHaqD73UL91sZJxUl1cZZTOQF/hBpzOEG5OSf50t2OOhVmkeNo/nBY84qvqMIu7WQM2GYbODg8+9c74m1WeCdViPJbt1/Gr+gXEl5EDcg7gP8AJprTQ6nh5QgqiZN4a0qPSZJEBLIvzctnFdAcySFkPzMMAnpioPLABZcZ44PelFykMBd5FMjAgelFuxhKTqu73Jt6IUUMMdMjr/8ArqZY1R/mzsYfMR2HtVO3MZKnGQBwfelmumLFTjC0ietiZkaR2KkKuRx3I9KddBSFycnv7U0S/Z4Ml8kDJ9zWX/bEHmt5jZ5wM9c0JaBGDnsjRwPMIU4Qjp6VGm/DDj5jwT3FNhu4rhXaN+FGDnvVRbz9w6kg4OR/s4ppaD5W3Yvu8eNjnj1HepI2jCjyiCH6V57deI52u2UbQobaQeOK6jSL5JbZSCCwHy5/mKdjathXCKZpXJVByMFjjHoKqBAZfMhHzfdJNKXMs43EdcYqUbFj2JgEnmp3MLcpKoUBWUZX9WqC/tY5QWUEEccH9KssBsynYYqtepNNbv8AZ2CuvAPqfWmhxeujKc1t9nU+WQEHUda4fxFKRLsbG7gZHBzXoDxEQKkoJfGS2e9czqulCZmYJlsUJ2O/DVEm7nKxkoTMpIWOTHzrjc3t7V2vh4l1Us25gMAEcZrK0/Qy2Y5AWA+6D2NdJbWYtYSABtUBR7mnJ3Y8RUjy2vqWzJ+7I7R/qazdTuGjt2dS2B09TWlHAqwN1xjPPrWXdQySbsqdnT6Cg46NubU4LVNWkl3bWfgkjPoK1fD96GYRoWw2GU4xj1zUF/4ckNwVjG5GbfgjPNb2h6ElvtZm5xnpim3oelOpHlfY6WzbKbiMA9KnmbZHtXI3HLN6CoY4zGoKkFc4B/nUkxLoVUZB4z3xUNnlWUpCZ8/BUjaOmKjeY2yAiNjI52jj9altYPLjIHCg8/4U+bbK2ScBeg96adxSXK9CKPLPn5vY9MnvRcRRTSRJIgPlnefY1JCxQndhsfdpssqiIkZ4OeP4jQ0EX2GruM/lIqjng461NLMkLOSflHBNQ284WUgcsw60yeaJIGVuWPJx2pWK62YtpdCZS0eCp5I9aRGyXkYEN1yfX0qvaM0mTGpVX6ZGOPWrkkirAXXonC8ZyfWky3ZOyKPlPc3wacZYfeAPfsK1mizMI+QBywHTAqpZR+VIWjGGY5yf5mp3jdHba24vy3P3RTWhM3d8o8lXfcPuj7opjRBVY4G1eTRF8qsSFA7e9N3rK20sCE5x2H+NNE2b0GxTO0qDJ+fkD0qSSFXZGC5J4+b9TRGedwBViOSewqa3dJHY5+ZTtA9KnyH5ofGp53j92nCAdzVPUvtH2d2teJiMAnpVud8BgoO1eMipYEeQY42KOSe31qiU7O5z1zqFtY+TBqEgSfaGKiNmznvwKfH4l0qIM5u2ZsYH7p/8K1tWvm03Rrq9QK8yofLDdPYn2rmZbrxHFJeRm+s/NtrZbriADcpznHvwapRT1M6lSTZ0jsJIEZPmTaHGBgnPIop9nL5un28gl87zI1kLkYLEjOcUUmhxloeJaho7STRM7kop4A7g9a09P04tEigNtxtx0we1dFJYqZSyjcPXsK1LK1SGNdxUk85FW5NKx6bxELcy3ZF4d017WE7nJY+tbLKB94nI/WovOESqeD7iplZJWXd+IqLaanDUqubuywnC/NgfLxx3oIDxoDjIGeaRWAQ5wR0xnvQ7qVJPDDiixi2JEX2ncQFxwKDu8vGeTRuXywd2PWoTJncSw3D0p2JZKvzYPl8ipAoSNnJwB271DFJlTtPPeoWYluCcd80lcpSuSXE5t7cyL97sKxNM1C/uNQZJ4AsaHIbHUVssdzLgjA6j1qQyIFJUbWJxik4s1p1Yxi01dl2I5Gchd36inSkuVyAADgE1SiKqpy7Z6Y7isrV/EVrprxpOxyeAO9O1iIwlUlaKOmBXbjg0jzYQLzjoAKybPUElQMHyzDNSST4XzGc9OKNgcJJ2ZLqES3aBGPy5H4VKNscXlpnAG3PrVSzZ3OSwYnn6VdVQwOO/f0qUuoSdvduYF1aQvL+8QFweCas26iBRuIVR1PrUVxp0n9omcTMQ2MoTwtNv2YwcBsHg01udLbklG4y61JIEkckso4A9KrQaqlxcRCfCx4+VT0Nc7q1zIeGGBkYHSq9rdF3Cy4LAbQRnj2FWo9Tshho28z0S2vAx4UBANoI5zSyyFYy+MNu4rI0cyPGoMh455rVuUVIVYseTkn0FQ2cM6ajPcZqLv9j3BhuUZNcFJOftpa5fjJwhJxXdDDAkHKt0HWub1jSklmyEx2Hsaal3OvCtQ0ZD4d1GYvkvuTPHbPNdeApU/L8rfMeOaw9D02OBORkg9BWzbMTJt6MeBn09aL3McVPmndGHfeH7a7uCQDuIyxHGa2bC1NvCoQZVBg/WrsmIvmAGc9BSgqYQxHzMeKlxMpYiUoqL2KrqY5A5OO2fYVJAhJbzBncev8qhNxHLcARsCF4PPerM7FWRUOOcluuaSQnfZlhZFIAJIUcfWhtyMNoxxVR2dQqkbtvNTeZ5seRwxOTmrOflaehPIGYIcLjtimeXwQqjPc1HJcRI/wB7oMfjUcModmCtuK9zxUs05ZWuSopEmEAz/epHYKDxkR9PcmrEcZ2jGOBng96jVcj5scHOB+lHmRzEDpL5ik48rGSM9KUQgKWYjPYVYmkTaSRubOMerVQnmWJtjMD3JNGxcby2JEgj2dcnOQBT4LULKGPXqKpSX6o+Y1+b7v0q7aTiUfKcEnP4UXNJU5JXJ5WyAcAgdBWekkZuWDPtYdV/pWh9+QqQML1YetVHsFE7zqPmbp2xQ32JhZaMkuZdsYUsMd8etUbRTGzI0m9icnn7oqa4XELAbQ+OpPFc7pN+i6w1qCzE8lj6+hqdTphDmg7dDr33+Wc8cVVHzny1PCjn6VNI4kVsHO3r9aq2G4yMCCMH061fU5lGyuT+QCQEOFHPPWmxIgc7hl88/SrBcK5HQdTUCjZOXLcH/wBCoYJssglYiQu0khc4rE1G+XzfIhk+4fm461sXEjGNmxuC8KfT3rOtrOJ7hpevPP1pGlLlS5pFy18wx5cjAHNPnWT7Ofm2sTkmpYgpfcDlV9O5pt1H5rKQ3yKcn/aNN7Ecy5isC7gIedozxWJJqMGnapDayCRpZ/mPfiuiGyFHZstgZx0zWXaCLU5mmZFIjJUHHIPoKk6KclZt7GtaN5paQjcjVKIFiYuo+Y/pTLaIRcIvzdBk4xUjiQBlGd/cn+VFjmbu3YkUHZjOSece1OG35kBOzq/P6VUDtGQjsfn79alMoBVU+VMfL7n+8adyJKxW1+6t47G5OoAC08o+av8As+lc7cxW8ujWt8yaqkSxeS2wjzfIzz5meo+nNXdfnsruObT7i6SMOnzMzAFc9GPtkVT+2ajc2rWn27RkDqYzdLN8xXGCQnQHFUmOcLLVHSqIY7OBbbm3WNcMpzxjgD8KKrRj7PaW0dqd0MaKseO4A6milccaV1cymRt2IFVT3yMD8qiZLrdg47ggVNGz7i7n5c9B2q0rLkbQCeuc9a1bsc8W0ylbsxlw68Z71op5aIDnIPOahYBS2wAv7mq0s6/6ssqt6VLZtbnLktwQGXHGMjFV2uXUrz2zVB5zjarhmB9abJfCMOWGCOMDkVn1No0n2LgumWUtJIVA9Kf9oDjh8BuSfWuYu5rm5DG2GSVICk9PerNmJ0t4xMCzHqTxiruaToJK9zqbYEIADx/OpljEbbmbANZ9ishRSxHHbNaiqWAU4z1P0ptnDKNmKi4y7Atz1xxilkVCv3SeRzik3gHYcDFMmuvK5B6dRSEk3oRyTrG5LnHPfjNZ82nWeoz+bJFvdfut1xXN+Lpry4j8yASMqHcMAnH4VreG71msIzOjxyMAMP8Az9qOa6O1UJU4e0i9SKPSL2LXhMlx/oZGDGOMD0rpJIzsCAZ+vSkWdWGC2CPUc02WdjESOR296lJ9TOrWc2uYlsUZXYswweBV4yBHJ6LWObxYBlwA3oKvxyLMkb8EY/WlsZyg92TT7Mbz1PWql+jTYEajZ3NTTuzOoVM07ayjaD8x7UO/QE+XU5bVNEScgqCG7N2rLtdFlWQj5i4PWu98tMHdkAZwKhjtgq5bOep45p2fRnXHGyirFTTLcRxCP5Wc4DEHpV+RDu2eWNo65pbcQoxMZXcemfSpjhom5OM9e5pWOWVS8rmRq062imXbhVGRj1rmBqXn3Cl3bLHAX+tdDqarNCYiWbPGPWsCz0creeY7swHABHSm0d+HlBQfNudFZIDHGcHJ/Sr0Np8pLMQT0+lMs4QsYAPzdMelWLjbkfvB8o5oZxTbcyASqZDGzA4PepbhFwfm7bVx0+tQRxwLK0nXPqc1eQRupAPT2qU3sEkk7owNH0k2Ms0kkrTFmLDI6VqvE7DcMgHt61dUL3yB2GKbK6BA7MQvTHrTuxyqObuxiRjOZGPJ6+1VLpyJG2ZXb9zPenS3MeAoPfj3qSdPMODkAjp2p3JS5Xqclq8d+bwS24LRr1x1PtXR6TE8UK7uMnkZ71Yt7cDg5JHrVjyg21RgYHAqTWpW5oqJIzHbxwO9Z19qCWzKXPAyelWrlhGuGzjtjvWXd2oui0coDAjoelPoZUormvLYsx3sUqJIpDqw+Uj9TVScFp3MgwvUEd6LaFY1Eaqo2dMU66fG0c5JAJ9qm+h0xSi/dFjslnT94CMYyPU1NZqlkdp3Oc9znFOt5PlIJAIycjuaQRl5BJvIPYA/0o6ClKT0expxYdgijnq1SSYZWIxjGKZbgxRknlyaguZQPlBwAOTjvTRzfE7IxdYvY7Rgpb7w4B71SsIoZZvNjCtK3LOOpPpVbxJp815sMKlpFbIPSr/h+0ltkAuMKFPAHNVuejaMKN09TTmnhtUXedvOAfVu9Ml1NYLdgud7Hr7VDqkTyzr5b7RzyCOh7VTuLVwg3DkDGAc/lU31MKUYu3MWI71ZoxhwjHIHOc+tQw6grzvArbnTjaew9aT7AZhGxBj2jovf61bt7GKN9+PnI5Penqav2auaVsS0XB6jG3sPenFPLjdCo9R7+9IDFCq/N7VmXWpRxuFZwNx4Ge1O2tzkjCU3oa9k4kth8pQ8jH9ae+0KFBwg/U+9Z8FzIXJwvk46k8ior65EEZYEu+QNo9aGhuk+YuNIX+U5K55HrU8EEcERMMeGzn8TWELtvOTeGDHoFHA+prZtpN45JwO5pJ3HUg4qxbDhV/vN/Ce59TWZqd5LEoWIbm7kVZnOEV1YknuP5VmFjGC8wLDqQOeaUm72FSir3ZZN7Eqo0gwWHAzU7zHG4gEn5VHYVyImSa9Nwd6rnaoYEDA9q6ZJt0akDovJ9KaNa1JQs+5zuurb7bi6MMcrmMhy4+VgOxNVooJ7Wxe4k8OWBi27nBcFgv0xXSzwWl3azW82FidDkjjaPX+tc7LdpP8A6C/iGJ7Vh5ZnFsys46Y3n5efWrijnqzTtH/I6HS9QNyGtJrZLaWONJFCPuRoz02n+lFQ2diLK+lmkk3jylhhix/q4x29z70VDY4wbRU1GVreFpI85UZ2461m2eoPdMs+x07bTxWhPdxnEcoO6odka8AHHatmYwslqiWe5BXLuU+lZrtE1z5p/wBZ2bNVdVIWJlG44/2ulca82pi+XaP3e7HLdqnQ7aVPS52c4U3CSozb0468Vk63e3UcRaJTg8HHertiJn8ssBg9ferOpxYQhVBGOecUWsbe05ZJGJ4fvLwSmGZGU5zluorq4JXKldzMW5wR0ri4La+S4fYUMZIbJHNdZZyzIgJUFgMA0OI67RsWbShmCEkDkn1rQjucS5fhj79qxY7wRDklQeKeLlZQUyw5z1pWPPlTk9TbMqu5PIb1zSPCHbIf655NY63zRMFwWHQmtK0mDjKjC9OT3p2M2nHUa77N2Rk4ztxjNZGvw3a24e2yXJ+77Vv4AwSAD61XneNn+8Dt5+tKxrTqtO+5l6VFdvCGvA2/vit9QEhwMcA8VAjqygbsf1qVA2FVuV6nFBnUmpu9rHNaxZaldXsbwziOED5kxktW7p5aOHy3bJA4J6055I0ALnn0qtHdx+YE5BJO0hai2p0Oq6kFG2iNaOUbMk5NPM77+2fSsWW6cSCNXCRnkt7e1W1nXyh5bFtvG4nmmjGUGtTRLsWAx2z9KjkmYnHTjmqR1HbgupC96R7kGNtvLHnA70ybPqh806+aqxsAw4460/EzwsC5XA6jvVNbaTduXbljls9RV6FGi4Zs56ZqUzSTSWhmNNcNOkKrmMjlsYxWkLdVXIIU+9FwQq5iUFwcUq5lK4YIVGTu70rtA5NrQlRRGoOeBzj1NPUB0dztLdOlMuc42quSBjPvSwNiHbtIx6027uxOq1KoMn2xYljxEeQ/atSMrjI7HH196gULjccgntTkUbSo6gdfSlFDnNPoSyuXZdpGOmKY+GjOBnj5ab8owFP0I/nSTTqudxC4GB7VViE3exjw2kcOoSSNKzMeNpPArahYMMoeayJURptxbLk5yKsxSlZAnRe2BzUqyNarctzTkO1cggZ7VCWYOCBmqGq73VVjkZRx060Qs+CXfAAznNFyVD3blyc+Z8pBIx+tRyEIEJUk9OKgNwsbeYSQoGM+9MS5WTADc9aLgrohjEv2qaT+DPygiiS4UNsPzOo4+tTefE7FI3BCnnmqc0PksJmIYg9qUrnRGaW5BaXvm3JhY7WU7SelXlnZbzbldmM5PeqcjgSeZ8oPYf1oF0hcBQMry2eooS1NJWlsjoHuwse8Kx9AKaxVky/bnishp87HU9exFXVlR48LyO9O7uczjYpTajELww7/AN6QGCnsKtCcOjZ4HqO5qGWxWRmmVF3/AN8DpUq2YEAV2PHIPrTsaSlB2sQxyAuVkBYj+IirI2SZO8ZHUVXlbcuEAPNV45lZim7MgHYdKgrl5tjSmnjhgYkgY561zzeI0kna1gYNMASat3aeZHsLhV9T61S03QYxI8+AZB0btV37G1KNOMW57mnbXMzWG+VR5nYHtWJa6Ymq3XnssqTocbdx210ltB+7CO33farbqLaJ5VAD9Tj0ouQqyjdR3ZIltHHaiEKG24685NYjwbZHWSY+ZIxIJPOPatOxlZ4vMZSpYk4Y9BVKaFHu/ObBZeNx7ClLYzpycZO4ySGUCMI4KqOSRy1aNmxCYIJcjqaqK0awl42LAd81EbiYeX5YLF2we2BSW5o7zVmazKzyJyPK7465pZFSKMKBwDwF9KzbO+mknZTFsReFOalmuVORuUYPPPSqdjF05J2KGpab9sZCzFih3deAaswOyxbVjKgcYzWlHt8pQMFn55/nUB2hmDFTjpjt9TTtYHUb0fQ5TW9QubuGWwtbZ90ylS3Y+x+tWn1MTac9gumXX2qSPylgaLCA4x97pgda0ZXtbaQLLPDE5GVV5Apx/eOaj1S/tRpd0I723MhhcLtlXIOD05qlczqyi/h0LllE8VvDDMxZ4o1RnHcgUVU0mSR9ItmHXyUCgnvtHJoqXFFK9jnk1mC6kO0rnPpzWitxHsyWAJ4A9arvpkIddm1O+R60jWELzCQsdy9s1o0zJzpPREksUE0hXB9c1WfTl3g8exq1vWF+Fxnue9I8suRlPmHQe1VGNyPayjs9CGNUtlyHAb1FBcTDnLgccDnNR6hZG7t3BldMj7y0aXCtrCI2ZncDq3XFJ6FRldczeo1Y2STKqCB2JqRdzSYGelOuZIkkRmcljx04Jpq3Q3uoVgAOTimjTV6lDVb1reJWXucYNVNK1szzbRyM4OO1aTKsh2ttKDsaom0hgm8yGNRj+IVPKdkKsXHlsar3DZ+Tkd6lTUFtdvmPhM9/Suc1PVJLaSMooKYJYnoKfDfC+iL7SygcKO9LlsHJGejR2R1SKSIlH+UcnFYVyz3dzHJbSuibujDg1jxag8MqosLxk9yM10Vv84TevBGflqXcXs1Qd4m3YwKEQFznqc1oZ+UgOCPasmK4VVCHIyMDip7aQKCGYkf3jQjzql5O7JZVcMd20pUaupzmMhegI7U+4ljUJvcAsePc048xrngnnApPUSdlqZmoQeam9GAK55Nc9f8AiE6ZgMCVPpXWvAG3ZYnPGKzLrTrN2/0iNWboMimddKrFaS1IdH1UaigkA5P97vXQWoO7J5YD8qyrC0jgU+WgUjpWrFlMKv3u59aLIzxFSLfuFqLasnzEnJzUm/cSXXaByPeog2Bk9xzTTIAfmO5RRY502yQyLG+WBx1qSMgsu4Hnkn2qp56EkEgHOcUpue2QD6+tFkPU0ZCrquzpnp/Wo5rmOOMLjp19qxY7ieGQmRywPbHSkuZJZSypyO4pXRqoa2ZPBrMMl1NDE2Wzj8fStS1YtGu84J6+1cEbFLS7aVQ6SOcsxPBrqLeZgo+Y4HQUyq0IpWibLSRIxcEYAwKxdbifUY9iMUI/iz19ql8szIPNbgfwgdakVPK3AAE9qm9yab5XdPVFayjeEpGxGemcelbGViRVI+Zuaz2GX3A4HrUsc3z9ckD8qVgm3J3ZJeSlA5GDIFyBXOXd7LLASY9vYrmt+VVkUtkZPGe9Yd8CZNjgsDwvsfWhq5tRlHZkS6g0sSoqcqMD3NMiuZFuHM6HYx4HfA9asQW2E2jG3OcYoQQyXJSMEMPvd6SRXNG5DLOtjE1wBtWRufWrun6iLm3WR42KscAH+dP1G1jNrhow6jovpUEKFLaNIECLn8apl80ZR8x+pWDczRuysOSAOD7VRt5FZws6lGcZ3DuPSugMyCEEsDnjJ9apSeW0reVhnA+UtyPyosRCu9pIglhLPGgfDqOmKuWwNsu0sMA4x1JNRLHOpLTFQuOqjqapX16FIUOF2nJbvTSJcnP3VsdJ9oVY8nNQPOrru5OfWsDTNUFwWUEEoetakb5XYP4utNq5HJ7N6kKuwuRuICHt61YhSNtxhUbmP15qG4tUnUxyAonGCDjp71ZtbcW0IWDlT37/AJ1CVtDd1Fy6blW5tmkkC7fl4NXdPE6SSK67Yl/1Y9feq9ms6iX7W6EbvkwOcVe2gRqXOXPbv9KqxM5u3KywjgR/ODxyxPeoVnhuVKI+Cp5B71A86op4J3diKit4kYPIj7W/vUmRGCSuWbtvKhJx144Nc+Lp5ZJIs4bO0dwK0b1i0Xl7yrtwSO1R2NjBBKJJAWbpz/M0M2pNQi3LcnsUbiNo0KAdemTS6jcLZxFiB87ckD+VaBMc24ggH7uelV5YkkPlvzihIyc7u7IrbEkO9uMjOBxmsm/RYJTIiMTnlR3NaczCNGEQLSDoB3rBmvLlBukXfMTjCcgU2b0buV1sdJYt+5TfkSEZGe3tVjaGOSM89Pf3rN01ZGVQcl2xn2rUlcLGEDc9uO9DOWr8TSKFzZWcsoku7WCaXpudQePSo20jTmjO3T7UH/rmOvYVU1e7khuIYhZmdJyE8wTBBv8A7p44+tWGu9VWPaui4KjH/H0vH6VSuZtwW+463f7PJslIHYKB90eg9aKo6hbSs8Mw3rNgFkDfdPuaKzbZ3xpwkk7lRpWbcAy59aSKOVm3mRQenTNc5p165jDSIy5/hJya2Yn80A7ipPSux6njTg4ss6jM0UO44LDnAHJqpFfPOvmBfl9+KSTErDc5LIeoplwDt2o+D70R3CTTja2poJcSbQDGu30qDz9jbgwBPBqjEjRKS8xfjioWh+1Md26Mocg96mUew4WvrsbQMmMKqhTz161DIM/fDKe5FVyZSmxZFBHRvU1ZjeQJtZlJH3gB1qVFmnNyjDL+6zFEC3TnvVaaUvEfMUI3fHSrqJhCWc+w9Koz2XmgkOSxBxkcU7F06iuZ8rxSoVIU4PWi1SCFS2AhrLmsby3diE+U5J+vrTIBeSZDKBx35pWR6Ct0ZrNdozZQjcPfmteG5VlV1G11Hr1rlbe0dbgM0rbVHTOBWvFOTJsZSo7NSsiZO61Nm41GaRMwxZYdQa1rSeOa3D5AA6j3rl5Jre2ZXMjb25yTxmrtjdxSxt5Uynnn0pWOWpG8TZEiGYBstjkEDNWY5AHOAcVz8l15LZVsHPK0lvqjm6dGcGMgYGOc0rGTpu1zog+Q2QcA+lZd3dPbyh9jyAtjpzUou9kQQ7ePfmmJcRSA5J46+hoYU7x3RJA8lyBsUoR0z/WtFC8a5yCQOc1BGUEYEOcnsKkGAvzZBPQGkJvUe1wwUEA4FJcSN5I2fKW9aI8j5eGHtSfuy+XbOOAuelIIu2o1lyqnHOOTVS4uFiKrGRuJ/iPSr0sSOoPAPbB4FVGitFbdO6hwOhPWixpCSe5NHPGPvEZHXB6n1pr3MYk+YgBu/U1nzsVidouAOm6uU1HVrvf5ERx6lVyQKLG0KPO9DvAsTjLkFR2NTAeWCU4B6GuL0q7lnZSWkIUYyT1966QXbrHggEAZ+tKwqlKzsajXEcMSuzlTnrToZ/O3OB82OTXP22pwX05i5OOue1a6OkOxAcFu3c0BKnyK3Utbl77cnqAaT7THGduenRV5xUSiOPkjBP3s1VeaF8qMBx1Pc0KxnHXViz6wFJWGItnP4VLbO0sKkj94T+VUxbCT5g2EPOPWnfaBbxsyKflGABQkaSs17qLbypE2wkZHXHWqP2yJbgmNgSeM9MU/cZITKWUbh1xg5rJKFGkcsXxxgDnNOxpThHqdB5rTqN0m3PA96rX0v2dEZOSOOO/0rEsru587dOAI1PAx2rbyHgEgUNIOntRYqUVBrsNkmZY1eVgrMOnPFMgumYeYAsZAxk96oX0j3heOVjHCmMsnU1aiii8lFBcLjg55/OlYrlilruXIruS4jLOu0DpWI+lTXN5JJLLujlGNnTHvW9DINoGVMQ456tVadnYY/wBWmeo60yacuWVkVYdNW1cDeVVeQo6mtiwBklYyDYDwPwqnGUbasnzuv+easySgL8h2t7f40XJq80tzQkUPlfM+X0NPSQRKFOCg4JrLgkkCHL7iedx7UlxctEY0OWMh9M0vkY8jbsX5HjaZWAx7YqvqN6LYBsnHt1AplvcgP84Ut/Cv9aklhMw4QE4yfQUXLjFRepHDdCdgcBUYcZ601Ve1wsO6Qk/dPU//AFqpagxjZAWVXbIArRsZzHCu/aR3NLc2m7K62J4/9UzFCW+9jv8A/rqpKZpZVJ3RKByo7/8A16txXImXOzBznNDRB9zuCWHcdqdrow9o4u7QyUSJGr7uvAHpUwz5eW49x/KlkUfKDwfQU4suMd/ahInnuinI7puKLvbr9KqFgkJmZfLjHJJGDWhMQiFkBYis2J3u/wB1Op2EnFCOiErotadqEV1F5sJO3OOBVq6ckAAbs+potLeKGIRwoiJ3pxzIwVRiMDrjrQ7swlKPN7uxTubmzhjWC8ntlJwTHMwGR2ODTxrWnyMC9/ajHT96Kj1KC1ukinmeO3eBw0ckigj3Bz1B9KmWfSJ1IgNhJKeAqhSc07Ixc3cmPaSI7zIMh+oI7GipLYlEEbADA5PYUUWRpzPqeSs9zINqryODjoasWyXEcilZSPY9KrLeRKOGx+dKNSt84DlSfUV3NeR5Xtpdy/Jd+WzMxCnocGqUmrR4JaTP8qhlnQnkgr6GqU/2OSIqg2Y5+UUuU1hUUtzQF9dPIFSJTCRkNmp7eW5MoEjYH3vl71ixzuIPkBY9s8Zq3ZSHAeUPG56qWzUWOjnsjYuLwx8ncAO4FQw6/FFKFdju9cdqFmjYfvTkelMMEGMqFBJ9OBRy9iY14pWkjTGqLJhlbfn071PDeNIgG1l3c4rGgjRSMrtC81bjuFAALjHbaM0cpnKrH7KL7zl12Bfz60JbMVzhQAKrfbwqfMePXFKLtSpYbvzpOJKqNET2kkpZHChAcipIbSRck7SByCvOKcZI5vUt6U4ShE/cuA3oaXKbqs3oQtHMGJnVZF6gAdKmtGQxExR9+4HFVp7mSaIhFB/rVeG4UxFNrRyk8laVrGik5KzLuoW7XBJjcLkduoqGws5LUEySF8dN1Pgsmjbzhc5PUqxrQT94fnbjvkVNtTT2zS5UylfTywwrhMknJbPSsQaoyljI6q277tdHcGFmCIw59u9UpNNinOZIkJJ6jgg0loaU6yWjRsaJeebEHBxgYPOK1yzPIAxyO2K5vT0ltmCuQoPT5hjFXnaSRCkM2G9RU2Malm79Db37BsjIJ7e1U3jVbgyM5DDrk9arxyskKh2DMO/eqF3rUUUwSRGVwcADnJpEQi3flN3zxH833vYdqrhIZJv3ql89T6VRiuSeW4VuckVPbydZEcbj2x0qnFhF8jsLqNuWhEcLEL3Y9qx7zQYpHRiST7GtiSZmJRzxnkikeVTHhM5Hap1NVVcdDPt9NSz/AOWhC9R7VtWsMckWVYFSPXOaqSK7pk4KYxtq1DsjgGxemAQp6UEyqSmiAwwWUoKrt3enFXo9pKSSDhelVACWZsBox/e9agaVBdIm5gB+RoS7lczluTahPvQqjnk8+9Y8uoCO4+bBxwKt3SmV2ZGwpPBrLm0eUhjHIOOeeSTQkjek4LRm1Y3hnwrYHbA7CtB7iJGEUY3E/e7Y965awS8t3ZZGUgnk55q00TvcLK0xXaPun1osaSpxva5u6pGktoFjbHuKzrW5jiTY0oZxyTjtSSDzrfBkI9/X6VQgghUOYRln4YMadiIOKjZmjLPHerkAoqnlx0/KrsUyC3/dbipOMgVnwwyQunkp+7J5CjIq5dytHagh1iY9SB2pWJm0/hJRGrM7FRGnbvn61XnxgxpJweeaBbNcWpTe6AnIyetWbeEooVgrYHLUWI9pbVkdlZlJC5lLZGCD0H0q44izh2/eY+VajXy7cl1OWbt/U+1Z2o3MyzK1rH5rlgG9qRUeapK7LE6Sq+2IKobl+c1Np1iUR1llLlznJ7D2p0cLvGTMpy4+Yg4qaW332oiQuqjjg8mkU6nS5GMtMYoANuOTngVYlUiMIhywH3h/Sm2cENnAYwx/2ixyTUhlRF8xmCqO2Oaq9iHK8tCpbWjq7u5G89D6CtSIjby5x0z3JrOS5M2QpGxT265pl7qK2ibtpfjGB2pDkpzdg1oKv70QmVh0A659qsWIaaONpI9pI+76UtpceZD5kgG4jgVYCNtZkYM5P4UWCdRqPL2I5om3ERMVB6571NCpgVRIxOB09aaJSiYZdzY6imxyTO4EuF7/AIUzJSb0JLghRucnJ5yKgCtMNy5WL071Wvpt8mzfgD+Fe/1qxYzZVvMDADgZ6UrmyhyxuRXIk8wmMnCjABNWIz5KKsi4Pr61NMUKbnKkn8hWLq6zy27R28hJYUWHB82hpNefOMKGA/hX+tW7afKZBDknPzf0rltGiu43H2k44xgHNdXZqhiy4+p703sTWhGGxz+uuiaxHcajbNNaGLbG2zekb55JH071k6pcafcRMtpbrK5GEEUJD7uxBxxXR3jXlzqzWVhOkCxxCZ3dN5OTgDB7etQy6hNBbXtteIkOoxQtJGyDCTKB95f6imnc51JRZf0OG6S1ia8kBl2LuHXBx+tFJY3oa0ti/wA8jRKzHpkkCio1NnGUtT5YbUrzPFzKffdT4Nd1BXw8+5R2YZrS8ceGLrwp4mvtKujvMD4Vx9119RXNsuSetenbQ+Vu4s6Wy1+Z8LOQQT9K7DS9Jj1Rcw3gU7dxyDgV5cmT7V6B8OtVhguQlw42ehNYzclsepgpUpu1RHUr4H1cqBC0Nwo5yJcfzqAeGdcjZgtlM59VdWH869S0y6tjblolx5oOcHoK07WGL7Pvg5XG761i60kz0HhaVtLo8Vfw7rzHd9iuyPQJUD6dqtsB5tpeBPeMnFe5MfLiZmUqAp5HJArDe6uAwVQWjx94HrS9u1uhwwPPopHlSTXAG420+OmdhpTd4ySOffjFev6dcSfZikaks3QdRmodVhWSWMNYQS/wMTGOPWq9v3Qv7NblZSPKUvF+6zqeM8mk3S7g0MwZOuMV7DB4R0K4UG40y254+Ubf5VQ1PwLoiAPBbvGvI2rMar2sX0Of6tUi7KSPLTey7v3JBYe9SrqLZCyDafb1rrLnwhpAZVhnuI2I5bcGA/MVVfwHHMCbfUsv23J/9ej2kWa/V6iV3Ew4b5QpVh845zntR/akCsBlQxp9x4SvkneH7TbPjpklS1Rf8IbrqjfFaRSKrYysgOfpmnzRZn7GcXdxZowX5ZOTgHuKm+0ZGGche+eKwrnStfsQWn025UAD5gu5fzFQLe3iKyXEcsfpuQ/4U7J7Gb5ou5uedGHAWZV9RjrWfqmoyQLuhyzZwBnrWNc3mWTegkUHk5xitezvLVlUMvI6d6XIbe2jFamlaSreR/6SGJ9jWrGUt4so2BjAB5rDiulMhbZsx0PTNSG/kdsEYSk4ozlWu9DcWc+UA+0k/wB0YFU3KM4dwqsvQkVRW+XPyjoc89Kje8LA7lUD3PWlyCVV30HXepmOeNERnXuccfnVyC5kkPyusfHRck1hfa4J5ijMEA44Oati6WNALdVP1OP1p8rNPaJ6M3TMYbdiGLNjlqqRakScrJn1DDmqLS7gHH7px1+bNV5IZ358/bk8leanlsaRmup0y3geP73PXGOazLl7mW5DRTkRg8rjrVUOpwGuBv8AXpxVg3EcEJZWDEDjBo5b7hGfK/dNKzneNds7cE5xT5GZ5MKFC4zmsKO/ldt80ZUZ446j1qWKYNPu8wlT2zS5R63uzZEm0KRjavQAdaRbyPflvlNUJ7jaTsT5/rSW1y0mM43nqMdKVhRaerL8jJPGzxkIx5zjNU98KsCzsXxgDnNLcXCqBlc4OCV6CoGmEkg+cKyjjGDRY1jJ9DSXJUM5A4GAewqSC1h5CrgdSBWQzTPIzTNmPGRnvU8c5jjDJJuU/wAC84+tFhSd1ozXhmRPkjDZHpVa6V1l8yTGW6E8jFOs5gUBYjDdu9TSJHMpBb2pcpKnyMpWeopK5WNi7p1OeVP0rQjneQH5yCejEYqlHaRwzMdrIvUlR96tE7VQdweQfSixpOcXsgZxBCzuwxgDJ7+/0pIBHawmYkFX+Ynufamv9ngR3LfM3JVv6VQe+3uyqQMDgelSolRba0NCHUGmwMNtychuMCrDXiLHhpAMDqDXPRW15KZGkmGG6YFC6fMZg0k24KOVUU7F8tO+rNu0u4riUxsSc8n+6P8A69WZZoNzxIQR6Hqa5y2nlEnlwxOvPUitl0SMGSQAk9T3qbBJRTHylERQmxR3K1GpW6UrGmccZ9aq3zm5AhjYIDgCr+lWbWkRzIZJCMFjx+FFrFStGN3uROHSaMNKqQr95e59var8l4FiBjG9v7oqhdhEcG8ZclvkRP61GDIbjJ2JEBwoPJoBQUjcSY+RkAb2/Q+lSNGHtwCPnIycH9KxLeSSScneViQ/KDVlJ5nlMe1xGoyzjofxoMfZakGoGNWX98I0U8gdz71pwsHhT+7/ADrGuRbSShGRHUtkA5rTtXUriRCNvH1+lBtNe6ixeAGP7xVF688VWgmjkUeWQV6etM1SOSe2It1Dtjhc4zTtLs/ItNpQK+PujsaV7CioqGu5Os0UIBdlVe565NWoLgMvmKMRj7oPeoI7WOPG8BgTnaBxn3pZGCRnAyw74/kKSepErNaEU6R3F7Fct5iXEZ+Uxtgsv91vVasarZW2rWgivI245R0OGU+oP9K5y8Ym+eQyTphVDiI/O5Y4VF9OhJNPupJLKULYJdROykqHlMiSkDJVsng4zyKpGbjF7F/+zpUmgMMpEUShQP72BjmiiG7E9tDl1jLKHChs8GipsjrUppaIsfHzwtFrOgw3FqA11bsz+cBy2eo9hXy/faXd2RY3NvLGobG8qdpPselfaevgPolwGAYeQ3XntXFfEG3hb4SyBooyBbIwyoOD616aWh8pOPNI+VuiZ61JZTmCdXBwAelJJ0P1qAVLVyYtxd0e4fD/AMVwsscdwynA4ya9S02bzbJ3UscrlQeo9q+YvBfN4ufUfzr6P0o40+HHHT+dck0fQ0Zc1O7L8UpaPYS5lI5GO3pRd2xiiG1SBjI4p1r/AMfo/GresE/ZDz6VjudTfLOyKWlhYYCwAQqeQKtzQobUgls4zxWNbE/ZJOT94Vo5O9+T0FHQ0mm5bkthdqfJ+YkqSCvp7moNUvfJKGXJDNhcUWwAExAwc9avXagxx5A6UrszcUqmxj3EUcrxLtclj94DpQ1iIH32yfL2Y8nNSXHH2fHFasX/AB6fjTWqHUlyxXmc3dWEstx5gA2jjntVmG4MKpvB25x+NaM3+on+tYxJ2OM8ZouOMnNWZpui3VqHDsqqSOPWqMxWdjG2zCAcnBzWhY/8eTDtk1iQD97N/vf1NHmKK3XYjOmWF6SZ7G3xnqUBzism40DRp5JUis0icdGQkYrpW/5ZDtmq8IH9oXAwMZpps0dODu2jIPgKwurQkT3cL/72RWZfeBHs4gbXUppOuFkX+td4hJklBJxgVKgzGM+pqvaS7nC6NNy1ieXp4S1aZAUuYVJHO/K1DL4X11SU/cTBe6yY/nXo0/8ArH/Clk4tpCOu80e3kgng6XRHmJ8Pa1HIRHZhmxn5SCapXdvq1u2Hsp1PYeXn+VeloT/aL8/wVqXH/Hqp7560LEvsOWXQTSTZ42BfhT5lrOHPGfKNRfaJYoyh3qRwSykc+le2yk+vYVYeKNl+aNDwp5UVoqretjP6q1tI8HWaPA82Qg1ZhltyoVHwo5Yk9a7/AF2GIyygxpjP90VkQ2lu0km6CI/L3QVSmn0IqUJJX5jlprpXKqGLRjjJbt7VNBewxfIu4dhWjq1laqIyttCDg8iMVzE4CzKAMDPQVpY5m5LRs321GBEwWJ+nWl+2fINkixk8knnishAN54FKo4oUbmTqNOxpefGrsssvns38PSrMKxxnfEgJ6H5sce1ZVsAVUkDO41OnVx6YqWkbKszWW68w7ckAf3u1DXbxqQqqFH8WcA+1Yrk715NMuCTIASSKVjWE23Y3WvyWVFLqT1bdgCr1lcFUwzKydstuNcVHI/22Zd7YzjGa6O048nHf/CixrN2R0RnMoICtjHJP9KqvI/mJyoUf3uTmqm5vJ6n86yAzHVkyT09anlRNFt3N2Ri7bpMyFehaoVjgNzvn5zyFPH8qJycJyfvVLAAfOJGSAKHFI1hNvQ1YJVSLCDavoKR7iOKT72Fzzkdar23R6lQAkZAPB6/SpZMVdkhvUDDywXZ+QasTxs0BbChyO4rn9J+9J/vf1rpT/rD/ALtBpUShblKVlaeW/mTANjnj1q1c3MsePIi4/iI61IvRfoKQfej/ABqWTztvUiQmcebIdp/uHt75qKa4g80KgZmY7S5zgVT8QuyQx7GZc4zg4q/pfzQru54HWkdEdFcarEkhFYL0UEdafdpdzxRwwPsQ/ewO3tVoffi+lTMcA4pGbq67DbK2SOP958zHuearX0Fw52wt5S5528nFaCfcP4/yqKInyQe5YUDjN3bIYbkKViO7I6kVdhlSEbVJO78aw9WYrqihSQMdBUemOzahhmJHuaDSVNONzppJtq4Ax2+lVpSq4bPUY5PWpZv+PeuSuJHOropdtuBxn3pGdKHMa+rWrGQSrDI0ciqJPLP7yMqcrIueuOhFVGWe6GI3uJZAGVJJYPJjjyMFj3ZsdBW5HzIM81PKclgeQDx7U72MuXqZyadDGIsZxGoVfw4oqXVCRpkxB5wOaKR0U3J31P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory papules are present. Some lesions demonstrate necrosis and crusting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9685=[""].join("\n");
var outline_f9_29_9685=null;
var title_f9_29_9686="Micafungin: Pediatric drug information";
var content_f9_29_9686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Micafungin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"    see \"Micafungin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/42/8868?source=see_link\">",
"    see \"Micafungin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mycamine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mycamine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1761796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Echinocandin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Not currently FDA approved for use in children; studies in children are limited to pharmacokinetic modeling studies, short-duration trials, and case reports.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disseminated candidiasis (Benjamin, 2010; Heresi, 2006; Hope, 2010; Smith, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;1000 g: 10 mg/kg/day once daily; doses as high as 10-15 mg/kg/day have been used in extremely low birth weight neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;1000 g: 7-10 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspergillosis, esophageal candidiasis: 8-12 mg/kg/day once daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1761806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"      see \"Micafungin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Not currently FDA approved for use in children; studies in children are limited to pharmacokinetic modeling studies, short-duration trials, and case reports.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prophylaxis of",
"     <i>",
"      Candida",
"     </i>",
"     infections in hematopoietic stem cell transplant recipients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: 1.5-2 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disseminated candidiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: 2-4 mg/kg/day once daily (maximum dose: 200 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspergillosis, esophageal candidiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: 4-8.6 mg/kg/day once daily (maximum dose: 325 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No adjustment needed in mild-to-moderate hepatic impairment; the effect of severe hepatic impairment on micafungin pharmacokinetics has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycamine&reg;: 50 mg, 100 mg [contains lactose 200 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3884043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1761807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Flush line with NS prior to administration. Infuse over one hour at a final concentration of 0.5-1.5 mg/mL in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W; more rapid infusions may result in a higher incidence of histamine-mediated reactions. Do not coinfuse with other medications since precipitation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reconstitute vial with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W by gently dissolving powder by swirling the vial. Do",
"     <b>",
"      not",
"     </b>",
"     vigorously shake the vial. Further dilute the reconstituted dose in 100 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W or to a final concentration between 0.5-1.5 mg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3097497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, bumetanide, calcium chloride, calcium gluconate, carboplatin, cyclosporine, dopamine, doripenem, eptifibatide, esmolol, etoposide, fenoldopam, furosemide, heparin, hydromorphone, lidocaine, lorazepam, magnesium sulfate, mesna, milrinone, nitroglycerin, nitroprusside, norepinephrine, phenylephrine, potassium chloride, potassium phosphate, sodium phosphate, tacrolimus, theophylline, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Albumin, amiodarone, cisatracurium, diltiazem, dobutamine, epinephrine, insulin (regular), labetalol, meperidine, midazolam, morphine, mycophenolate, nesiritide, nicardipine, octreotide, ondansetron, phenytoin, rocuronium, telavancin, vecuronium.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1761803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); reconstituted solution may be stored in the original vial for up to 24 hours at 25&deg;C (77&deg;F); diluted infusion may be stored for up to 24 hours at 25&deg;C (77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1761797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with esophageal candidiasis (FDA approved in adults); treatment of candidemia, acute disseminated candidiasis,",
"     <i>",
"      Candida",
"     </i>",
"     peritonitis and abscess (FDA approved in adults); prophylaxis of",
"     <i>",
"      Candida",
"     </i>",
"     infections in patients undergoing hematopoietic stem cell transplant (FDA approved in adults); has been used for treatment of invasive",
"     <i>",
"      Aspergillosis",
"     </i>",
"     ; micafungin is ineffective against cryptococcosis, fusariosis, and zygomycosis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F196271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, bradycardia, edema, flushing, hyper-/hypotension, peripheral edema, phlebitis, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fatigue, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid overload, hyper-/hypoglycemia, hyper-/hypokalemia, hypernatremia, hypocalcemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, mucosal inflammation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, febrile neutropenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, serum alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis (with peripheral administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacteremia, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acidosis, acute renal failure, anaphylactoid reactions, anaphylaxis, anuria, apnea, arrhythmia, arthralgia, atrial fibrillation, BUN increased, cardiac arrest, coagulopathy, creatinine increased, cyanosis, deep vein thrombosis, delirium, disseminated intravascular coagulation (DIC), encephalopathy, erythema multiforme, facial edema, hemoglobinuria, hemolysis, hemolytic anemia, hepatic dysfunction, hepatic failure, hepatitis, hepatocellular damage, hepatomegaly, hiccups, hyperbilirubinemia, hyponatremia, hypoxia, infection, injection site necrosis, injection site thrombosis, intracranial hemorrhage, jaundice, MI, mucosal inflammation, oliguria, pancytopenia, pneumonia, pulmonary embolism, renal impairment, renal tubular necrosis, seizure, shock, skin necrosis, Stevens-Johnson syndrome, thrombotic thrombocytopenia purpura, thrombophlebitis, toxic epidermal necrolysis, urticaria, vasodilatation, WBC decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1761799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to micafungin, other echinocandins, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1761835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, hepatic impairment, and in patients receiving concomitant hepatotoxic drugs; monitor for evidence of worsening function. Use caution with administration through a peripheral line; local reactions may occur more frequently including infusion site inflammation, phlebitis and thrombophlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1761800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of hypersensitivity reactions including anaphylactoid reactions and anaphylaxis with shock have been reported in patients who received micafungin; if reaction occurs, discontinue infusion and provide appropriate treatment. Rare cases of acute intravascular hemolysis, hemoglobinuria, and hemolytic anemia have been reported. Isolated cases of hepatitis, hepatic failure, and acute renal failure have also been reported; monitor for evidence of worsening of these conditions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F747105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F747104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Visceral teratogenic and abortifacient effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1761808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, renal function tests, CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1761804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits synthesis of beta (1,3)-D-glucan, an essential cell wall component of susceptible fungi, disrupting the cell wall structure and leading to osmotic stress and lysis of the fungal cell.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1761805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into lung, liver, spleen, and kidney",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.34-0.76 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-8 years: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.35 &plusmn; 0.18 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 9-17 years: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.28 &plusmn; 0.09 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults : V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.39 &plusmn; 0.11 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to M-1, catechol form by arylsulfatase; further metabolized to M-2, methoxy form by catechol-O-methyltransferase; hydroxylation to M-5 by CYP3A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates: 6.7 &plusmn; 2.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-8 years: 11.6 &plusmn; 2.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 9-17 years: 13.3 &plusmn; 4.3 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;\">",
"     Healthy Adults: 14-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults receiving bone marrow or peripheral stem-cell transplantation: 10.7-13.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% of dose is eliminated unchanged renally; 71% is eliminated in the feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates: 0.45-0.57 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-8 years: 0.385 &plusmn; 0.15 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 9-17 years: 0.285 &plusmn; 0.12 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis:  Not dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arrieta AC, Seibel N, Kovanda L, et al,  \"Safety, Efficacy and Pharmacokinetics of Micafungin in Pediatric Patients,\" Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006, September 27-30, (abstract M-876).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antachopoulos C and Walsh TJ, \"New Agents for Invasive Mycoses in Children,\"",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2005, 17(1):78-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/15659969/pubmed\" id=\"15659969\" target=\"_blank\">",
"        15659969",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benjamin DK Jr, Driscoll T, Seibel NL, et al, \"Safety and Pharmacokinetics of Intravenous Anidulafungin in Children With Neutropenia at High Risk for Invasive Fungal Infections,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(2):632-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/16436720/pubmed\" id=\"16436720\" target=\"_blank\">",
"        16436720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benjamin DK Jr, Smith PB, Arrieta A, et al, \"Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(1):93-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/19890251/pubmed\" id=\"19890251\" target=\"_blank\">",
"        19890251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carver PL, &ldquo;Micafungin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(10):1707-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/15340133/pubmed\" id=\"15340133\" target=\"_blank\">",
"        15340133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Denning DW, Marr KA, Lau WM, et al, \"Micafungin (FK463), Alone or in Combination With Other Systemic Antifungal Agents, for the Treatment of Acute Invasive Aspergillosis,\"",
"      <i>",
"       J Infect",
"      </i>",
"      , 2006, 53(5):337-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/16678903/pubmed\" id=\"16678903\" target=\"_blank\">",
"        16678903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn PM, Seibel N, Arrieta A, et al, \"Treatment of Invasive Aspergillosis in Pediatric Patients With Micafungin Alone or in Combination with Other Systemic Antifungal Agents,\" Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006, September 27-30 (abstract M-891).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heresi GP, Gerstmann DR, Reed MD, et al, \"The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(12):1110-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/17133155/pubmed\" id=\"17133155\" target=\"_blank\">",
"        17133155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hope WW, Mickiene D, Petraitis V, et al, \"The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous Candida Meningoencephalitis: Implications for Echinocandin Therapy in Neonates,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2008, 197(1):163-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/18171300/pubmed\" id=\"18171300\" target=\"_blank\">",
"        18171300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hope WW, Seibel NL, Schwartz CL, et al, \"Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2007, 51(10):3714-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/17638696/pubmed\" id=\"17638696\" target=\"_blank\">",
"        17638696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hope WW, Smith PB, Arrieta A, et al, \"Population Pharmacokinetics of Micafungin in Neonates and Young Infants,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2010, 54(6):2633-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/20308367/pubmed\" id=\"20308367\" target=\"_blank\">",
"        20308367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kawada M, Fukuoka N, Kondo M, et al, \"Pharmacokinetics of Prophylactic Micafungin in Very-Low-Birth-Weight Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(9):840-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/19636279/pubmed\" id=\"19636279\" target=\"_blank\">",
"        19636279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kobayashi S, Murayama S, Tatsuzawa O, et al, \"X-Linked Severe Combined Immunodeficiency (X-SCID) With High Blood Levels of Immunoglobulins and",
"      <i>",
"       Aspergillus",
"      </i>",
"      Pneumonia Successfully Treated With Micafangin Followed by Unrelated Cord Blood Stem Cell Transplantation,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2007, 166(3):207-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/16915374/pubmed\" id=\"16915374\" target=\"_blank\">",
"        16915374",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kontoyiannis DP, Ratanatharathorn V, Young JA, et al, \"Micafungin Alone or in Combination With Other Systemic Antifungal Therapies in Hematopoietic Stem Cell Transplant Recipients With Invasive Aspergillosis,\"",
"      <i>",
"       Transpl Infect Dis",
"      </i>",
"      , 2009, 11(1):89-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/18983417/pubmed\" id=\"18983417\" target=\"_blank\">",
"        18983417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kusuki S, Hashii Y, Yoshida H, et al, \"Antifungal Prophylaxis With Micafungin in Patients Treated for Childhood Cancer,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(4):605-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/19533659/pubmed\" id=\"19533659\" target=\"_blank\">",
"        19533659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al, \"International, Open-Label, Noncomparative, Clinical Trial of Micafungin Alone and in Combination for Treatment of Newly Diagnosed and Refractory Candidemia,\"",
"      <i>",
"       Eur J Clin Microbiol Infect Dis",
"      </i>",
"      , 2005, 24(10):654-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/16261306/pubmed\" id=\"16261306\" target=\"_blank\">",
"        16261306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Queiroz-Telles F, Berezin E, Leverger G, et al, \"Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2008, 27(9):820-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/18679151/pubmed\" id=\"18679151\" target=\"_blank\">",
"        18679151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santos RP, S&aacute;nchez PJ, Mejias A, et al, \"Successful Medical Treatment of Cutaneous",
"      <i>",
"       Aspergillosis",
"      </i>",
"      in a Premature Infant Using Liposomal Amphotericin B, Voriconazole and Micafungin,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007,  26(4):364-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/17414408/pubmed\" id=\"17414408\" target=\"_blank\">",
"        17414408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seibel NL, Schwartz C, Arrieta A, et al, \"Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(8):3317-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/16048942/pubmed\" id=\"16048942\" target=\"_blank\">",
"        16048942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer MS, Seibel NL, Vezina G, et al, \"Successful Treatment of Invasive",
"      <i>",
"       Aspergillosis",
"      </i>",
"      in Two Patients With Acute Myelogenous Leukemia,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2003, 25(3):252-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/12621247/pubmed\" id=\"12621247\" target=\"_blank\">",
"        12621247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith PB, Walsh TJ, Hope W, et al, \"Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(5):412-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/19319022/pubmed\" id=\"19319022\" target=\"_blank\">",
"        19319022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Burik JA, Ratanatharathorn V, Stepan DE, et al, \"Micafungin Versus Fluconazole for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(10):1407-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/29/9686/abstract-text/15546073 /pubmed\" id=\"15546073 \" target=\"_blank\">",
"        15546073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12713 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9686=[""].join("\n");
var outline_f9_29_9686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196257\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505640\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761796\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443889\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761806\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196241\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3884043\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761807\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3097497\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761803\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761797\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196271\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761799\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761835\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761800\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F747105\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F747104\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196238\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196248\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761808\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761804\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1761805\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12713|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=related_link\">",
"      Micafungin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/42/8868?source=related_link\">",
"      Micafungin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_29_9687="Investigational approaches to the pharmacologic therapy of osteoarthritis";
var content_f9_29_9687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational approaches to the pharmacologic therapy of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9687/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/29/9687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy of osteoarthritis (OA) consists of both nonpharmacologic and pharmacologic (analgesics, nonsteroidal antiinflammatory drugs, intraarticular glucocorticoids) approaches. However, these modalities are often incompletely effective, and surgical interventions for OA may be indicated for those who have failed less invasive modes of therapy. Clinical research is ongoing using other pharmacologic agents that might provide additional benefit.",
"   </p>",
"   <p>",
"    A review of investigational approaches to pharmacotherapy of OA will be presented here. Established nonpharmacologic, pharmacologic, and surgical therapies of OA are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34171215\">",
"    <span class=\"h1\">",
"     TOPICAL NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proprietary formulations of nonsteroidal antiinflammatory drugs (NSAIDs) are available for topical use in some countries. Topical NSAIDs offer efficacy similar to oral administration, reducing some aspects of both gastrointestinal and renal toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Systemic versus topical effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two preparations of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    are available for use in the United States: a 1 percent gel for treatment of symptoms of OA and a patch for treatment of musculoskeletal pain due to minor trauma (strains, sprains, and contusions) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      gel was compared with vehicle in two studies. The first randomly assigned 385 patients with symptomatic OA of the hand to receive either 2 grams of gel or an inert vehicle four times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/3\">",
"       3",
"      </a>",
"      ]. At the end of six weeks, both groups had improved, with mean decreases of 34 and 26 percent in the gel and vehicle groups, respectively.",
"     </li>",
"     <li>",
"      The second study randomly assigned 492 patients with symptomatic OA of one knee to receive either 4 grams of 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      gel or vehicle four time daily [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/4\">",
"       4",
"      </a>",
"      ]. At the end of 12 weeks, there was a statistically significant difference between the mean pain scores of the diclofenac and vehicle groups (mean decrease in the 0 to 20 scale Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] pain score from baseline of 5.9 versus 4.7, respectively). Adverse event incidence was similar, with headache, arthralgia, and back pain being the most commonly reported; discontinuation rates were 5.1 versus 3.8 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    patch (diclofenac epolamine topical patch) is approved for use by the US Food and Drug Administration (FDA) for musculoskeletal pain due to minor trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/2\">",
"     2",
"    </a>",
"    ]. It may also be effective for pain relief in patients with OA of the knee. Its efficacy was illustrated in a study that randomly assigned 103 patients to a diclofenac epolamine (180 mg in a 10 x 14 cm adhesive patch) or a placebo-containing skin patch [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/5\">",
"     5",
"    </a>",
"    ]. Self-reported knee pain decreased statistically significantly more in the group receiving diclofenac than in the group receiving the placebo (from a mean of 5.7 to approximately 2 and 4, respectively). The manufacturer&rsquo;s labeling information warns of serious cardiovascular and gastrointestinal risks, and use is contraindicated in patients with a history of asthma, urticaria, or allergic reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another proprietary topical preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    in a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    (DMSO)-containing vehicle (Pennsaid&reg;) is also more efficacious than a placebo topical solution containing a small concentration of DMSO [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], and it is similar in efficacy to, but with fewer gastrointestinal adverse effects than, oral diclofenac [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. It is available in Canada and in the United Kingdom and may be sold in some other countries. Local skin irritation is a relatively frequent adverse effect in those receiving the",
"    <span class=\"nowrap\">",
"     diclofenac/DMSO",
"    </span>",
"    preparation. Twenty-seven percent of patients on the active topical treatment had dry skin, and 12 percent had rash, while only 1 and 2 percent of those receiving oral diclofenac and a low concentration DMSO-containing vehicle had these skin problems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/10\">",
"     10",
"    </a>",
"    ]. The use of DMSO for rheumatic disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=see_link\">",
"     \"Complementary and alternative remedies in rheumatic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the efficacy of topical NSAIDs appears to be of relatively short duration. A 2004 meta-analysis included 13 trials involving almost 2000 patients who were randomly assigned to treatment with a topical NSAID, an oral NSAID, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/11\">",
"     11",
"    </a>",
"    ]. There was evidence of significant short-term (one to two weeks) efficacy for pain relief and functional improvement when topical NSAIDs were compared with placebo, but the effect was not apparent at three to four weeks. Topical NSAIDs were generally inferior to oral NSAIDs, although the topical route was safer than oral use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34171222\">",
"    <span class=\"h1\">",
"     COUNTER-IRRITANTS AND RUBEFACIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical application of counter-irritants or agents that cause vasodilation (rubefaction) of the skin may provide some symptomatic benefit for patients with OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34171229\">",
"    <span class=\"h2\">",
"     Capsaicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    , the active principle of hot chili pepper, exerts its therapeutic effect by enhancing the release of substance P from unmyelinated C nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/12\">",
"     12",
"    </a>",
"    ]. Substance P is then rapidly depleted, and signal transmission of pain from C fibers to higher neurologic centers is reduced in the area of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    was assessed in a randomized, double-blind, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/13\">",
"     13",
"    </a>",
"    ]. In this study, 70 patients with OA and 31 with rheumatoid arthritis were treated with topical capsaicin (0.025 percent) or its vehicle (placebo) applied four times per day to painful knees. After four weeks, patients with rheumatoid arthritis and OA demonstrated mean pain reduction of 57 and 33 percent, respectively; these changes were statistically significant compared with those of the placebo group. The most common side effects were local irritation (burning, stinging, and erythema), which occurred in approximately 40 percent of patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    appears to be useful and relatively safe in patients with OA. However, it is relatively expensive when applied four times per day. Twice daily application of a higher strength preparation (0.075 percent) may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34171236\">",
"    <span class=\"h2\">",
"     Rubefacients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2004 systematic review that included several placebo gel or cream controlled trials of various topical salicylate-containing topical agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/58/1955?source=see_link\">",
"     trolamine",
"    </a>",
"    salicylate, hydroxyethyl salicylate, diethylamine salicylate) assessed the efficacy of these preparations for both acute and chronic pain due to musculoskeletal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/15\">",
"     15",
"    </a>",
"    ]. Published studies included in the meta-analysis were generally of small size and often of poor design. Despite these limitations, it appeared that salicylate-containing rubefacients were significantly better in relieving acute pain in the short term (seven days), and, in chronic pain, they were also significantly better. Mean pooled response rates for active treatment and placebo were 54 and 36 percent, respectively.",
"   </p>",
"   <p>",
"    Considering the chronic nature of the musculoskeletal disorders that were being treated, the typical two-week duration of trial of rubefacients is inadequate to allow a recommendation to be made regarding long-term use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TETRACYCLINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetracyclines have a variety of antiinflammatory effects that are mediated by mechanisms independent of their antimicrobial activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/16\">",
"     16",
"    </a>",
"    ]. One such mechanism may be inactivation of matrix metalloproteinases (MMPs). This group of proteolytic enzymes, which includes collagenases, stromelysins, and gelatinases, degrades all components of articular extracellular matrix and can cause destruction of articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/17\">",
"     17",
"    </a>",
"    ]. Two proteins that inhibit the effects of metalloproteinases have been identified; these tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) block the proteolytic activity of MMPs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tetracyclines appear to be potent inhibitors of two major MMPs, collagenase and gelatinase; there appears to be preferential inhibition of neutrophil collagenase (MMP-8) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/19\">",
"     19",
"    </a>",
"    ]. Inhibition of MMPs by tetracyclines seems to occur through chelation of zinc",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium, which maintain the normal structural hydrolytic activity and conformation of MMPs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In osteoarthritis, the activities of collagenase, gelatinase, and stromelysin are increased in articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    has been shown to inhibit type XI collagenolytic activity in homogenates of human osteoarthritis cartilage and to inhibit the activity of purified kidney epithelial cell gelatinase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/23\">",
"     23",
"    </a>",
"    ]; both of these effects can be overcome by the addition of excess zinc or calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a dog model of OA, prophylactic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    markedly reduced the severity of osteoarthritis in the weightbearing regions of the medial femoral condyle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    may slow the rate of progression of osteoarthritis in humans. This potential beneficial effect of long-term treatment was suggested in a study that randomly assigned 431 obese women with symptomatic and radiographically apparent unilateral knee osteoarthritis to receive doxycycline (100 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/25\">",
"     25",
"    </a>",
"    ]. The results of the 30-month trial are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of joint space narrowing, determined by serial radiographs with fluoroscopically assisted knee positioning in the affected knee, was statistically significantly less in those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      than in the placebo group; at 30 months, the mean amount of narrowing was 0.3 mm and 0.45 mm, respectively, or 33 percent less.",
"     </li>",
"     <li>",
"      There were no significant differences in the rate of joint space narrowing in the contralateral knees.",
"     </li>",
"     <li>",
"      There was no significant difference between the two groups in reduction of mean amount of knee pain.",
"     </li>",
"     <li>",
"      Recognized side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , particularly gastrointestinal symptoms of nausea, dyspepsia, and heartburn; monilial vaginitis; and skin sensitivity to sunlight, were seen significantly more often in the doxycycline-treated group. Withdrawals due to adverse effects were more frequent in the doxycycline group (23 versus 9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this well-designed study are encouraging in that a chronic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , a widely available, relatively safe drug, can slow the progression of joint space narrowing, as a radiographic surrogate for cartilage loss, in women with relatively mild osteoarthritis. Additional study of this novel approach is needed to assess issues such as the effect, if any, of chronic doxycycline use on the incidence and progression of osteoarthritis in high-risk populations and on outcomes such as joint replacement surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MODULATION OF CARTILAGE CONSTITUENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to affect glycosaminoglycan and proteoglycan constituents of articular cartilage by the use of oral glucosamine and chondroitin sulfate in patients with osteoarthritis and by the intraarticular injection of glycosaminoglycan polysulfate in patients with patellofemoral pain syndrome. Glycosaminoglycan polysulfate, an artificially polysulfated glycosaminoglycan, can inhibit degradative enzyme reactions in the cartilaginous matrix in vitro and in vivo, but it has not proven clinically effective in OA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The use of oral glucosamine and chondroitin sulfate is discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIACEREIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diacerein (diacerhein) is metabolized to rhein, an agent that has antiinflammatory and analgesic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/29\">",
"     29",
"    </a>",
"    ]. In cultured chondrocytes, rhein stimulates prostaglandin E2 synthesis while inhibiting production of interleukin (IL)-1 beta [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 systematic review of seven clinical trials that included 2069 patients with OA noted a clinically modest but statistically significant benefit of diacerein compared with placebo in pain relief (a weighted mean difference of 5.2 mm [95% CI -9.75 to -0.57] on a 0 to 100 mm visual analog pain scale) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar efficacy was noted for pain due to knee and hip OA. Diarrhea was a frequent adverse effect and was reported by 42 percent of those taking diacerein. A 2006 meta-analysis of randomized trials comparing diacerein with placebo, NSAIDs, or other agents also concluded that diacerein was more efficacious than placebo and was roughly equivalent in both efficacy and tolerability to NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/33\">",
"     33",
"    </a>",
"    ]. The only long-term placebo-controlled studies of diacerein with radiographic results are the two noted below [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a dose of 50 mg twice daily was compared with placebo in a study that randomly assigned 301 patients with OA of the knee to one of three treatment arms (intraarticular hyaluronate injections plus oral placebo, intraarticular saline plus oral placebo, or intraarticular saline plus diacerein), there were no significant differences in the mean decrease in pain at any time during a year of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/34\">",
"       34",
"      </a>",
"      ]. Radiographic progression and mean decrease in joint space width were similar in all three groups (overall mean decrease of 0.09",
"      <span class=\"nowrap\">",
"       mm/year).",
"      </span>",
"     </li>",
"     <li>",
"      Diacerein may slow the radiographic progression of OA of the hip. This was the primary result of a three-year study that randomly assigned 507 patients to diacerein (50 mg twice daily) or to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/35\">",
"       35",
"      </a>",
"      ]. The rate of joint space narrowing was modestly but significantly less among those receiving diacerein than among those in the placebo group (0.18 versus 0.22 mm per year, respectively). The clinical importance of a 0.04 mm difference is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a modest short-term beneficial effect on pain due to OA appears to be supported by a preponderance of the placebo-controlled trial data, additional long-term studies may be warranted to address the potential of this agent to retard the progression of joint space narrowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2074724\">",
"    <span class=\"h1\">",
"     TANEZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression of nerve growth factor is increased in injured or inflamed tissue and is associated with increased pain; the inhibition of nerve growth factor in patients with OA can reduce pain but is associated with adverse effects that limit its clinical use. The administration of a range of doses of tanezumab, a monoclonal antibody that inhibits nerve growth factor, significantly reduced knee pain while walking, compared with placebo, in a randomized trial involving 450 patients with OA of the knee (45 to 62 versus 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/36\">",
"     36",
"    </a>",
"    ]. Reversible abnormalities in sensation occurred in some of the treated patients.",
"   </p>",
"   <p>",
"    Trials of tanezumab were halted, however, by the US Food and Drug Administration (FDA) on June 22, 2010 because of the development of progressively worsening OA associated with bone necrosis in at least 16 patients from one of the trials for OA of the hip and knee. All of these patients required total joint arthroplasty of the affected joints. The joint failure in these patients is presumed to be related to injury from excessive use allowed by the absence of joint pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/37\">",
"     37",
"    </a>",
"    ]. Further study would be required to determine if this or similar agents have a role in the treatment of OA or other painful disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106453431\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical research is ongoing using various pharmacologic agents that might provide benefit in patients with osteoarthritis (OA).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical formulations of nonsteroidal antiinflammatory drugs (NSAIDs) are available in some countries and, upon initiation, exhibit efficacy similar to oral administration, with less gastrointestinal and renal toxicity than orally administered NSAIDs. However, the benefits of topical NSAIDs appear to wane within several weeks. (See",
"      <a class=\"local\" href=\"#H34171215\">",
"       'Topical NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical application of counter-irritants or agents that cause vasodilation (rubefaction) of the skin may provide some symptomatic benefit for patients with OA. Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      , which appears to be useful and relatively safe in patients with OA, exerts its therapeutic effect by enhancing the release of substance P from unmyelinated C nerve fibers, resulting in rapid depletion of substance P and in reduced signal transmission of pain from C fibers to higher neurologic centers in the area of administration. (See",
"      <a class=\"local\" href=\"#H34171222\">",
"       'Counter-irritants and rubefacients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34171229\">",
"       'Capsaicin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34171236\">",
"       'Rubefacients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tetracyclines have a variety of antiinflammatory effects that are mediated by mechanisms independent of their antimicrobial activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9687/abstract/16\">",
"       16",
"      </a>",
"      ]. One such mechanism may be inactivation of matrix metalloproteinases (MMPs).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      may slow the rate of progression of osteoarthritis in humans but requires further study. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tetracyclines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diacerein (diacerhein) is metabolized to rhein, an agent that has antiinflammatory and analgesic properties. It may result in a modest short-term beneficial effect on pain due to OA, but additional long-term studies would be needed to determine if it can retard the progression of joint space narrowing. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diacerein'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/1\">",
"      Diclofenac gel for osteoarthritis. Med Lett Drugs Ther 2008; 50:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/2\">",
"      A diclofenac patch (Flector) for pain. Med Lett Drugs Ther 2008; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     Altman, R, Zacher, J, Dreiser, RL, et al. Efficacy and safety of diclofenac sodium gel 1% in patients with osteoarthritis of the hand: a prospective 8-week, randomized, double-blind, vehicle-controlled, multicenter phase 3 trial. www.rheumatology.org/annual/07wrapup.asp (Accessed on May 01, 2008).",
"    </li>",
"    <li>",
"     Barthel HR, Haselwood D, Parikh P, et al. Efficacy and safety of diclofenac sodium gel 1% in patients with osteoarthritis of th knee: a prospective 12-week randomized, double-blind, vehicle-controlled, multicenter, phase 3 trial. www.rheumatology.org/annual/07wrapup.asp (Accessed on May 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/5\">",
"      Br&uuml;hlmann P, Michel BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol 2003; 21:193.",
"     </a>",
"    </li>",
"    <li>",
"     Flector patch (diclofenac epolomine topical patch) 1.3% www.fda.gove/cder/foi/label/2007/021234lbl.pdf (Accessed on May 02, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/7\">",
"      Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004; 164:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/8\">",
"      Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004; 171:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/9\">",
"      Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006; 33:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/10\">",
"      Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004; 31:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/11\">",
"      Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004; 329:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/12\">",
"      Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995; 7:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/13\">",
"      Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/14\">",
"      Schnitzer TJ, Posner M, Lawrence ID. High strength capsaicin cream for osteoarthritis pain: rapid onset of action and improved efficacy with twice daily dosing. J Clin Rheumatol 1995; 1:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/15\">",
"      Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004; 328:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/16\">",
"      Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/17\">",
"      Clark IM, Powell LK, Ramsey S, et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/18\">",
"      Firestein GS. Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. Curr Opin Rheumatol 1992; 4:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/19\">",
"      Sorsa T, Konttinen YT, Lindy O, et al. Collagenase in synovitis of rheumatoid arthritis. Semin Arthritis Rheum 1992; 22:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/20\">",
"      Macartney HW, Tschesche H. The metal ion requirement for activation of latent collagenase from human polymorphonuclear leucocytes. Hoppe Seylers Z Physiol Chem 1981; 362:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/21\">",
"      Pelletier JP, Martel-Pelletier J, Howell DS, et al. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983; 26:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/22\">",
"      Martel-Pelletier J, Pelletier JP, Cloutier JM, et al. Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis Rheum 1984; 27:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/23\">",
"      Yu LP Jr, Smith GN Jr, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991; 18:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/24\">",
"      Yu LP Jr, Smith GN Jr, Brandt KD, et al. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992; 35:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/25\">",
"      Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005; 52:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/26\">",
"      Hannan N, Ghosh P, Bellenger C, Taylor T. Systemic administration of glycosaminoglycan polysulphate (arteparon) provides partial protection of articular cartilage from damage produced by meniscectomy in the canine. J Orthop Res 1987; 5:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/27\">",
"      Olijhoek G, Drukker J, van der Linden TJ, Terwindt-Rouwenhorst EA. Drug effects on arthrosis. Comparison in rabbits of 3 modes of action. Acta Orthop Scand 1988; 59:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/28\">",
"      Kannus P, Natri A, Niittym&auml;ki S, J&auml;rvinen M. Effect of intraarticular glycosaminoglycan polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double-blind trial comparing glycosaminoglycan polysulfate with placebo and quadriceps muscle exercises. Arthritis Rheum 1992; 35:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/29\">",
"      Spencer CM, Wilde MI. Diacerein. Drugs 1997; 53:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/30\">",
"      Pelletier JP, Mineau F, Fernandes JC, et al. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998; 25:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/31\">",
"      Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1999; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/32\">",
"      Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; :CD005117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/33\">",
"      Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006; 166:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/34\">",
"      Pham T, Le Henanff A, Ravaud P, et al. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004; 63:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/35\">",
"      Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001; 44:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/36\">",
"      Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010; 363:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9687/abstract/37\">",
"      Wood JN. Nerve growth factor and pain. N Engl J Med 2010; 363:1572.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5493 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9687=[""].join("\n");
var outline_f9_29_9687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H106453431\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34171215\">",
"      TOPICAL NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34171222\">",
"      COUNTER-IRRITANTS AND RUBEFACIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34171229\">",
"      Capsaicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34171236\">",
"      Rubefacients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TETRACYCLINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MODULATION OF CARTILAGE CONSTITUENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIACEREIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2074724\">",
"      TANEZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106453431\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=related_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_29_9688="Pathogenesis of common variable immunodeficiency";
var content_f9_29_9688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of common variable immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Sam Ahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Lloyd Mayer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Charlotte Cunningham-Rundles, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9688/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9688/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/29/9688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID) is a heterogeneous immune disorder characterized by recurrent sinopulmonary infections, autoimmune disorders, granulomatous disease, and an enhanced risk of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVID is defined by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markedly reduced serum concentrations of IgG, in combination with low levels of IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM",
"     </li>",
"     <li>",
"      Poor or absent response to immunization",
"     </li>",
"     <li>",
"      An absence of any other defined immunodeficiency state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of CVID will be reviewed here. The clinical manifestations, diagnosis, and management of CVID are discussed separately. Special issues in children are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"     \"Treatment and prognosis of common variable immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CVID has been recognized since the 1950s, its pathophysiology remains incompletely understood despite dramatic advances in the molecular elucidation of many other primary immunodeficiency diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/7\">",
"     7",
"    </a>",
"    ]. The clinical heterogeneity of CVID suggests that multiple immunoregulatory defects can result in the final common pathway of hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. The entity now called CVID will probably prove to be a group of disorders with a common endpoint of defective immunoglobulin production and dysregulated immune responses.",
"   </p>",
"   <p>",
"    The hallmark immune defect in CVID is failed B cell differentiation with impaired secretion of immunoglobulin. However, CVID is associated with a high incidence of inflammatory, autoimmune, and malignant conditions, whereas these disorders are not observed in X-linked agammaglobulinemia (XLA), a disease that specifically affects B cell development [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/10\">",
"     10",
"    </a>",
"    ]. This suggests that CVID represents a more global form of immune dysfunction. Accordingly, several deficits in T cell function and cytokine production have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     B CELL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall B cell number is usually normal, although many patients have reduced percentages of isotype switched memory B cells (and also plasma cells) capable of producing antigen-specific IgG and IgM, immunoglobulin isotypes that are critical for recall (or secondary) antibody responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Toll like receptor signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell maturation is defective in patients with CVID, and the function of toll-like receptor TLR7 and TLR9 on both B cells and dendritic cells is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Normally, B cell responses may be initiated by binding of viral RNA to TLR7 or bacterial DNA to TLR9, both of which lead to B cell activation, cytokine secretion, proliferation, and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/13\">",
"     13",
"    </a>",
"    ]. The loss of these stimuli may contribute to the B cell defects observed. The relevance of impaired TLR9 dysfunction in CVID was demonstrated in a study showing that stimulation with microbial extracts from Streptococcus pneumoniae and Haemophilus influenzae resulted in impaired activation and proliferation of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the mechanism(s) by which TLR function is impaired is not yet defined. The normal development of B cells and the cellular interactions that are necessary for normal antibody production in response to an antigenic challenge are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Memory B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Memory B cells in humans can be identified by the presence of CD27, a member of the tumor necrosis factor (TNF) receptor gene family (that is also found on a subset of T lymphocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/15\">",
"     15",
"    </a>",
"    ]. Memory B cells can be subdivided into those cells that have not yet undergone isotype switching and produce predominantly IgM (CD27+IgM+IgD+), and those that have isotype switched (CD27+IgM-IgD-) and synthesize IgG, IgM, or IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have attempted to identify and classify CVID patients based on numbers of isotype switched memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study proposed that &lt;0.4 percent switched CD27+IgM-IgD- memory B cells based on total blood lymphocytes (compared to healthy donors at 1.6 percent&thinsp;&plusmn;&thinsp;0.6 percent) could be used to classify patients with CVID, as these patients had a higher prevalence of splenomegaly and autoimmune cytopenias [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study classified CVID patients into three groups based on different subpopulations of memory B cells, and found that certain disorders that are seen in patients with CVID (eg, splenomegaly, lymphoid proliferation, and granulomatous disease) were more prevalent in patients with the lowest numbers of memory B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subsequently, a study of 105 patients with CVID found that a level of &lt;0.55 percent switched memory B cells based on total blood lymphocytes, was an independent risk factor for autoimmune disease, granuloma formation, and splenomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/18\">",
"       18",
"      </a>",
"      ]. In addition, female patients were found to have significantly higher levels of memory B cells.",
"     </li>",
"     <li>",
"      Lower levels of circulating IgM memory B cells and poor anti-pneumococcal polysaccharide IgM responses were associated with recurrent bacterial pneumonia and the development of bronchiectasis in patients with CVID [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/19\">",
"       19",
"      </a>",
"      ]. In contrast, CVID patients with no chronic pulmonary disease had relatively normal measurements of these two parameters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER CELLULAR ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other cellular abnormalities in CVID include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/1,20-28\">",
"     1,20-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased T lymphocyte proliferation to mitogens and antigens (demonstrated in approximately 40 percent of patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/1\">",
"       1",
"      </a>",
"      ]. Phytohemagglutinin, pokeweed, and concanavalin A are used to measure mitogen response; candida albicans and tetanus toxoid are used to measure antigen response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"       \"Laboratory evaluation of the immune system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T cell ratio due to a decrease in CD4+ cells or an increase in the absolute number of CD8+ cells in some. Those with the most reduced numbers (&lt;200 x 10^6",
"      <span class=\"nowrap\">",
"       cells/L)",
"      </span>",
"      may have opportunistic infections and a higher prevalence of splenomegaly, granulomatous disease, gastrointestinal disease, and lymphoma. The term late-onset combined immunodeficiency (LOCID) has been proposed for this subset [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with increased numbers of CD8+ cells, chronic infection with cytomegalovirus (CMV) has been proposed to play a role in the pathogenesis of inflammatory disease, such as granulomatous disorders and enteropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced numbers of T regulatory cells in a subset of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced numbers of T cell receptor excision circles (TRECS), suggesting thymic dysregulation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deficiency of antigen-primed T cells.",
"     </li>",
"     <li>",
"      Reduced T cell production or expression of IL-2 and other cytokines.",
"     </li>",
"     <li>",
"      Defective T cell receptor signal transduction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced capacity of dendritic cells to secrete IL-12 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of plasma cells in tissue such as the gastrointestinal tract and bone marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum levels of transmembrane activator and calcium-modulator and cyclophilin ligand (TACI), its ligand a proliferation inducting ligand (APRIL), and B cell activating factor of the tumor necrosis factor family (BAFF), can be markedly elevated in patients with CVID, although the biologic significance of these findings is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/38\">",
"     38",
"    </a>",
"    ]. Elevations in these proteins are also found in several rheumatologic disorders and hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHENOTYPIC APPROACH TO CATEGORIZING PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phenotypic approach to categorizing CVID has been proposed, based upon the type of complications the patient develops. This arose from an analysis of the European Common Variable Immunodeficiency Disorders registry (composed of patients from nine centers in Europe and the United Kingdom), in which 334 patients with CVID were followed for an average of 26 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/42\">",
"     42",
"    </a>",
"    ]. Five phenotypic categories were proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with no complications",
"     </li>",
"     <li>",
"      Patients with autoimmune disease",
"     </li>",
"     <li>",
"      Patients with lymphocytic organ infiltration (ie, lymphocytic enteropathy, granulomas, unexplained hepatomegaly, persistent lymphadenopathy, splenomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymphoid interstitial pneumonitis)",
"     </li>",
"     <li>",
"      Patients with predominant enteropathy",
"     </li>",
"     <li>",
"      Patients with lymphoid malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 80 percent of patients had just one of these phenotypes. The best and worst prognoses were seen in patients with no complications and malignancy, respectively. Patients with lymphocytic organ infiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    higher levels of serum IgM were at the highest risk (fivefold) of eventually developing lymphoid malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/42\">",
"     42",
"    </a>",
"    ]. In a cohort of 473 patients with CVID followed over four decades, noninfectious complications were observed in 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/43\">",
"     43",
"    </a>",
"    ]. The risk of death was 11 times higher for patients with noninfectious complications (hazard ratio = 10.95). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment and prognosis of common variable immunodeficiency\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional in vitro abnormalities have been reported, although these have not been as well characterized as those discussed above. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accelerated peripheral B cell apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased serum TNF-alpha and soluble TNF receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Defective T cell activation from impairment of TNF-RII co-signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased levels of CD30, which is expressed on activated T cells, though the clinical implication of this is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of patients with CVID appear to have disease that has resulted from a sporadic mutation, while 10 percent of patients have at least one family member with either CVID or selective IgA deficiency and demonstrate a familial pattern of inheritance (both autosomal dominant and autosomal recessive) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family members of patients with CVID may have an array of humoral immune abnormalities, including CVID, selective IgA deficiency, IgG subclass deficiency, selective antibody deficiency with normal immunoglobulins, and relative hypogammaglobulinemia (ie, less than 2 SDs below normal levels). The relationship between CVID and IgA deficiency suggests that the two clinical disorders may represent an allelic condition reflecting the variable expression of a common defect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mutations in specific molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic defects have been demonstrated in patients with CVID, each of which affects the normal processes of B cell maturation and differentiation into memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Aside from defects in TACI, mutations in these cases have been quite rare and for the most part, found in families with consanguineous inheritance. Defects in the following molecules have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       TACI",
"      </strong>",
"      - Transmembrane activator and calcium-modulator and cyclophilin ligand (TACI), is encoded on chromosome 17p and expressed on B cells and activated CD4+ T cells. TACI mediates isotype switching through its ligand, a proliferation inducting ligand (APRIL) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/56\">",
"       56",
"      </a>",
"      ]. The gene encoding TACI is called tumor necrosis factor receptor superfamily 13B (TNFRSF13B). Mutations in this gene appear to induce susceptibility to CVID, rather than directly causing the disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/57-60\">",
"       57-60",
"      </a>",
"      ]. Various mutations in this gene have been found in 8 to 9 percent of CVID patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/61-65\">",
"       61-65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       ICOS",
"      </strong>",
"      - Inducible co-stimulator of activated T cells (ICOS) is expressed on activated T cells and encoded on chromosome 2q [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. The signaling generated by ligation of ICOS and its ligand is important in activating type 1 and 2 T helper cells, and in allowing T and B cells to cooperate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/68\">",
"       68",
"      </a>",
"      ]. A homozygous deficiency resulted from autosomal recessive inheritance in one extended kindred.",
"     </li>",
"     <li>",
"      <strong>",
"       BAFF-R",
"      </strong>",
"      - B cell activating factor of the tumor necrosis factor family receptor (BAFF-R), encoded on chromosome 22q, was defective in two siblings in one family [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/69\">",
"       69",
"      </a>",
"      ]. Both adult siblings had lower IgG and IgM serum levels, but unlike most CVID patients, normal IgA concentrations. They also did not mount a T-independent immune response against pneumococcal cell wall polysaccharides, although only one BAFF-R-deficient sibling developed recurrent infections.",
"     </li>",
"     <li>",
"      <strong>",
"       CD19",
"      </strong>",
"      - Homozygous or compound heterozygous mutations in the CD19 gene on chromosome 16p can give rise to the CVID phenotype as shown in a few cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. Early B cell development is apparently normal [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/70\">",
"       70",
"      </a>",
"      ]. CD19 is part of the co-receptor complex associated with the B cell receptor and normally lowers the antigenic threshold for activation of B cells through this receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CD81",
"      </strong>",
"      - A homozygous deletion in the CD81 gene was shown to be a phenocopy of CD19 deficiency, with decreased memory B cell numbers, impaired specific antibody responses, and an absence of CD19 expression on B cells in one patient. CD19, required for stabilization of the B cell antigen receptor, requires CD81 for expression [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CD20",
"      </strong>",
"      - A homozygous mutation in a splice junction of the CD20 gene led to CD20 deficiency and impaired T cell-independent (TI) antibody responses in one child [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CD21",
"      </strong>",
"      &ndash; A heterozygous mutation in the CD21 gene was described in a 28 year old man with recurrent respiratory tract infections, hypogammaglobulinemia, chronic diarrhea, and splenomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The functions of TACI, BAFF-R, CD19, CD20, and CD21 in B cell activation and maturation to memory B cells are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HLA association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies involving families with an autosomal dominant pattern of inheritance and multiple affected family members failed to demonstrate an HLA association [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/76\">",
"     76",
"    </a>",
"    ]. However, a tentative susceptibility locus in the class",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    region of the MHC has been identified in case-control HLA association and linkage analysis studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/49\">",
"     49",
"    </a>",
"    ]. Differential expression of Msh5, a gene encoded in the MHC class III region that has a role in regulating homologous recombination, can lead to dysregulated Ig class switch recombination (CSR) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/77\">",
"     77",
"    </a>",
"    ]. However, Msh5 knockout mice did not show antibody deficiency, further supporting a multigenic etiology for CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8338983\">",
"    <span class=\"h2\">",
"     Genome wide association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genome-wide association (GWAs) and gene copy number variation (CNV) study in patients with CVID found a strong association with the MHC region and associations with a disintegrin and metalloproteinase (ADAM) genes, among others. In addition, CNV analysis defined 16 disease-associated deletions and duplications, suggesting that CVID may result from a variety of gene defects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9688/abstract/78\">",
"     78",
"    </a>",
"    ]. The interpretation of genetic association studies is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by markedly reduced serum levels of IgG",
"    <strong>",
"     AND",
"    </strong>",
"    low IgA or IgM, with impaired antibody responses, despite the presence of B cells. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disorder is characterized by defective B cell differentiation with impaired secretion of immunoglobulin. However, CVID is associated with a high incidence of inflammatory, autoimmune, and malignant conditions, features of more fundamental immune dysregulation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall B cell numbers are normal in approximately 90 percent of subjects with CVID. Many patients have low percentages of isotype switched memory B cells (and also plasma cells) capable of producing antigen-specific IgG and IgM, immunoglobulin isotypes that are critical for recall (or secondary) antibody responses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'B cell abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell abnormalities include a low",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T cell ratio (present in a subset of patients) and impaired responses to mitogens and antigens. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other cellular abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CVID appears to result from a variety of gene defects, most of which are sporadic rather than familial. A small number of these have been described, which together are found in 10 to 15 percent of CVID patients. These include defects in ICOS, TACI, BAFF-R, CD19, CD20, CD21, and CD81. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/1\">",
"      Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/2\">",
"      Primary immunodeficiency diseases. Report of a WHO scientific group. Clin Exp Immunol 1997; 109 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/3\">",
"      Spickett GP, Farrant J, North ME, et al. Common variable immunodeficiency: how many diseases? Immunol Today 1997; 18:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/4\">",
"      Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/5\">",
"      Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/6\">",
"      Sneller MC, Strober W, Eisenstein E, et al. NIH conference. New insights into common variable immunodeficiency. Ann Intern Med 1993; 118:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/7\">",
"      JANEWAY CA, APT L, GITLIN D. Agammaglobulinemia. Trans Assoc Am Physicians 1953; 66:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/8\">",
"      Saiki O, Ralph P, Cunningham-Rundles C, Good RA. Three distinct stages of B-cell defects in common varied immunodeficiency. Proc Natl Acad Sci U S A 1982; 79:6008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/9\">",
"      Bryant A, Calver NC, Toubi E, et al. Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin Immunol Immunopathol 1990; 56:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/10\">",
"      Gaspar HB, Kinnon C. X-linked agammaglobulinemia. Immunol Allergy Clin North Am 2001; 21:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/11\">",
"      Cunningham-Rundles C, Radigan L, Knight AK, et al. TLR9 activation is defective in common variable immune deficiency. J Immunol 2006; 176:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/12\">",
"      Yu JE, Knight AK, Radigan L, et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J Allergy Clin Immunol 2009; 124:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/13\">",
"      Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/14\">",
"      Escobar D, Pons J, Clemente A, et al. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cell Immunol 2010; 262:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/15\">",
"      Tangye SG, Liu YJ, Aversa G, et al. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998; 188:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/16\">",
"      Warnatz K, Denz A, Dr&auml;ger R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 2002; 99:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/17\">",
"      Piqueras B, Lavenu-Bombled C, Galicier L, et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 2003; 23:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/18\">",
"      S&aacute;nchez-Ram&oacute;n S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol 2008; 128:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/19\">",
"      Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/20\">",
"      Cunningham-Rundles S, Cunningham-Rundles C, Siegal FP, et al. Defective cellular immune response in vitro in common variable immunodeficiency. J Clin Immunol 1981; 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/21\">",
"      North ME, Spickett GP, Allsop J, et al. Defective DNA synthesis by T cells in acquired 'common-variable' hypogammaglobulinaemia on stimulation with mitogens. Clin Exp Immunol 1989; 76:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/22\">",
"      Stagg AJ, Funauchi M, Knight SC, et al. Failure in antigen responses by T cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol 1994; 96:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/23\">",
"      Kondratenko I, Amlot PL, Webster AD, Farrant J. Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. MRC Immunodeficiency Group. Clin Exp Immunol 1997; 108:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/24\">",
"      Kruger G, Welte K, Ciobanu N, et al. Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol 1984; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/25\">",
"      Pastorelli G, Roncarolo MG, Touraine JL, et al. Peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) produce reduced levels of interleukin-4, interleukin-2 and interferon-gamma, but proliferate normally upon activation by mitogens. Clin Exp Immunol 1989; 78:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/26\">",
"      Sneller MC, Strober W. Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol 1990; 144:3762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/27\">",
"      Spickett GP, Farrant J. The role of lymphokines in common variable hypogammaglobulinemia. Immunol Today 1989; 10:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/28\">",
"      Wright JJ, Wagner DK, Blaese RM, et al. Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood 1990; 76:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/29\">",
"      Malphettes M, G&eacute;rard L, Carmagnat M, et al. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009; 49:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/30\">",
"      Marashi SM, Raeiszadeh M, Workman S, et al. Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. J Allergy Clin Immunol 2011; 127:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/31\">",
"      Marashi SM, Raeiszadeh M, Enright V, et al. Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. J Allergy Clin Immunol 2012; 129:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/32\">",
"      Horn J, Manguiat A, Berglund LJ, et al. Decrease in phenotypic regulatory T cells in subsets of patients with common variable immunodeficiency. Clin Exp Immunol 2009; 156:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/33\">",
"      Yu GP, Chiang D, Song SJ, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol 2009; 131:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/34\">",
"      Serana F, Air&ograve; P, Chiarini M, et al. Thymic and bone marrow output in patients with common variable immunodeficiency. J Clin Immunol 2011; 31:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/35\">",
"      Fischer MB, Hauber I, Eggenbauer H, et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood 1994; 84:4234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/36\">",
"      Cunningham-Rundles C, Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clin Immunol 2005; 115:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/37\">",
"      Ochtrop ML, Goldacker S, May AM, et al. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood 2011; 118:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/38\">",
"      Knight AK, Radigan L, Marron T, et al. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol 2007; 124:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/39\">",
"      Nakajima K, Itoh K, Nagatani K, et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/40\">",
"      Matsushita T, Fujimoto M, Hasegawa M, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007; 34:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/41\">",
"      Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sj&ouml;gren's syndrome. Scand J Immunol 2008; 67:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/42\">",
"      Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/43\">",
"      Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/44\">",
"      Guo BC, Saxon A. B cell lines from a subset of patients with common variable immunodeficiency undergo enhanced apoptosis associated with an increased display of CD95 (Apo-1/fas), diminished CD38 expression, and decreased IgG and IgA production. Cell Immunol 1995; 166:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/45\">",
"      Aukrust P, Lien E, Kristoffersen AK, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences. Blood 1996; 87:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/46\">",
"      Aukrust P, Berge RK, M&uuml;ller F, et al. Elevated plasma levels of reduced homocysteine in common variable immunodeficiency--a marker of enhanced oxidative stress. Eur J Clin Invest 1997; 27:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/47\">",
"      Aspalter RM, Eibl MM, Wolf HM. Defective T-cell activation caused by impairment of the TNF receptor 2 costimulatory pathway in common variable immunodeficiency. J Allergy Clin Immunol 2007; 120:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/48\">",
"      Rezaei N, Haji-Molla-Hoseini M, Aghamohammadi A, et al. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol 2008; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/49\">",
"      Vorechovsk&yacute; I, Cullen M, Carrington M, et al. Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000; 164:4408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/50\">",
"      Burrows PD, Cooper MD. IgA deficiency. Adv Immunol 1997; 65:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/51\">",
"      Castigli E, Geha RS. Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol 2006; 117:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/52\">",
"      Kopeck&yacute; O, Lukesov&aacute; S. Genetic defects in common variable immunodeficiency. Int J Immunogenet 2007; 34:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/53\">",
"      Bacchelli C, Buckridge S, Thrasher AJ, Gaspar HB. Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency. Clin Exp Immunol 2007; 149:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/54\">",
"      Sch&auml;ffer AA, Pfannstiel J, Webster AD, et al. Analysis of families with common variable immunodeficiency (CVID) and IgA deficiency suggests linkage of CVID to chromosome 16q. Hum Genet 2006; 118:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/55\">",
"      van de Ven AA, van de Corput L, van Tilburg CM, et al. Lymphocyte characteristics in children with common variable immunodeficiency. Clin Immunol 2010; 135:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/56\">",
"      Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/57\">",
"      Poodt AE, Driessen GJ, de Klein A, et al. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol 2009; 156:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/58\">",
"      Pan-Hammarstr&ouml;m Q, Salzer U, Du L, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet 2007; 39:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/59\">",
"      Castigli E, Wilson S, Garibyan L, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet 2007; 39:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/60\">",
"      Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009; 27:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/61\">",
"      Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/62\">",
"      Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/63\">",
"      Garibyan L, Lobito AA, Siegel RM, et al. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest 2007; 117:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/64\">",
"      Salzer U, Bacchelli C, Buckridge S, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 2009; 113:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/65\">",
"      Lougaris V, Gallizzi R, Vitali M, et al. A novel compound heterozygous TACI mutation in an autosomal recessive common variable immunodeficiency (CVID) family. Hum Immunol 2012; 73:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/66\">",
"      Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/67\">",
"      Salzer U, Maul-Pavicic A, Cunningham-Rundles C, et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 2004; 113:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/68\">",
"      Nurieva RI, Duong J, Kishikawa H, et al. Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity 2003; 18:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/69\">",
"      Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A 2009; 106:13945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/70\">",
"      van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/71\">",
"      Kanegane H, Agematsu K, Futatani T, et al. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun 2007; 8:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/72\">",
"      Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/73\">",
"      van Zelm MC, Smet J, Adams B, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/74\">",
"      Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/75\">",
"      Thiel J, Kimmig L, Salzer U, et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol 2012; 129:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/76\">",
"      Nijenhuis T, Klasen I, Weemaes CM, et al. Common variable immunodeficiency (CVID) in a family: an autosomal dominant mode of inheritance. Neth J Med 2001; 59:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/77\">",
"      Sekine H, Ferreira RC, Pan-Hammarstr&ouml;m Q, et al. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A 2007; 104:7193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9688/abstract/78\">",
"      Orange JS, Glessner JT, Resnick E, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 2011; 127:1360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3904 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9688=[""].join("\n");
var outline_f9_29_9688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      B CELL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Toll like receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Memory B cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER CELLULAR ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHENOTYPIC APPROACH TO CATEGORIZING PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mutations in specific molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HLA association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8338983\">",
"      Genome wide association studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_29_9689="Endovascular devices for abdominal aortic repair";
var content_f9_29_9689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endovascular devices for abdominal aortic repair",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Rabih A Chaer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9689/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9689/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/29/9689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1191828461\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aortic repair requires that specific anatomic criteria are fulfilled, and, for those with appropriate anatomy, this technique has become a preferred approach and allows the treatment of patients who might not otherwise be candidates for surgical aortic repair due to medical comorbidities.",
"   </p>",
"   <p>",
"    Endovascular repair with abdominal stent-graft devices is primarily used to treat infrarenal abdominal aortic aneurysm with or without associated iliac artery aneurysm. Although not yet approved for clinical use in the United States, branched and fenestrated endovascular aortic devices have been developed to allow perfusion into specific aortic branches depending upon the level of repair (eg, renal artery, internal iliac artery). These advanced devices allow endovascular management of juxtarenal and potentially suprarenal aneurysms, and preservation of hypogastric flow when an adequate landing zone in the common iliac artery is not present.",
"   </p>",
"   <p>",
"    The placement of aortic endovascular grafts is associated with device-related complications, which can include component disconnection, stent-graft buckling and migration over time. Secondary intervention is frequently needed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As such, these devices require lifelong surveillance; the long-term outcomes for these devices continue to be studied.",
"   </p>",
"   <p>",
"    The specific devices available for endovascular repair of the abdominal aorta will be reviewed here. The indications for, placement of, and complications of these devices are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191837832\">",
"    <span class=\"h1\">",
"     AORTIC ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aorta is the major arterial conduit conveying blood from the heart to the systemic circulation. It originates immediately beyond the aortic valve ascending initially, then curving to form the aortic arch, and finally descending caudally adjacent the spine. The descending thoracic aorta continues through the hiatus of the diaphragm to become the abdominal aorta which extends retroperitoneally to its bifurcation into the common iliac arteries at the level of the fourth lumbar vertebra. The abdominal aorta lies slightly left of the midline to accommodate the inferior vena cava which is in close apposition. The branches of the abdominal aorta (superior to inferior) (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 1",
"    </a>",
"    ) include the left and right inferior phrenic arteries, left and right middle suprarenal arteries, the celiac axis, superior mesenteric artery, left and right renal arteries in addition to occasional accessory renal arteries, left and right gonadal arteries, inferior mesenteric artery, the paired lumbar arteries (L1-L4) and middle sacral artery. The abdominal aorta bifurcates into the left and right common iliac arteries, which most often arise at the level of the 4",
"    <sup>",
"     th",
"    </sup>",
"    lumbar vertebra. The common iliac artery bifurcates into the external iliac and internal iliac arteries at the pelvic inlet. The internal iliac artery has superior and inferior divisions that supply the pelvic viscera and muscles. The external iliac artery passes beneath the inguinal ligament to become the common femoral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191837912\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular aneurysm repair refers to the insertion of endovascular graft components (",
"    <a class=\"graphic graphic_figure graphicRef50772 \" href=\"UTD.htm?13/21/13663\">",
"     figure 2",
"    </a>",
"    ), usually via a femoral approach. The endovascular graft is constructed by the in vivo delivery and deployment of the device components in an established order determined by the specific anatomy of the patient. Upon deployment, the endograft expands, contacting the aortic wall proximally and aorta or iliac vessels distally, excluding the aneurysmal aortic wall from blood flow and pressure.",
"   </p>",
"   <p>",
"    Although there are significant variations in endovascular graft design, three types of components are common to all: a delivery system, main body device, and device (limb) extensions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620227127\">",
"    <span class=\"h2\">",
"     Delivery system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various endograft components are typically delivered through the femoral artery, either by direct surgical cutdown or percutaneously. If the femoral artery is too small to accommodate the delivery system, access can be obtained by suturing a synthetic graft of appropriate diameter (often 10 mm) to the common iliac artery to create an iliac conduit through a retroperitoneal incision. The size of the delivery system varies depending upon the device diameter required to provide proper endograft fixation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620227120\">",
"    <span class=\"h2\">",
"     Main device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main body device for the abdominal aorta is usually bifurcated. Endovascular grafts rely primarily upon outward tension in the proximal graft to maintain the positioning of the graft. Fixation systems may also include barbs or a suprarenal uncovered extension. Bifurcated abdominal aortic grafts require adjunctive placement of iliac artery limbs to complete the graft. The iliac limbs on the main body device vary in length depending upon whether the graft is a two- or three-component graft. Two-component grafts have one short and one long iliac limb. Three-component devices have two short limbs.",
"   </p>",
"   <p>",
"    Endovascular grafts for the abdominal aorta are generally bifurcated; however, some situations require the use of a unibody (ie, not bifurcated) graft, also known as an aorta-uni-iliac (AUI) device. These grafts are used in patients with severe unilateral iliac artery stenosis or occlusion. AUI devices can also be used for the treatment of some ruptured aneurysms. A bifurcated-to-unilateral graft conversion kit can be used in the situation when contralateral iliac artery access or contralateral gate cannulation is difficult or impossible. This kit effectively turns a bifurcated main body graft into a unilateral graft by covering one of the iliac limbs proximally. After deployment of an AUI device, a plug may be inserted into the contralateral iliac artery to prevent retrograde flow of blood into the aneurysm sac, if needed. The contralateral extremity typically requires a femoro-femoral crossover bypass for perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H441029#H441029\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Choice of graft'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H2369876151#H2369876151\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Endograft placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620227113\">",
"    <span class=\"h2\">",
"     Extensions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more extension devices may be needed to provide a complete proximal or distal seal. Following the deployment of the main device and any necessary contralateral limbs or extensions, an aortogram is performed to assure that the endograft has completely excluded the aneurysm from the circulation. The term &ldquo;endoleak&rdquo; was coined to describe the persistence of blood flow into the aneurysm. If additional ballooning of the device does not firmly appose the graft to the aortic wall and eliminate a type I endoleak, placement of additional proximal aortic or iliac extensions may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191828485\">",
"    <span class=\"h1\">",
"     ABDOMINAL DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal endovascular devices are increasingly being used as a minimally-invasive alternative to open surgical repair of the aorta. The main indication for these devices is treatment of abdominal aortic aneurysm. Endovascular repair of the abdominal aorta has also been used to treat isolated infrarenal aortic dissection, traumatic aortic injuries, and aortic atheroembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Endovascular grafts for the abdominal aorta are generally modular, bifurcated devices; however, an aorta-uni-iliac (AUI) device or bifurcated-to-unilateral graft conversion kit may be needed. (See",
"    <a class=\"local\" href=\"#H620227120\">",
"     'Main device'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Controlled comparisons of abdominal aortic stent-grafts have not been performed. Devices available to treat the abdominal aorta include the AneuRx&reg;, Zenith&reg;, Excluder&reg;, AFX and Powerlink&reg;, Talent&reg;, and Endurant&reg; grafts (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ). A number of investigational devices are in early clinical testing phases. The essential features of the grafts approved for use in the United States and clinical data supporting them are discussed below. &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829325\">",
"    <span class=\"h2\">",
"     AneuRx&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AneuRx&reg; AAAdvantage&reg; stent-graft (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) is a modular, bifurcated graft of woven polyester sutured to and supported by a self-expanding nitinol exoskeleton introduced as a second-generation device in 2008 with alterations to the delivery system.",
"   </p>",
"   <p>",
"    The main device is available in diameters that range from 20 to 28 mm for the main body and 12 to 16 mm for the ipsilateral limb, and in lengths of 13.5 or 16.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/7\">",
"     7",
"    </a>",
"    ]. The contralateral iliac stent component ranges from 12 to 16 mm in diameter with 8.5 and 11.5 cm lengths. The internal diameter of the delivery sheath for all the bifurcated grafts is 21 French (7 mm) and the sheaths for other components range from 15 to 19 French (5 to 6.33 mm).",
"   </p>",
"   <p>",
"    The AneuRx&reg; stent graft was approved for use in the United States in 1999 based upon the outcomes of phase II trials that included 1192 patients, 1019 of whom received the device configuration that is currently marketed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    The",
"    <sup>",
"    </sup>",
"    early stiff graft design used in phase I and early phase II studies was replaced with a more flexible, segmented graft.",
"   </p>",
"   <p>",
"    The Phase II trial was a prospective, nonrandomized study that compared endovascular repair using the AneuRx&reg; stent graft with standard open surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The AneuRx&reg; stent graft was associated with a significant reduction in surgical blood loss, decreased transfusion requirements, decreased length of intensive-care unit (ICU) stay, earlier return of gastrointestinal function, and earlier time to discharge. Two intraoperative ruptures were reported (0.17 percent) and three patients suffered from postoperative aneurysm rupture (&lt;30 days, 0.25 percent). Compared with open surgical repair, the risk of major complications was reduced in the endovascular group (12 versus 23 percent), including myocardial infarction, stroke, arrhythmia, and renal failure. Kaplan-Meier analysis of the endograft group found a freedom from all-cause rupture of 99.5 percent at one year, 98.5 percent at two years, 98.4 percent at three years, and 98.4 percent at four years. Freedom from surgical conversion was 98.5 percent at one year, 96.9 percent at two years, 94.2 percent at three years, and 90.4 percent at four years. In spite of a low aneurysm-related mortality, all-cause mortality at four years in the endovascular group was 37.6 percent, reflecting the severity of comorbidities and high-risk of this group of patients.",
"   </p>",
"   <p>",
"    Using a subgroup of the patient cohort from Medtronic's investigational premarket study, aneurysm-related mortality with the AneuRx&reg; graft was evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/11\">",
"     11",
"    </a>",
"    ]. The perioperative (30-day) death rate was 1.61 percent. Among 931 patients followed for an average of 3.48 years, the rate of abdominal aortic aneurysm-related mortality was 0.18 percent after 3 years (excluding perioperative deaths), and 1.39 percent thereafter. The authors concluded that the longer-term mortality associated with implantation of an AneuRx&reg; graft (as determined in this study) probably exceeds the mortality rate of open repair (based on historical data) at some point in time, likely about four years after implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829332\">",
"    <span class=\"h2\">",
"     Zenith&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Zenith&reg; abdominal endograft (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) is a bifurcated, modular, three-component system. It is composed of woven polyester (ie, Dacron&reg;) sutured to stainless steel Gianturco Z-stents, with a bare suprarenal stent for active fixation of the proximal graft.",
"   </p>",
"   <p>",
"    The main body is available in diameters that range from 22 to 36 mm and lengths that range from 82 to 149 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/12\">",
"     12",
"    </a>",
"    ]. The iliac limbs are available in 8 and 24 mm diameters in lengths ranging from 3.7 to 12.4 cm. The delivery sheath for bifurcated grafts is between 18 and 20 French (6.0 to 7.67 mm) depending upon the size of the graft, and the sheaths for other components range from 14 to 16 French (3.67 to 5.33 mm).",
"   </p>",
"   <p>",
"    The safety and efficacy of the Zenith abdominal endograft was evaluated in a comparison study involving 352 patients in four study groups: an open surgical control group, a standard-risk (SR) group, a high-risk group, and a roll-in group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/13\">",
"     13",
"    </a>",
"    ]. Eighty control patients were enrolled with the intent of comparing them with the standard repair endovascular group. The technical success rate for endovascular repair was 99.7 percent. Perioperative (30-day) morbidity (cardiac, pulmonary, renal) was significantly decreased compared with the control group. Endovascular repair was also associated with fewer transfusion requirements, diminished blood loss, shorter length of hospital and intensive care unit stay, and quicker return to daily activities. Perioperative (30-day) mortality was significantly lower in the endovascular repair group (0.5 versus 2.5 percent) compared with the open surgical group. At one year of follow-up, all-cause mortality was not significantly different between the groups (3.5 percent in the standard risk endovascular repair group versus 3.8 percent in the control group). There were no significant differences in all-cause mortality or aneurysm-related death between the standard risk endovascular group and the control group on Kaplan-Meier analysis.",
"   </p>",
"   <p>",
"    There were no immediate conversions reported, but three late conversions were performed: one for endoleak, one for a rapidly expanding supraceliac pseudoaneurysm, and one for rupture at 222 days postoperatively. The need for reintervention was significantly higher (11 versus 2.5 percent) for the standard risk endograft group compared with the control group at one year follow-up. The incidence of endoleak (mostly Type II) was 7.4 percent at 12 months and 5.4 percent at 24 months. Migration was not seen in any patient after 12 months. At two years follow-up, the majority of the aneurysms demonstrated shrinkage of the aneurysm sac.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829339\">",
"    <span class=\"h2\">",
"     Excluder&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Excluder&reg; device (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) is a self-expanding modular bifurcated two-component graft made of expanded polytetrafluoroethylene (ePTFE) material bonded to a nitinol exoskeleton and covered with a reinforcing sleeve of",
"    <span class=\"nowrap\">",
"     ePTFE/fluorinated",
"    </span>",
"    ethylene propylene (FEP) composite film. The proximal graft and ipsilateral limb have scalloped flares lined with graft material. The proximal graft and distal limbs have an ePTFE sealing cuff to improve apposition to the arterial wall.",
"   </p>",
"   <p>",
"    The main body graft is available in diameters ranging from 23 to 31 mm with an ipsilateral limb measuring 12 or 14.5 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/14\">",
"     14",
"    </a>",
"    ]. The length of the body of the graft ranges from 12 to 18 cm. The contralateral limb is available in diameters ranging from 12 to 20 mm and lengths from 9.5 to 13.5 cm. The main device is delivered in an 18 or 20 French (6 to 6.67 mm) sheath. The device employs a unique delivery system that relies upon a pull-cord similar to a dog food bag. Once the device is positioned, the deployment line unlaces from the middle of the device toward both ends.",
"   </p>",
"   <p>",
"    The safety and efficacy of the Excluder&reg; graft was evaluated in a prospective nonrandomized trial that enrolled 334 patients (235 endovascular and 99 open surgical control patients) in 19 different centers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared with the control group, the Excluder&reg; group had less blood loss, shorter length of hospital stay, and decreased length of recovery. At one-year and two-year follow-up, the Excluder&reg; group had a significantly lower incidence of major complications (33 versus 67 percent). There were no significant differences between the groups in survival rate at two-year follow-up. In the Excluder&reg; group, the incidence of aneurysm-related death was 2.6 percent, but there were no late aneurysm ruptures at four-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aneurysm sac enlargement, defined as &ge;5 mm change from baseline size, occurred in 3 and 36 percent of patients at one and five years, respectively, after graft placement in the Excluder&reg; 98-03 Pivotal Trial, the majority occurring without any apparent endoleaks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/17\">",
"     17",
"    </a>",
"    ]. This phenomenon led the company to release an updated version of the Excluder&reg; device in July 2004. The new device incorporated the additional low-permeability layer (FEP) to reduce exudation of fluid flow across the graft material. Following these improvements, minimal aneurysm sac expansion and significant aneurysm sac regression have been found after endovascular repair of abdominal aortic aneurysms using the new Excluder&reg; device at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/18\">",
"     18",
"    </a>",
"    ], and with longer follow-up at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829346\">",
"    <span class=\"h2\">",
"     AFX and Powerlink&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AFX and IntuiTrak Powerlink&reg; systems (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) are modular bifurcated grafts composed of expanded polytetrafluoroethylene (ePTFE) supported by a self-expanding internal cobalt-chromium alloy skeleton. The main body of the endograft has symmetric iliac limbs. The proximal graft has a bare stent for active fixation and the bifurcation of the graft rests on the aortic bifurcation for anatomic distal fixation. The AFX graft has replaced the initial Powerlink&reg; graft design, and is distinguished by a lower profile and a multilayered STRATA ePTFE graft material that is intended to provide greater strength and better conformability.",
"   </p>",
"   <p>",
"    The main device is available in diameters ranging from 22 to 28 mm in lengths ranging from 6 to 10 cm with limbs measuring 13 or 16 mm in diameter and lengths from 3 to 5.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/20\">",
"     20",
"    </a>",
"    ]. The limb extensions range from 16 to 20 mm in diameter in lengths from 5.5 to 8.8 cm. The main device is delivered in a 21 French (7 mm) sheath and the contralateral limb is delivered through a 17 or 19 French (5.67, 6.33 mm) sheath.",
"   </p>",
"   <p>",
"    The safety and efficacy of the Powerlink&reg; graft was evaluated in a multicenter, nonrandomized comparison study conducted at 15 sites that enrolled 192 patients who received the graft and 66 open surgical patients between 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/21\">",
"     21",
"    </a>",
"    ]. Technical success was achieved in 97.9 percent of patients. Patients treated with the Powerlink&reg; stent-graft had significantly decreased blood loss (341 versus 1582 mL), operative time (133 versus 222 minutes), length of intensive care unit stay (0.78 versus 4.1 days) and hospital stay (3.3 versus 9.5 days) compared with the open control group. There were no significant differences in mortality rates. There were no reported graft-related endoleaks (Type I, III, or IV) at four years of follow-up, and also no reports of ruptures, graft fabric defects, or wire fractures. Aneurysm sac regression was noted in 83 percent of patients. The six-year follow-up results also reported no stent fractures, graft disruptions, or aneurysm ruptures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/22\">",
"     22",
"    </a>",
"    ]. No differences in all-cause morbidity were found between the Powerlink&reg; and open surgical groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829355\">",
"    <span class=\"h2\">",
"     Talent&trade;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Talent&trade; abdominal stent-graft (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) is a modular, bifurcated graft that is composed of a woven polyester fabric with an external self-expanding support structure of M-shaped nitinol stents. The proximal graft has an uncovered stent for aortic fixation.",
"   </p>",
"   <p>",
"    The main device is available in diameters ranging from 22 to 36 mm with limbs measuring 8 to 24 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/23\">",
"     23",
"    </a>",
"    ]. The diameter of the limb extensions ranges from 8 to 22 mm with lengths from 7.5 to 14 cm. The main device is delivered in a 22 French (7.33 mm) sheath and the contralateral limb is delivered through an 18 or 20 French (6, 6.67 mm) sheath.",
"   </p>",
"   <p>",
"    The safety and efficacy of the Talent&trade; device was established in phase I and II clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The success rate in the phase II study of 127 high-risk patients was 94 percent. Perioperative (30-day) mortality was 1.5 percent. The phase II low-risk trial included a first-generation and a second-generation Talent&trade; stent-graft. Deployment success rates were 97 to 99 percent. Perioperative mortality was 2 percent in the phase II low-risk study, and the mortality and adverse-event rates for the second-generation device were 0 and 1.8 percent, respectively.",
"   </p>",
"   <p>",
"    The long-term results for Talent&trade; grafts placed between the years 2000 and 2007 have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/26\">",
"     26",
"    </a>",
"    ]. Perioperative mortality (30-day) for the entire Talent&trade; group was 1.1 percent (4 of 365 patients). Primary clinical success rates were 98 percent at one year, 93 percent at two years, 88 percent at three years, 79 percent at four years, 64 percent at five years, 51 percent at six years, and 48 percent at seven years using Kaplan-Meier estimates. Secondary interventions were performed in 20 percent of patients, and included 10 conversions for failed endografts",
"    <span class=\"nowrap\">",
"     (10/365).",
"    </span>",
"    Follow-up to 84 months was available for 24 patients. During follow-up, 122 patients (33 percent) died; in nine, death was related to the abdominal aortic aneurysm (AAA) (including 30-day mortality). Life-table analysis identified an annual risk for AAA-related reintervention of 6 percent, annual risk for conversion to open repair of 1.1 percent, annual risk for total mortality of 8.9 percent, and annual risk for AAA-related mortality of 0.8 percent. The results of this trial indicate a high initial technical success rate, with an acceptable annual risk for conversion and AAA-related mortality. However, a substantial number of endovascular re-interventions were needed during long-term follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191829362\">",
"    <span class=\"h2\">",
"     Endurant&reg;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Endurant&reg; endograft (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ) is a modular, bifurcated device composed of a multifilament polyester fabric with an external self-expanding support structure of M-shaped electro-polished nitinol stents. Proximally, it has a suprarenal nitinol stent with anchoring pins for suprarenal fixation. The graft design is intended to treat aneurysms with more challenging anatomy (eg, neck angulation).",
"   </p>",
"   <p>",
"    The main device is available in diameters that range from 23 to 36 mm for the main body and 13 to 20 mm for the ipsilateral limb, and in lengths of 12.4, 14.5 and 16.6 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/27\">",
"     27",
"    </a>",
"    ]. The contralateral iliac stent component ranges from 10 to 28 mm in diameter with 8.2, 9.3 and 12.4 cm lengths. The internal diameter of the delivery sheath for the bifurcated grafts is 18 or 20 French (6.0, 6.67 mm) and the sheaths for other components range from 14 to 16 French (4.67 to 5.33 mm).",
"   </p>",
"   <p>",
"    A single arm, multicenter trial evaluating the safety and performance of the Endurant&reg; graft was conducted at 26 sites in the United States and enrolled 150 patients between April 2008 and May 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/28\">",
"     28",
"    </a>",
"    ]. The technical success rate was 99.3 percent. One failure was due to inability to cannulate the contralateral gate and one patient ruptured during the procedure, but was still treated successfully. The perioperative mortality (30-day) rate was zero and the incidence of major adverse events was 4 percent. At one-year follow-up there were no migrations, ruptures, open conversions or graft-related endoleaks (type I or III). Ten aneurysm-related re-interventions were performed during the first year of follow-up, mostly for graft limb thrombosis or stenosis (five) or type II endoleak (two). Aneurysm sac diameter decreased &gt;5 mm at one year in 47 percent of patients and remained stable in 53 percent. No instances of sac growth were reported. Late deaths occurred in 4.7 percent of patients but were not related to the aneurysm repair.",
"   </p>",
"   <p>",
"    A European trial enrolled 80 patients between November 2007 and August 2008, 71 of whom had moderate infrarenal aortic neck angulation and nine with a high degree of angulation (60&deg; to 75&deg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/29\">",
"     29",
"    </a>",
"    ]. The device was successfully delivered and deployed in all cases. At one-year follow-up, all-cause mortality was 5 percent, with potentially one device-related death. Serious adverse events were comparable between the high and moderate angulation groups. There were no device migrations, stent fractures, aortic ruptures, or conversions to open repair. Maximal aneurysm diameter decreased &gt;5 mm in 43 percent of cases. Three secondary endovascular procedures were performed for outflow vessel stenosis, graft limb occlusion, and iliac extension, resulting in a secondary patency rate of 100 percent. No re-interventions were required in the high angulation group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H861292399\">",
"    <span class=\"h2\">",
"     Withdrawn and investigational devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several devices introduced for endovascular repair of abdominal aortic aneurysm (AAA) have been withdrawn from the market, were not used clinically, or are still awaiting approval after the initial trial data. Their status is briefly reviewed.",
"   </p>",
"   <p>",
"    The Ancure graft was a flexible, unsupported fabric graft with active fixation at the ends of the graft using wire hooks that penetrated the aortic wall. The graft was approved for use in the United States in 1999 but was recalled in 2001. Production of the graft was suspended in 2003 due to device malfunctions and adverse events associated with device deployment.",
"   </p>",
"   <p>",
"    Other devices that are no longer available include the Lifepath device, which had problems with stent fractures, and the Fortron and Quantum grafts which were re-designed into the Incraft&trade; device.",
"   </p>",
"   <p>",
"    The Aorfix&trade; AAA bifurcated endograft is a bifurcated woven polyester graft supported by a nitinol skeleton. Active fixation is provided by proximal nitinol hooks. The graft is intended to treat angulated aortic necks for up to 90 degrees and tortuous iliac anatomy. The proximal portion of the main graft body is fish-mouthed (rather than circular) in shape, and when positioned properly, the surface area of the potentially achievable seal-zone is increased in the anterior-to-posterior dimension. Because of this feature, the distance from the superior mesenteric artery to the lowest renal artery needs to be at least 15 mm in length to prevent inadvertent coverage of the superior mesenteric artery orifice during graft deployment.",
"   </p>",
"   <p>",
"    The Aorfix&trade; graft is currently approved for clinical use and available in Europe, and is awaiting approval in the United States. Short-term and mid-term data from European trials have confirmed the safety of the device and its suitability for treating hostile aorto-iliac anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/30\">",
"     30",
"    </a>",
"    ]. The PYTHAGORAS trial is currently recruiting participants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emerging technologies are focusing on improving the delivery profile and are awaiting approval or further testing in clinical trials. These include the 14-French (4.7 mm) Ovation endograft system, the 14-French (4.7 mm) Incraft&trade; AAA stent graft system, and the 18-French (6 mm) Zenith LP device.",
"   </p>",
"   <p>",
"    Advanced graft designs that are investigational are discussed below. (See",
"    <a class=\"local\" href=\"#H1191837723\">",
"     'Advanced devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191828718\">",
"    <span class=\"h1\">",
"     EVAR RANDOMIZED TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have compared endovascular aneurysm repair using a variety of endografts to open surgical repair for the treatment of infrarenal AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/32-39\">",
"     32-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The devices used in the Dutch Randomized Endovascular Aneurysm Management (DREAM) trial included the Zenith&reg; in 35 percent of EVAR patients, Talent&trade; in 28 percent, AneuRx&reg; in 7 percent, Excluder&reg; in 21 percent and other devices in the remaining 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The endografts used in the EVAR1 and EVAR2 trials included Zenith&reg; in 51 percent, Talent&trade; in 33 percent, Excluder&reg; in 7 percent, AneuRx&reg; in 4 percent, and Quantum in 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Devices used in the OVER trial included the Excluder&reg; in 37 percent, Zenith&reg; in 39 percent, and AneuRx&reg; in 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/38\">",
"       38",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials have consistently demonstrated significantly reduced perioperative morbidity and mortality (1 to 2 versus 3 to 5 percent) for endovascular compared with open surgical repair; however, long-term mortality is not significantly different. Endovascular repair is associated with a significantly greater number of graft-related secondary interventions, but the overall need for reintervention may be similar when all open surgical complications (eg, hernia, adhesiolysis for small bowel obstruction) are taken into account. The details of these trials and factors that enter into the decision to offer open versus endovascular management of elective and ruptured AAA repair are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=see_link&amp;anchor=H108751558#H108751558\">",
"     \"Surgical and endovascular repair of ruptured abdominal aortic aneurysm\", section on 'Open surgical versus endovascular repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191837723\">",
"    <span class=\"h1\">",
"     ADVANCED DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When aortic disease is more extensive and involves branch vessels, the complexity of the repair and risk of complications increases. Approaches to manage more complicated anatomy include debranching procedures and the use of fenestrated and branched endografts.",
"   </p>",
"   <p>",
"    Debranching procedures involve ligation of an aortic branch that will be covered by the endograft and surgical revascularization (eg, carotid-subclavian bypass, hepatorenal bypass). The role of debranching in the treatment of aneurysmal disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H444449#H444449\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Advanced devices and techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fenestrated and branched grafts are available for clinical use in Europe, but are considered investigational devices in the United States and are still undergoing clinical trials. The Zenith&reg; Fenestrated AAA Endovascular Graft is the most studied device. Several other device manufacturers are currently working on off-the-shelf designs of branched and fenestrated grafts with clinical trials underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620227574\">",
"    <span class=\"h2\">",
"     Fenestrated grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fenestrated-endovascular aneurysm repair (FEVAR) to manage more challenging aortic anatomy continues to evolve [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/40-51\">",
"     40-51",
"    </a>",
"    ]. The Zenith&reg; Fenestrated AAA Endovascular Graft is the most studied device. The device is similar in construction to the Zenith device discussed above with the addition of fabric openings (fenestrations) created in the graft based upon measurements obtained with high-resolution computed tomographic (CT) angiography. These grafts have been used primarily to manage juxtarenal abdominal aortic aneurysms (AAA).",
"   </p>",
"   <p>",
"    A systematic review identified 11 studies describing a total of 660 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/52\">",
"     52",
"    </a>",
"    ]. Initial success in placing the graft was &gt;99 percent. Target vessel perfusion ranged from 90.5 to 100 percent. Double fenestrations were more common than triple or quadruple fenestrations. The perioperative (30-day) mortality rate was 2 percent.",
"   </p>",
"   <p>",
"    The largest of these studies evaluated the outcome of 134 patients following repair of juxtarenal abdominal aortic aneurysm treated with a Zenith&reg; Fenestrated AAA Endovascular Graft at 16 French centers between May 2004 and January 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/42\">",
"     42",
"    </a>",
"    ]. A total of 403 visceral vessels were perfused through a fabric fenestration, including 265 renal arteries. The technical success of graft placement was 99.3 percent with one patient requiring open conversion. The success of target vessel revascularization was 99 percent. Perioperative mortality (30-day) was 2 percent. Dialysis was required in 4 percent of patients (transient in 3 percent and permanent in 1 percent). Endoleaks occurred in 12 percent of patients prior to discharge (one each type I and type III endoleak). Three patients had sac enlargement within the first year, associated with a persistent endoleak. No aneurysms ruptured or required open conversion during the follow-up period.",
"   </p>",
"   <p>",
"    During follow-up, four renal artery occlusions were detected. A total of 12 procedure-related re-interventions were performed in 12 patients during follow-up, including 6 to correct endoleaks, and 5 to correct threatened visceral vessels. Longer-term mortality was 9 percent over the follow-up period but none of the deaths were related to the aneurysm repair. Actuarial survival at 12 and 24 months were 93 and 86 respectively. Aneurysm sac size decreased &gt;5 mm in 52, 66, and 75 percent of patients at one, two, and three years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620227567\">",
"    <span class=\"h2\">",
"     Branched grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Branched grafts have a separate smaller side-arm graft sutured to the basic endovascular graft for deployment into a vessel to preserve flow into it. Another approach places a self-expanding stent-graft through the opening of a fenestrated graft. The Zenith&reg; Fenestrated AAA Endovascular Graft (Cook Medical) is the primarily-studied device. (See",
"    <a class=\"local\" href=\"#H620227574\">",
"     'Fenestrated grafts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Branched abdominal aortic grafts have been used in patients with suprarenal and juxtarenal aortic aneurysms, and common iliac artery aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/53\">",
"     53",
"    </a>",
"    ]. Initial experience with branched aortic grafts has shown similar perioperative mortality as conventional endovascular repair but the rate of aneurysm-repair-related mortality may be higher.",
"   </p>",
"   <p>",
"    Branched grafts to the visceral vessels allow endovascular repair of more extensive aortic disease. The use of visceral branch devices in endovascular repair of abdominal aortic aneurysm is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H444449#H444449\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Advanced devices and techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iliac branched grafts are intended to preserve flow into the internal iliac artery during endovascular repair (abdominal aortic aneurysm or iliac artery aneurysm) that requires extension beyond the internal iliac artery orifice. The PRESERVE study will evaluate the safety and efficacy of the Zenith&reg; Iliac Branch Device (Cook Medical). The use of iliac branch devices is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=see_link&amp;anchor=H519609340#H519609340\">",
"     \"Surgical and endovascular repair of iliac artery aneurysm\", section on 'Branched grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620225163\">",
"    <span class=\"h1\">",
"     CHOICE OF DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials comparing specific aortic endografts for the treatment of abdominal aortic aneurysm (AAA). However, although the primary comparison in the endovascular aneurysm repair trials was between endovascular and open surgical repair, comparisons between the Talent&trade; and Zenith&reg; devices in the EVAR trials failed to find significant device-specific differences [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparisons between different grafts have also been made in observational studies. One study that included 703 patients who underwent endovascular abdominal aortic aneurysm repair at a single institution over a six-year period found no significant differences for important outcomes. The devices used were Ancure (no longer available), AneuRx&reg;, Excluder&reg;, Talent&trade;, and Zenith&reg;. The outcomes included aneurysm-related death, conversion to open repair, need for secondary intervention, device migration, freedom from aortic rupture, and detection of Type I or III endoleaks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/55\">",
"     55",
"    </a>",
"    ]. Adhering to the device manufacturer&rsquo;s criteria for anatomic suitability appears to be the more important issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link&amp;anchor=H958070867#H958070867\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Endograft complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the graft design doesn&rsquo;t appear to have a major impact on outcomes of straightforward endovascular aneurysm repair, most operators choose one endograft for routine use, reserving others for one or more features that might be more suited to a specific patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9689/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The operator should become familiar with specific advantages inherent to endograft designs (",
"    <a class=\"graphic graphic_table graphicRef67461 \" href=\"UTD.htm?4/16/4365\">",
"     table 1",
"    </a>",
"    ). A device with a lower profile is more advantageous in the patient with narrow access vessels, whereas a device with better conformability and active fixation would be more helpful in the patient with challenging aortic neck anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191828469\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endovascular repair with abdominal endograft devices is used primarily to treat infrarenal abdominal aortic aneurysm. Endovascular aortic repair requires that specific anatomic criteria be fulfilled, and for those with appropriate anatomy, this technique has become a preferred approach and allows the treatment of patients who might not otherwise be candidates for aortic repair. (See",
"      <a class=\"local\" href=\"#H1191828461\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular aortic repair involves the insertion of endovascular graft components, usually via a femoral approach. The endovascular graft is constructed in vivo by the delivery and deployment of these components in an established order. Upon deployment, the endograft expands, contacting the aortic wall proximally and aorta or iliac vessels distally to exclude the native, dilated portion of the aortic wall from aortic blood flow and pressure. (See",
"      <a class=\"local\" href=\"#H1191837912\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are significant variations in endovascular graft design, three types of components are common to all: the delivery system, main body device, and device extensions. Devices available in the United States to treat the abdominal aorta include the AneuRx&reg;, Zenith&reg;, Excluder&reg;, AFX and Powerlink&reg;, Talent&trade;, and Endurant&reg; grafts. The characteristics for each graft are described above. (See",
"      <a class=\"local\" href=\"#H1191828485\">",
"       'Abdominal devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When aortic disease is more extensive and involves branch vessels, the complexity of the repair and risk of complications increases. Approaches to manage more complicated anatomy include debranching procedures and the use of fenestrated and branched endografts. These endografts preserve blood flow into specific aortic branches depending upon the level of repair, but are available only for investigational use in the United States. (See",
"      <a class=\"local\" href=\"#H1191837723\">",
"       'Advanced devices'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Several trials have compared endovascular aneurysm repair with open surgical repair using a variety of endografts for the treatment of infrarenal abdominal aortic aneurysm. These trials have consistently demonstrated significantly reduced perioperative (30-day) morbidity and mortality (1 to 2 versus 3 to 5 percent) for endovascular compared with open surgical repair; however, long-term mortality is not significantly different. Secondary intervention is frequently needed in patients who receive an abdominal endograft. As such, these devices require lifelong surveillance; the long-term outcomes for these devices continue to be studied. (See",
"      <a class=\"local\" href=\"#H1191828718\">",
"       'EVAR randomized trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The few comparisons that are available for specific endograft designs for the treatment of abdominal aortic aneurysm (AAA) have found no significant differences between devices for important outcomes. Because the graft design doesn&rsquo;t appear to have a major impact on the outcomes of straightforward endovascular aneurysm repair, most operators choose one endograft for routine use, reserving others for one or more features that might be better suited to a specific patient. (See",
"      <a class=\"local\" href=\"#H620225163\">",
"       'Choice of device'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/1\">",
"      Ohrlander T, Dencker M, Acosta S. Morphological state as a predictor for reintervention and mortality after EVAR for AAA. Cardiovasc Intervent Radiol 2012; 35:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/2\">",
"      Brown LC, Greenhalgh RM, Powell JT, et al. Use of baseline factors to predict complications and reinterventions after endovascular repair of abdominal aortic aneurysm. Br J Surg 2010; 97:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/3\">",
"      Karthikesalingam A, Holt PJ, Hinchliffe RJ, et al. Risk of reintervention after endovascular aortic aneurysm repair. Br J Surg 2010; 97:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/4\">",
"      Sandhu RS, Pipinos II. Isolated iliac artery aneurysms. Semin Vasc Surg 2005; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/5\">",
"      Caronno R, Piffaretti G, Tozzi M, et al. Stent-graft treatment for isolated infrarenal aortic dissecting aneurysms. World J Surg 2006; 30:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/6\">",
"      Halkos ME, Nicholas J, Kong LS, et al. Endovascular management of blunt abdominal aortic injury. Vascular 2006; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@endov/documents/documents/aaa_brochure.pdf (Accessed on February 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/8\">",
"      Zarins CK, AneuRx Clinical Investigators. The US AneuRx Clinical Trial: 6-year clinical update 2002. J Vasc Surg 2003; 37:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/9\">",
"      Zarins CK, White RA, Moll FL, et al. The AneuRx stent graft: four-year results and worldwide experience 2000. J Vasc Surg 2001; 33:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/10\">",
"      Howell MH, Strickman N, Mortazavi A, et al. Preliminary results of endovascular abdominal aortic aneurysm exclusion with the AneuRx stent-graft. J Am Coll Cardiol 2001; 38:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/11\">",
"      Tavris DR, Liu CH, Gross TP, Greenfield LJ. Aneurysm-related mortality rates in the US AneuRx clinical trial. J Am Coll Surg 2010; 211:646.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cookmedical.com/ai/familyListingAction.do?family=AAA",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/13\">",
"      Greenberg RK, Chuter TA, Sternbergh WC 3rd, et al. Zenith AAA endovascular graft: intermediate-term results of the US multicenter trial. J Vasc Surg 2004; 39:1209.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.goremedical.com/excluder/configurations/",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/15\">",
"      Matsumura JS, Brewster DC, Makaroun MS, Naftel DC. A multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysm. J Vasc Surg 2003; 37:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/16\">",
"      Melissano G, Bertoglio L, Esposito G, et al. Midterm clinical success and behavior of the aneurysm sac after endovascular AAA repair with the Excluder graft. J Vasc Surg 2005; 42:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/17\">",
"      Peterson BG, Matsumura JS, Brewster DC, et al. Five-year report of a multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysms. J Vasc Surg 2007; 45:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/18\">",
"      Haider SE, Najjar SF, Cho JS, et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device. J Vasc Surg 2006; 44:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/19\">",
"      Hogg ME, Morasch MD, Park T, et al. Long-term sac behavior after endovascular abdominal aortic aneurysm repair with the Excluder low-permeability endoprosthesis. J Vasc Surg 2011; 53:1178.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.endologix.com/fls/IntuiTrak_Product_Specifications_MM0157_Rev_05_usa.pdf",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/21\">",
"      Carpenter JP, Endologix Investigators. Midterm results of the multicenter trial of the powerlink bifurcated system for endovascular aortic aneurysm repair. J Vasc Surg 2004; 40:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/22\">",
"      Wang GJ, Carpenter JP, Endologix Investigators. The Powerlink system for endovascular abdominal aortic aneurysm repair: six-year results. J Vasc Surg 2008; 48:535.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medtronicendo.com/us/product/abdominal/talent-aaa?quicktabs_8=3#quicktabs-8",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/24\">",
"      Criado FJ, Fry PD, Machan LS, et al. The talent endoluminal AAA stent-graft system. Report of the phase I USA trial, and summary of worldwide experience. J Mal Vasc 1998; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/25\">",
"      Criado FJ, Wilson EP, Fairman RM, et al. Update on the Talent aortic stent-graft: a preliminary report from United States phase I and II trials. J Vasc Surg 2001; 33:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/26\">",
"      Verhoeven BA, Waasdorp EJ, Gorrepati ML, et al. Long-term results of Talent endografts for endovascular abdominal aortic aneurysm repair. J Vasc Surg 2011; 53:293.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@cardio/documents/documents/wcm_prod067491.pdf (Accessed on February 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/28\">",
"      Makaroun MS, Tuchek M, Massop D, et al. One year outcomes of the United States regulatory trial of the Endurant Stent Graft System. J Vasc Surg 2011; 54:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/29\">",
"      Rouwet EV, Torsello G, de Vries JP, et al. Final results of the prospective European trial of the Endurant stent graft for endovascular abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2011; 42:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/30\">",
"      Perdikides T, Georgiadis GS, Avgerinos ED, et al. The Aorfix stent-graft to treat infrarenal abdominal aortic aneurysms with angulated necks and/or tortuous iliac arteries: midterm results. J Endovasc Ther 2009; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     Prospective Aneurysm Trial: High angle Aorfix bifurcated stent graft (PYTHAGORAS). file://clinicaltrials.gov/ct2/show/NCT00522535 (Accessed on February 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/32\">",
"      Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004; 351:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/33\">",
"      Blankensteijn JD, de Jong SE, Prinssen M, et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005; 352:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/34\">",
"      De Bruin JL, Baas AF, Buth J, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med 2010; 362:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/35\">",
"      EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005; 365:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/36\">",
"      United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med 2010; 362:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/37\">",
"      United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010; 362:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/38\">",
"      Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA 2009; 302:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/39\">",
"      Veith FJ, Lachat M, Mayer D, et al. Collected world and single center experience with endovascular treatment of ruptured abdominal aortic aneurysms. Ann Surg 2009; 250:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/40\">",
"      Tambyraja AL, Fishwick NG, Bown MJ, et al. Fenestrated aortic endografts for juxtarenal aortic aneurysm: medium term outcomes. Eur J Vasc Endovasc Surg 2011; 42:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/41\">",
"      Greenberg RK, Sternbergh WC 3rd, Makaroun M, et al. Intermediate results of a United States multicenter trial of fenestrated endograft repair for juxtarenal abdominal aortic aneurysms. J Vasc Surg 2009; 50:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/42\">",
"      Amiot S, Haulon S, Becquemin JP, et al. Fenestrated endovascular grafting: the French multicentre experience. Eur J Vasc Endovasc Surg 2010; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/43\">",
"      Greenberg RK, Haulon S, O'Neill S, et al. Primary endovascular repair of juxtarenal aneurysms with fenestrated endovascular grafting. Eur J Vasc Endovasc Surg 2004; 27:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/44\">",
"      O'Neill S, Greenberg RK, Haddad F, et al. A prospective analysis of fenestrated endovascular grafting: intermediate-term outcomes. Eur J Vasc Endovasc Surg 2006; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/45\">",
"      Verhoeven EL, Vourliotakis G, Bos WT, et al. Fenestrated stent grafting for short-necked and juxtarenal abdominal aortic aneurysm: an 8-year single-centre experience. Eur J Vasc Endovasc Surg 2010; 39:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/46\">",
"      Semmens JB, Lawrence-Brown MM, Hartley DE, et al. Outcomes of fenestrated endografts in the treatment of abdominal aortic aneurysm in Western Australia (1997-2004). J Endovasc Ther 2006; 13:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/47\">",
"      Anderson JL, Berce M, Hartley DE. Endoluminal aortic grafting with renal and superior mesenteric artery incorporation by graft fenestration. J Endovasc Ther 2001; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/48\">",
"      Kristmundsson T, Sonesson B, Malina M, et al. Fenestrated endovascular repair for juxtarenal aortic pathology. J Vasc Surg 2009; 49:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/49\">",
"      Ziegler P, Avgerinos ED, Umscheid T, et al. Fenestrated endografting for aortic aneurysm repair: a 7-year experience. J Endovasc Ther 2007; 14:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/50\">",
"      Scurr JR, Brennan JA, Gilling-Smith GL, et al. Fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg 2008; 95:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/51\">",
"      Bicknell CD, Cheshire NJ, Riga CV, et al. Treatment of complex aneurysmal disease with fenestrated and branched stent grafts. Eur J Vasc Endovasc Surg 2009; 37:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/52\">",
"      Cross J, Gurusamy K, Gadhvi V, et al. Fenestrated endovascular aneurysm repair. Br J Surg 2012; 99:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/53\">",
"      Greenberg RK, Qureshi M. Fenestrated and branched devices in the pipeline. J Vasc Surg 2010; 52:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/54\">",
"      Brown LC, Greenhalgh RM, Kwong GP, et al. Secondary interventions and mortality following endovascular aortic aneurysm repair: device-specific results from the UK EVAR trials. Eur J Vasc Endovasc Surg 2007; 34:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9689/abstract/55\">",
"      Ouriel K, Clair DG, Greenberg RK, et al. Endovascular repair of abdominal aortic aneurysms: device-specific outcome. J Vasc Surg 2003; 37:991.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16919 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9689=[""].join("\n");
var outline_f9_29_9689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1191828469\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191828461\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191837832\">",
"      AORTIC ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191837912\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620227127\">",
"      Delivery system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620227120\">",
"      Main device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620227113\">",
"      Extensions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191828485\">",
"      ABDOMINAL DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829325\">",
"      AneuRx&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829332\">",
"      Zenith&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829339\">",
"      Excluder&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829346\">",
"      AFX and Powerlink&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829355\">",
"      Talent&trade;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191829362\">",
"      Endurant&reg;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H861292399\">",
"      Withdrawn and investigational devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191828718\">",
"      EVAR RANDOMIZED TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191837723\">",
"      ADVANCED DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620227574\">",
"      Fenestrated grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620227567\">",
"      Branched grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H620225163\">",
"      CHOICE OF DEVICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191828469\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16919|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 1\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/21/13663\" title=\"figure 2\">",
"      Bifurcated modular aortic endograft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/16/4365\" title=\"table 1\">",
"      Characteristics of abdominal endovascular devices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8809?source=related_link\">",
"      Surgical and endovascular repair of iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30904?source=related_link\">",
"      Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_29_9690="Evaluation and diagnosis of hair loss";
var content_f9_29_9690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and diagnosis of hair loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Jerry Shapiro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Nina Otberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/29/9690/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/29/9690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H638313\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Hair loss&rdquo; is a common clinical complaint that is a manifestation of a wide variety of disorders. Although the cause of hair loss is easily diagnosed in some cases, such as in patients who present with classic male pattern hair loss or patchy hair loss due to alopecia areata, the diagnosis of hair loss also can be challenging.",
"   </p>",
"   <p>",
"    An overview of the basic principles of hair biology, potential causes of hair loss, and the assessment of patients who present with a complaint of hair loss is provided here. Specific types of hair disorders are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=see_link\">",
"     \"Chemotherapy-induced alopecia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638320\">",
"    <span class=\"h1\">",
"     HAIR BIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871668\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human scalp contains approximately 100,000 to 150,000 hair follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/1\">",
"     1",
"    </a>",
"    ]. Each hair follicle sits above a dermal papilla, a collection of mesenchymally derived tissue with inductive properties (",
"    <a class=\"graphic graphic_figure graphicRef53952 \" href=\"UTD.htm?30/38/31332\">",
"     figure 1",
"    </a>",
"    ). The dermal papilla induces the development of hair follicles in the fetus, and appears to play an important role in follicular cycling and hair growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1871661\">",
"     'Hair cycle'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hair follicles consist of four segments: the bulb, suprabulbar region, isthmus, and infundibulum (",
"    <a class=\"graphic graphic_figure graphicRef53952 \" href=\"UTD.htm?30/38/31332\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/3\">",
"     3",
"    </a>",
"    ]. The bulb, the lowest portion of the hair follicle, is the site of the hair matrix, a group of rapidly proliferating keratinocytes responsible for the production of hair [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"     2",
"    </a>",
"    ]. The suprabulbar region of the follicle extends from the bulb to the isthmus, which is the portion of the follicle between the insertion of the arrector pili muscle and the insertion of the sebaceous gland. The uppermost portion of the follicle, the infundibulum, extends from the insertion of the sebaceous gland to the interfollicular epithelium.",
"   </p>",
"   <p>",
"    The hair shaft is a layered structure that consists of three major components. The medulla, the innermost layer, is surrounded by the cortex and cuticle. Between the hair bulb and the isthmus, the hair shaft is surrounded by the inner root sheath, a structure that is composed of the cuticle of the inner root sheath, Huxley layer, Henle layer, and companion layer. The inner root sheath plays an important role in the shaping of the hair shaft [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"     2",
"    </a>",
"    ]. The outer root sheath surrounds both the inner root sheath and the hair shaft, and extends from the hair bulb to the epidermis. The outer root sheath and each of the components of the hair shaft and inner root sheath have distinct keratin profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A region near the insertion of the arrector pili muscle, referred to as the bulge region of the hair follicle, has been identified as a site that harbors hair follicle stem cells that are essential for follicular cycling and hair growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/5\">",
"     5",
"    </a>",
"    ]. The loss of the hair follicle stem cells in the bulge is postulated to contribute to permanent loss of hair in cicatricial alopecias (see",
"    <a class=\"local\" href=\"#H1871427\">",
"     'Cicatricial alopecia'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Mouse studies have demonstrated that hair follicle stem cells may also support wound healing by contributing to repopulation of interfollicular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871675\">",
"    <span class=\"h2\">",
"     Hair types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major types of hair follicles on the human body are terminal hair follicles and vellus hair follicles. Terminal hair follicles are larger than vellus hair follicles and extend into the subcutaneous fat (2 to 5 mm from the skin surface) during hair growth. In contrast, the lowest portions of vellus hair follicles generally extend only into the reticular dermis. Hairs produced by terminal hair follicles are usually at least 0.06 mm in diameter while vellus hairs are short, fine, and usually less than 0.03 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/8\">",
"     8",
"    </a>",
"    ]. The term &ldquo;intermediate hairs&rdquo; has been used to describe hairs with characteristics that are between vellus and terminal hairs (0.03 to 0.06 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At birth, terminal hairs are found on the scalp, eyebrows, and eyelashes, and vellus hairs populate the remaining hair-bearing areas. During puberty, vellus hairs in certain areas, such as the genital area and axilla, are stimulated to become terminal hairs. Transitioning between terminal and vellus hair follicles may also occur in pathological states. Abnormal transitioning of vellus hairs to terminal hairs occurs in hirsutism in women, and transitioning of terminal hairs to vellus hairs (follicular miniaturization) is a classic feature of androgenetic alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871661\">",
"    <span class=\"h2\">",
"     Hair cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once formed, hair follicles undergo lifelong cycling characterized by periods of growth (anagen), transformation (catagen), and rest (telogen). In humans, hair cycling is not synchronous, meaning that individual follicles cycle independently, preventing en mass shedding of hair. Although the lower portion of the hair follicle undergoes growth and regression during cycling, the isthmus and infundibulum remain stable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anagen &ndash;",
"      </strong>",
"      At any given time, approximately 90 percent of scalp hair follicles are in the anagen phase [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/11\">",
"       11",
"      </a>",
"      ]. The rate of hair growth and the duration of anagen vary with the type of hair and location. On the scalp, the growth rate of terminal hair is approximately 0.3 mm per day and the duration of anagen ranges from two to six years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]. In contrast, eyebrow hair grows only at a rate of 0.1 mm per day and has an anagen phase of two to three months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2,9\">",
"       2,9",
"      </a>",
"      ]. The abbreviated anagen phase accounts for the relatively short maximum length of eyebrow hair. Similarly, a short anagen phase is responsible for the short maximum length of vellus hairs (typically less than 20 mm) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Catagen &ndash;",
"      </strong>",
"      During catagen, the lower portion of the hair follicle regresses and hair production ceases. The deepest part of the hair follicle tracts upward toward the isthmus, and the dermal papilla migrates from within the subcutaneous fat into the reticular dermis. The duration of catagen on the scalp is usually around three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/9\">",
"       9",
"      </a>",
"      ]. Less than 1 percent of follicles on the scalp are in catagen [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Telogen &ndash;",
"      </strong>",
"      The telogen phase, also known as the resting phase, follows catagen and lasts for two to three months on the scalp [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/11\">",
"       11",
"      </a>",
"      ]. Normally, up to 10 percent of scalp follicles are in telogen [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/11\">",
"       11",
"      </a>",
"      ]. Telogen is characterized by the presence of a club hair (a fully keratinized hair with a club-shaped proximal end) that is ready for shedding from the hair follicle (",
"      <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"       2",
"      </a>",
"      ]. The term &ldquo;exogen&rdquo; has been used to describe the exact time point at which the hair is shed. Normally, between 50 and 150 telogen hairs are shed per day [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Anagen follows the telogen phase, resulting in the production of a new hair. Prolongation of the telogen phase, as may occur in telogen effluvium, can result in a reduction in hair density due to a failure of follicles to reenter anagen following shedding. The term &ldquo;kenogen&rdquo; has been used to describe a delay in the entry into anagen following shedding of a telogen hair [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638327\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss disorders are a large, heterogenous group of conditions that have various clinical features, pathological findings, and etiologies. Hair loss may occur due to disorders of hair cycling, inflammatory conditions that damage hair follicles, or inherited or acquired abnormalities in hair shafts.",
"   </p>",
"   <p>",
"    The major dividing lines for the various forms of hair loss are the distinction between cicatricial (scarring) alopecia, nonscarring alopecia, and structural hair disorders. Cicatricial alopecias are conditions that lead to the irreversible cessation of hair cycling and permanent hair loss. As noted above, the loss of hair follicle stem cells in the bulge region of the hair follicle is thought to contribute to the development of cicatricial alopecia (see",
"    <a class=\"local\" href=\"#H1871668\">",
"     'Anatomy'",
"    </a>",
"    above). In nonscarring alopecias, the hair follicle is not permanently damaged, making spontaneous or treatment-induced regrowth a possibility. Structural hair disorders that lead to hair loss demonstrate abnormalities within the hair shafts that result in hair fragility. (See",
"    <a class=\"local\" href=\"#H638369\">",
"     'Scalp and hair examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871427\">",
"    <span class=\"h2\">",
"     Cicatricial alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cicatricial alopecias are inflammatory disorders of the scalp that lead to permanent hair loss. The primary cicatricial alopecias are subdivided by the type of inflammation detected on histological examination. The three major classes are lymphocytic primary cicatricial alopecias, neutrophilic primary cicatricial alopecias, and mixed primary cicatricial alopecias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of the primary cicatricial alopecias are provided below. A summary of the clinical and histological features of the cicatricial alopecias is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef88347 \" href=\"UTD.htm?3/25/3486\">",
"     table 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lymphocytic primary cicatricial alopecia",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Alopecia mucinosa &ndash;",
"      </strong>",
"      Alopecia mucinosa (also known as follicular mucinosis) may result in scarring or nonscarring alopecia. Permanent hair loss results from the replacement of hair follicles by mucin, rather than from fibrosis. Patients usually present with erythematous or skin-colored indurated plaques of alopecia on the face or scalp (",
"      <a class=\"graphic graphic_picture graphicRef87485 \" href=\"UTD.htm?23/19/23862\">",
"       picture 1",
"      </a>",
"      ). Follicular papules may also be present.",
"      <br/>",
"      <br/>",
"      Two types of alopecia mucinosa have been described, idiopathic alopecia mucinosa and alopecia mucinosa that occurs as a manifestation of mycosis fungoides or cutaneous T-cell lymphoma. However, some authors believe that these disorders may represent aspects of a single disease spectrum [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/14\">",
"       14",
"      </a>",
"      ]. Whether all cases designated as idiopathic alopecia mucinosa are actually indolent forms of mycosis fungoides remains uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central centrifugal cicatricial alopecia",
"      </strong>",
"      &ndash; Central centrifugal cicatricial alopecia is a form of cicatricial alopecia that primarily affects women of African descent. Alopecia occurs on the crown of the scalp and gradually progresses in a centrifugal manner to the parietal areas (",
"      <a class=\"graphic graphic_picture graphicRef87198 \" href=\"UTD.htm?37/17/38168\">",
"       picture 2",
"      </a>",
"      ). Perifollicular hyperpigmentation and the emergence of multiple hairs from a single follicle may be present. Symptoms may include itching, tenderness, or prickling sensations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Discoid lupus erythematosus &ndash;",
"      </strong>",
"      Discoid lupus erythematosus (also known as chronic cutaneous lupus erythematosus) is a form of cutaneous lupus that may occur independently or in the setting of systemic lupus erythematosus. Patients typically present with well-demarcated inflammatory plaques that develop into atrophic scars (",
"      <a class=\"graphic graphic_picture graphicRef72588 graphicRef53535 \" href=\"UTD.htm?15/50/16170\">",
"       picture 3A-B",
"      </a>",
"      ). Follicular hyperkeratosis (follicular plugging), telangiectasias hypopigmentation, and hyperpigmentation are common clinical features [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/16\">",
"       16",
"      </a>",
"      ]. The head is the most common site of involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H4#H4\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Discoid lupus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Keratosis follicularis spinulosa decalvans (KFSD) &ndash;",
"      </strong>",
"      Keratosis follicularis spinulosa decalvans is a rare genetic disorder that commonly is associated with a mutation in the membrane-bound transcription factor protease site 2 (MBTPS2) gene on the X chromosome (MIM #308800) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/17\">",
"       17",
"      </a>",
"      ]. Familial cases of KFSD that demonstrate an autosomal dominant inheritance pattern have also been reported (MIM %612843) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Patients first present in infancy with follicular papules with keratotic spines on the scalp. Eyebrow, eyelash, and other involvement of hair-bearing skin may develop (",
"      <a class=\"graphic graphic_picture graphicRef87486 graphicRef87487 \" href=\"UTD.htm?18/38/19049\">",
"       picture 4A-B",
"      </a>",
"      ). Photophobia is common [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/18\">",
"       18",
"      </a>",
"      ]. Progression of the disease improves during puberty, leaving atrophic scars.",
"     </li>",
"     <li>",
"      <strong>",
"       Lichen planopilaris &ndash;",
"      </strong>",
"      Lichen planopilaris is a follicular variant of lichen planus that typically manifests with perifollicular erythema and follicular hyperkeratosis (",
"      <a class=\"graphic graphic_picture graphicRef86813 graphicRef52848 \" href=\"UTD.htm?24/23/24954\">",
"       picture 5A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/20\">",
"       20",
"      </a>",
"      ]. The areas of alopecia may be irregularly shaped and interconnected. Itching, burning, pain, or skin sensitivity is often present.",
"      <br/>",
"      <br/>",
"      Frontal fibrosing alopecia is considered a variant of lichen planopilaris. In this disorder, patients present with band-like alopecia affecting the frontal scalp. Follicular hyperkeratosis and perifollicular erythema may be seen. Concomitant eyebrow involvement is common [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/21\">",
"       21",
"      </a>",
"      ]. Facial involvement may manifest as small rough follicular papules that have a predilection for the temporal area [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pseudopelade of Brocq &ndash;",
"      </strong>",
"      Pseudopelade of Brocq is an idiopathic cicatricial alopecia that presents with small, skin-colored patches of alopecia on the scalp [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/16\">",
"       16",
"      </a>",
"      ]. The pattern of the disorder has been described as &ldquo;footprints in the snow&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/23\">",
"       23",
"      </a>",
"      ]. Follicular hyperkeratosis and erythema are minimal or absent.",
"     </li>",
"     <li>",
"      <strong>",
"       Neutrophilic primary cicatricial alopecia",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Dissecting cellulitis of the scalp &ndash;",
"      </strong>",
"      Dissecting cellulitis of the scalp (also known as perifolliculitis capitis abscedens et suffodiens of Hoffman) is a form of cicatricial alopecia that may occur independently or in association with acne conglobata and hidradenitis suppurativa as part of the &ldquo;follicular occlusion triad.&rdquo; The condition most commonly occurs in young black men [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/24\">",
"       24",
"      </a>",
"      ]. Patients develop follicular papules, pustules, fluctuant nodules, and abscesses on the scalp (",
"      <a class=\"graphic graphic_picture graphicRef75929 graphicRef81039 \" href=\"UTD.htm?16/7/16506\">",
"       picture 6A-B",
"      </a>",
"      ). Purulent drainage is common. Over time, hypertrophic or keloidal scars may develop.",
"     </li>",
"     <li>",
"      <strong>",
"       Folliculitis decalvans &ndash;",
"      </strong>",
"      Folliculitis decalvans often begins on the vertex of the scalp. Patches of alopecia, inflamed papules, pustules, and follicular hyperkeratosis are common features (",
"      <a class=\"graphic graphic_picture graphicRef87488 graphicRef87489 \" href=\"UTD.htm?36/28/37322\">",
"       picture 7A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/25\">",
"       25",
"      </a>",
"      ]. Tufted folliculitis (multiple hairs emerging from a single inflamed follicle) is a characteristic feature, but is not exclusive to this disorder. Pain, itching, and burning are common.",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      colonization and a defect in host cell-mediated immunity may be contributing factors [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mixed",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Acne keloidalis nuchae",
"      </strong>",
"      &ndash; Acne keloidalis nuchae primarily occurs in young black men [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/26\">",
"       26",
"      </a>",
"      ]. Affected patients present with dome-shaped follicular papules, pustules, and plaques on the occipital scalp (",
"      <a class=\"graphic graphic_picture graphicRef87490 \" href=\"UTD.htm?32/9/32921\">",
"       picture 8",
"      </a>",
"      ). Keloid-like plaques also may develop.",
"     </li>",
"     <li>",
"      <strong>",
"       Acne necrotica &ndash;",
"      </strong>",
"      Acne necrotica is a rare form of cicatricial alopecia that is characterized by the development of umbilicated papules on the scalp that undergo central necrosis. Patients usually experience pruritus or pain. Individual lesions resolve with small varioliform or pox-like scars [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Erosive pustular dermatosis of the scalp &ndash;",
"      </strong>",
"      Erosive pustular dermatosis of the scalp is a rare disorder that primarily occurs in elderly individuals. The condition often develops after trauma or surgery on the scalp [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients develop sterile pustules, erosions, and crusted plaques on the scalp that lead to scarring (",
"      <a class=\"graphic graphic_picture graphicRef87491 \" href=\"UTD.htm?39/60/40901\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide variety of conditions or events may cause",
"    <strong>",
"     secondary cicatricial alopecia",
"    </strong>",
"    . Inflammation from a condition that is not a primary scalp disease and physical trauma are potential causes. Examples include tinea capitis, neoplasms, radiation therapy, and surgical scars. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H3#H3\">",
"     \"Dermatophyte (tinea) infections\", section on 'Tinea capitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871434\">",
"    <span class=\"h2\">",
"     Nonscarring alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nonscarring alopecias, clinical signs of inflammation are usually mild or absent and destruction of the hair follicle does not occur. Recognition of the distribution of nonscarring alopecia is useful for narrowing the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef88346 \" href=\"UTD.htm?15/19/15678\">",
"     table 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Focal hair loss",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Alopecia areata &ndash;",
"      </strong>",
"      Alopecia areata is a relatively common form of nonscarring alopecia in which an autoimmune process contributes to the loss of hair on the scalp or other areas. Most frequently, hair loss occurs in patches (",
"      <a class=\"graphic graphic_picture graphicRef71583 graphicRef63538 \" href=\"UTD.htm?11/28/11722\">",
"       picture 10A-B",
"      </a>",
"      ). Occasionally, alopecia areata progresses to loss of all scalp or body hair. A diffuse variant of alopecia areata that manifests with diffuse hair thinning also occurs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alopecia areata\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Alopecia syphilitica &ndash;",
"      </strong>",
"      Secondary syphilis can present with patchy hair loss on the scalp, which has been described as &ldquo;moth-eaten&rdquo; alopecia (",
"      <a class=\"graphic graphic_picture graphicRef52213 \" href=\"UTD.htm?32/57/33683\">",
"       picture 11",
"      </a>",
"      ). Hair loss may also occur in other sites. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pressure-induced (postoperative) alopecia &ndash;",
"      </strong>",
"      Pressure-induced alopecia describes transient hair loss that occurs in areas of prolonged pressure on the scalp, as may occur during general anesthesia for long operative procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Hair loss usually develops a few weeks after the event. Regrowth occurs in most patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Temporal triangular alopecia &ndash;",
"      </strong>",
"      Temporal triangular alopecia (also known as congenital triangular alopecia) is a lifelong condition that is usually first noted in infancy or childhood as a triangular or oval patch of alopecia in the temporal area (",
"      <a class=\"graphic graphic_picture graphicRef87471 \" href=\"UTD.htm?33/8/33926\">",
"       picture 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The area of involvement is usually only a few centimeters in diameter. Most cases are unilateral, though bilateral involvement may also occur. Fine vellus hairs are visible in the affected area with close inspection. Hair transplantation is an effective treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Traction alopecia &ndash;",
"      </strong>",
"      Traction alopecia results from prolonged traction on the hair follicle, usually due to hairstyles such as tight ponytails or braids. Traction alopecia from braids or hair weaves is most commonly detected along the frontal and temporal hair lines (",
"      <a class=\"graphic graphic_picture graphicRef60331 \" href=\"UTD.htm?37/36/38468\">",
"       picture 13",
"      </a>",
"      ). Longstanding traction can result in a transition to cicatricial alopecia with permanent hair loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patterned",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Androgenetic alopecia in men (male pattern hair loss) &ndash;",
"      </strong>",
"      Androgenetic alopecia in men is characterized by the slow, progressive loss of hair in a characteristic distribution (",
"      <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef83805 \" href=\"UTD.htm?38/34/39466\">",
"       picture 14A-C",
"      </a>",
"      ). The condition is mediated by the action of androgens on androgen-sensitive hair follicles in genetically susceptible males. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"       \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Female pattern hair loss &ndash;",
"      </strong>",
"      Female pattern hair loss most frequently presents as hair thinning on the frontal and vertex areas of the scalp with relative sparing of the occipital scalp (",
"      <a class=\"graphic graphic_picture graphicRef87194 graphicRef87195 \" href=\"UTD.htm?17/25/17818\">",
"       picture 15A-B",
"      </a>",
"      ). The frequency of this condition increases with age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link\">",
"       \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Trichotillomania &ndash;",
"      </strong>",
"      Trichotillomania is a disorder in which individuals repeatedly pluck hairs from the scalp or other hair-bearing areas (",
"      <a class=\"graphic graphic_picture graphicRef67336 \" href=\"UTD.htm?2/30/2535\">",
"       picture 16",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/36\">",
"       36",
"      </a>",
"      ]. The areas of alopecia may have irregular, bizarre shapes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diffuse",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Anagen effluvium &ndash;",
"      </strong>",
"      Anagen effluvium occurs as a result of an acute interruption of the anagen phase, and leads to extensive hair loss without transition of follicles into the catagen or telogen phase. Hair loss typically occurs within two weeks of an inciting event. Chemotherapeutic agents are a major cause of anagen effluvium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=see_link\">",
"       \"Chemotherapy-induced alopecia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Loose anagen syndrome &ndash;",
"      </strong>",
"      Loose anagen syndrome usually presents in young children (ages two to five years) as slowly growing hair that can easily be pulled out without pain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/37\">",
"       37",
"      </a>",
"      ]. The hair density may appear normal or reduced (",
"      <a class=\"graphic graphic_picture graphicRef87472 \" href=\"UTD.htm?4/25/4501\">",
"       picture 17",
"      </a>",
"      ). Affected children are often females with blond hair. Loose anagen syndrome is characterized by the light microscopic finding of anagen hairs with a ruffled cuticle and an absent inner root sheath (",
"      <a class=\"graphic graphic_picture graphicRef87514 \" href=\"UTD.htm?4/4/4162\">",
"       picture 18",
"      </a>",
"      ). The condition often improves with age and may be sporadic or familial.",
"     </li>",
"     <li>",
"      <strong>",
"       Telogen effluvium &ndash;",
"      </strong>",
"      Telogen effluvium is a common cause of diffuse hair loss that usually presents with acute or chronic loss of hair due to an abrupt shift of numerous hair follicles in anagen to the telogen phase (",
"      <a class=\"graphic graphic_picture graphicRef76636 \" href=\"UTD.htm?9/36/9792\">",
"       picture 19",
"      </a>",
"      ). Chronic telogen effluvium may also occur. Examples of factors that may stimulate telogen effluvium include major physical or psychological stressors, childbirth, dietary restriction, and medications. Hair loss usually occurs two to three months after the inciting event. Arsenic, thallium, or mercury poisoning can also result in telogen effluvium [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H5#H5\">",
"       \"Nonscarring hair loss\", section on 'Telogen effluvium'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H638348\">",
"       'Medical and family history'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Other &ndash;",
"      </strong>",
"      Alopecia areata and female pattern hair loss may present with diffuse hair thinning. Additional rare causes of diffuse nonscarring hair loss include",
"      <strong>",
"       atrichia with papular lesions",
"      </strong>",
"      (MIM #209500), a condition caused by a mutation in the",
"      <em>",
"       hairless",
"      </em>",
"      gene that results in hair loss within the first year of life [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/39\">",
"       39",
"      </a>",
"      ], and",
"      <strong>",
"       hypotrichosis simplex",
"      </strong>",
"      . Hypotrichosis simplex comprises a group of hereditary alopecias in which diffuse hair loss usually begins in early childhood and progresses until adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/40\">",
"       40",
"      </a>",
"      ]. Multiple gene mutations have been linked to this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonscarring alopecia may also occur as a direct consequence of scalp involvement with acute or chronic inflammatory skin diseases. As examples, psoriasis, atopic dermatitis, seborrheic dermatitis, and contact dermatitis may result in focal or diffuse hair loss. In addition, patients with systemic lupus erythematosus may develop &ldquo;",
"    <strong>",
"     lupus hair",
"    </strong>",
"    ,&rdquo; which is described by dry, coarse hair along the frontal hair line that usually occurs in association with disease flares [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients with systemic lupus erythematosus may also develop telogen effluvium as a consequence of disease exacerbations or medical treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871773\">",
"    <span class=\"h2\">",
"     Inherited and acquired structural hair disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural hair abnormalities that result in brittle or fragile hair can lead to hair breakage or the appearance of a failure of hair to grow. The hair fragility may result from abnormal hair formation or external insults that damage the hair shaft. The most common structural hair abnormalities are acquired",
"    <strong>",
"     trichorrhexis nodosa",
"    </strong>",
"    and",
"    <strong>",
"     trichoptilosis",
"    </strong>",
"    , both of which may occur as a result of harmful hair care practices, such as chemical processing, excessive brushing or teasing of hair, or the application of excessive heat. Trichorrhexis nodosa is characterized by disruption of the protective cuticle and fraying of the hair shaft (",
"    <a class=\"graphic graphic_picture graphicRef87473 \" href=\"UTD.htm?35/22/36195\">",
"     picture 20A",
"    </a>",
"    ). Trichoptilosis is a term that describes splitting and fraying of the distal end of the hair shaft, which is commonly referred to as &ldquo;split ends.&rdquo;",
"    <strong>",
"     Bubble hair",
"    </strong>",
"    (bubble-like structures within the hair shaft) is another microscopic finding that may be seen in heat-damaged hair.",
"   </p>",
"   <p>",
"    Examples of genetic conditions that cause hair fragility and excessive hair breakage include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Menkes disease &ndash;",
"      </strong>",
"      Patients with Menkes disease (MIM #309400), an X-linked disorder associated with a defect in copper transport, develop hair fragility that is most prominent during childhood. The mutation is in the gene encoding a copper transporting ATPase (ATP7A) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/42\">",
"       42",
"      </a>",
"      ]. Sparse, short, and brittle hair with a kinky or steel wool-like quality is present (",
"      <a class=\"graphic graphic_picture graphicRef87477 \" href=\"UTD.htm?42/18/43302\">",
"       picture 21",
"      </a>",
"      ). Microscopic examination of the hair shaft reveals",
"      <strong>",
"       pili torti",
"      </strong>",
"      (flattened, twisted hair) (",
"      <a class=\"graphic graphic_picture graphicRef87478 \" href=\"UTD.htm?8/25/8592\">",
"       picture 20C",
"      </a>",
"      ). Pili torti may also be seen as an isolated congenital disorder or a manifestation of other genetic conditions.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of dietary trace minerals\", section on 'Menkes disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Monilethrix &ndash;",
"      </strong>",
"      Monilethrix (MIM #158000) is a genetic condition that is usually associated with an autosomal dominant pattern of inheritance. Most cases occur due to mutations in the hair cortex keratin genes, KRT81, KRT83, or KRT86 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients present with short, brittle hair (",
"      <a class=\"graphic graphic_picture graphicRef87479 \" href=\"UTD.htm?4/35/4663\">",
"       picture 22",
"      </a>",
"      ). Microscopic examination of the hair shaft reveals",
"      <strong>",
"       elliptical nodes",
"      </strong>",
"      , resulting in a beaded appearance (",
"      <a class=\"graphic graphic_picture graphicRef87480 \" href=\"UTD.htm?40/5/41040\">",
"       picture 20D",
"      </a>",
"      ). Examples of other potential findings in monilethrix include brittle nails, keratosis pilaris, cataracts, and tooth abnormalities.",
"     </li>",
"     <li>",
"      <strong>",
"       Trichothiodystrophy &ndash;",
"      </strong>",
"      Trichothiodystrophy (MIM #601675) is an autosomal recessive disorder that manifests with sulfur-deficient, short, brittle hair (",
"      <a class=\"graphic graphic_picture graphicRef87474 \" href=\"UTD.htm?37/6/37988\">",
"       picture 23",
"      </a>",
"      ). Microscopic examination of the hair reveals",
"      <strong>",
"       trichoschisis",
"      </strong>",
"      (transverse fractures of hair) (",
"      <a class=\"graphic graphic_picture graphicRef87475 \" href=\"UTD.htm?24/22/24935\">",
"       picture 20B",
"      </a>",
"      ). Examination of the hair shaft under polarized light demonstrates alternating light and dark bands that resemble a &ldquo;tiger tail&rdquo; pattern. Patients may have accompanying features such as photosensitivity, ichthyosis, intellectual impairment, decreased fertility, and short stature. Mutations in the XPD, XPB, and",
"      <span class=\"nowrap\">",
"       p8/TTDA",
"      </span>",
"      subunits of the",
"      <span class=\"nowrap\">",
"       transcription/repair",
"      </span>",
"      factor TFIIH have been linked to trichothiodystrophy with photosensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Trichorrhexis invaginata &ndash;",
"      </strong>",
"      Trichorrhexis invaginata (also known as &ldquo;bamboo hair&rdquo; or &ldquo;ball and socket&rdquo; deformity) is a hair shaft disorder that results from intussusception within the hair shaft (",
"      <a class=\"graphic graphic_picture graphicRef87483 \" href=\"UTD.htm?30/17/30992\">",
"       picture 20E",
"      </a>",
"      ). Trichorrhexis invaginata is a pathognomonic finding of Netherton&rsquo;s syndrome (OMIM #256500), but may also occur as a sporadic disorder or in combination with other hair shaft disorders.",
"      <br/>",
"      <br/>",
"      Individuals with Netherton syndrome (OMIM #256500), an autosomal recessive disorder, develop atopy, ichthyosis (ichthyosis linearis circumflexa), and short, sparse hair (",
"      <a class=\"graphic graphic_picture graphicRef87481 graphicRef87482 \" href=\"UTD.htm?20/39/21114\">",
"       picture 24A-B",
"      </a>",
"      ). Mutations in the SPINK5 gene encoding the serine protease inhibitor lymphoepithelial Kazal-type related inhibitor (LEKTI) lead to this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/45\">",
"       45",
"      </a>",
"      ]. Clinicians should be aware that trichorrhexis invaginata is not evident in every hair. Multiple hairs may need to be examined before trichorrhexis invaginata is detected.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of other rare inherited conditions that may result in hair fragility include inherited trichorrhexis nodosa, Bj&ouml;rnstad syndrome, ectodermal dysplasias, and argininosuccinic aciduria.",
"   </p>",
"   <p>",
"    Structural hair disorders may also occur without associated hair fragility. Examples include pili annulati, uncombable hair syndrome (",
"    <a class=\"graphic graphic_picture graphicRef87484 \" href=\"UTD.htm?1/22/1384\">",
"     picture 25",
"    </a>",
"    ), and woolly hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638334\">",
"    <span class=\"h1\">",
"     PATIENT INTERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient interview, if performed carefully, can provide valuable clues for diagnosis. In general, the interview should include an assessment of the nature of hair loss, the patient&rsquo;s medical history (including medication and supplement use), the patient&rsquo;s hair care practices, and the patient&rsquo;s family history as it relates to hair loss and potential causes of hair loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638341\">",
"    <span class=\"h2\">",
"     Description of hair loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questioning about the nature of hair loss consists of an assessment of the course and pattern of hair loss, as well as associated symptoms. This can be particularly helpful for narrowing the differential diagnosis in patients with physical findings that suggest nonscarring alopecia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Duration and rate of progression of hair loss &ndash;",
"      </strong>",
"      Knowledge of the duration and progression of hair loss is useful for differentiating between congenital and acquired disorders, and between acute, chronic, or transient conditions.",
"     </li>",
"     <li>",
"      <strong>",
"       Location and pattern of hair loss &ndash;",
"      </strong>",
"      In conjunction with the physical examination, the patient&rsquo;s description of the distribution of hair loss may help to distinguish focal, patterned, and diffuse hair loss (see",
"      <a class=\"local\" href=\"#H1871434\">",
"       'Nonscarring alopecia'",
"      </a>",
"      above). Since some disorders characterized by scalp hair loss may involve other hair-bearing areas, patients should also be asked about the presence of additional sites of hair loss.",
"     </li>",
"     <li>",
"      <strong>",
"       Extent of hair loss &ndash;",
"      </strong>",
"      When evaluating patients with a complaint of diffuse hair loss, the knowledge that normal hair loss ranges from 50 to 150 hairs per day is useful for comprehending the magnitude of the patient&rsquo;s complaint [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"       2",
"      </a>",
"      ]. Of note, for patients who shampoo hair infrequently, marked increases in hair loss may be noted on shampoo days due to the manual dislodging of telogen hairs that would have been progressively shed with more frequent manipulation of the hair.",
"      <br/>",
"      <br/>",
"      Patient descriptions of physical changes noted (eg, a thinning ponytail or increased visibility of the scalp through hair) and review of prior photographs also may be useful for assessing the degree of hair loss. On average, a 30 percent decrease in hair density occurs before hair loss is easily appreciated by individuals other than the affected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/41\">",
"       41",
"      </a>",
"      ]. In particular, patients with thick, coarse hair at baseline may not appear to have clinically concerning hair loss until a major reduction in hair density has occurred.",
"     </li>",
"     <li>",
"      <strong>",
"       Associated symptoms &ndash;",
"      </strong>",
"      Although symptoms such as pain, tenderness, pruritus, or burning sensations are not always consistently detected in specific types of hair loss, the recognition of associated symptoms can be useful for supporting a diagnosis. In addition, in patients who appear to have a form of hair loss that is typically asymptomatic, the presence of symptoms may indicate the presence of an additional disorder (eg, pruritus from seborrheic dermatitis in a patient with androgenetic alopecia).",
"     </li>",
"     <li>",
"      <strong>",
"       Differentiation of hair shedding from hair breakage &ndash;",
"      </strong>",
"      Patients who are focused on their hair loss may be able to communicate information that helps to distinguish hair shed from the follicle from hair breakage. Patients with disorders associated with shedding of telogen hairs from follicles may describe the hair loss as occurring from &ldquo;the roots,&rdquo; meaning that they have noticed a small white bulb at the proximal end of lost hairs (",
"      <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"       figure 2",
"      </a>",
"      ). In contrast, the follicular portion of the hair shaft is absent in broken hairs.",
"     </li>",
"     <li>",
"      <strong>",
"       Hair care practices &ndash;",
"      </strong>",
"      Questions about hair care practices are particularly relevant in patients with features suggestive of hair breakage or traction alopecia. Hair care practices that damage the hair shaft are a common cause of hair breakage and prolonged traction of hair by tight braids, ponytails, or other means can lead to traction alopecia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638348\">",
"    <span class=\"h2\">",
"     Medical and family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions about the patient&rsquo;s medical and family history may be useful for diagnosis. As an example, for women with clinical features suggestive of patterned hair loss, questions about irregular menses, hirsutism, infertility, and signs of virilization may provide clues about an underlying hormonal disorder as a contributor to the condition (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link&amp;anchor=H109567572#H109567572\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    ). In addition, telogen effluvium, one of the most common causes of nonscarring hair loss, may be induced by factors that can be detected via a medical history (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonscarring hair loss\", section on 'Telogen effluvium'",
"    </a>",
"    ). Potential contributing factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Drugs",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_table graphicRef80170 \" href=\"UTD.htm?14/47/15099\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Poor diet (caloric or protein restriction)",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Medical disorders and medical events",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Major illness or surgeries",
"     </li>",
"     <li>",
"      Major psychological stress",
"     </li>",
"     <li>",
"      Significant weight loss",
"     </li>",
"     <li>",
"      Chronic iron deficiency",
"     </li>",
"     <li>",
"      Thyroid disorders",
"     </li>",
"     <li>",
"      Childbirth",
"     </li>",
"     <li>",
"      Poisoning from arsenic, mercury, or thallium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical history may also be useful when a diagnosis that may present with associated clinical findings is being considered. Examples of questions that may be useful include inquiries about a history of lichen planus in a patient with lichen planopilaris and questions about a history of hidradenitis suppurativa or severe acne in a patient with folliculitis decalvans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link&amp;anchor=H6#H6\">",
"     \"Lichen planus\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obtaining a family history of similar hair loss can be useful because genetics play a role in susceptibility to multiple hair diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638362\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the patient with a complaint of scalp hair loss involves the examination of the scalp, hair, and other body sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638369\">",
"    <span class=\"h2\">",
"     Scalp and hair examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the scalp and hair examination should be performed with the patient in a position that allows the clinician to examine the scalp from above comfortably, such as the clinician in a standing position and the patient seated in a chair. Good lighting is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88147727\">",
"    <span class=\"h3\">",
"     Visual inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step of the physical examination consists of inspection of the entire scalp for physical clues that may aid with diagnosis, such as erythema, scales, papules, pustules, erosions, or excoriations. The presence or absence of follicular ostia within affected areas also should be noted;",
"    <strong>",
"     a lack of follicular ostia suggests a scarring alopecia",
"    </strong>",
"    . Among the primary cicatricial alopecias, pustules are most likely to be seen in neutrophilic or mixed cicatricial alopecias.",
"   </p>",
"   <p>",
"    The examination of the hair should include an assessment of the distribution and density of hair on the scalp to identify the pattern and degree of hair loss. Hair density is best assessed by parting the hair and noting the amount of space between the parts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"     46",
"    </a>",
"    ]. Comparing the frontal hair density to the occipital hair density is particularly useful for female pattern hair loss. In female pattern hair loss, hair density on the frontal and vertex scalp is reduced, while hair on the occipital scalp is relatively spared. A Christmas-tree like pattern of hair loss is often evident in the involved area (",
"    <a class=\"graphic graphic_picture graphicRef87194 graphicRef87195 \" href=\"UTD.htm?17/25/17818\">",
"     picture 15A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=see_link&amp;anchor=H605925941#H605925941\">",
"     \"Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hair shafts are then evaluated for caliber, length, shape, fragility, and texture. Distinguishing between terminal and vellus hairs is particularly helpful for the diagnosis of male and female pattern hair loss, disorders in which terminal hairs transition to vellus hairs. Broken hairs, which suggest a structural hair disorder, may also be noted during this step. Hair fragility can be further assessed by grasping a cluster of hair fibers in two places and tugging in opposite directions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features associated with certain forms of hair loss may also be detected during examination of the hair and may aid in diagnosis. Examples include exclamation point hairs in alopecia areata (",
"    <a class=\"graphic graphic_picture graphicRef65864 \" href=\"UTD.htm?35/0/35844\">",
"     picture 26",
"    </a>",
"    ), tufted folliculitis in folliculitis decalvans and other cicatricial alopecias (",
"    <a class=\"graphic graphic_picture graphicRef87489 \" href=\"UTD.htm?39/50/40744\">",
"     picture 7B",
"    </a>",
"    ), follicular plugging in discoid lupus erythematosus (",
"    <a class=\"graphic graphic_picture graphicRef72588 \" href=\"UTD.htm?17/22/17766\">",
"     picture 3A",
"    </a>",
"    ), and keratotic follicular papules in lichen planopilaris (",
"    <a class=\"graphic graphic_picture graphicRef52848 \" href=\"UTD.htm?9/34/9767\">",
"     picture 5B",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Dermoscopy, a technique in which a handheld magnifier is used to visualize skin structures, can aid in the examination of patients with hair loss. Dermoscopy facilitates the examination for follicular ostia and can be used to examine individual hairs. Certain dermoscopic findings have been linked to particular forms of hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional tool that can be helpful during the hair examination is a small piece of white or black paper. The color should contrast with the color of the patient&rsquo;s hair (eg, white paper for a patient with dark hair). Placing the paper behind the hairs being examined facilitates visualization of the hairs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"     46",
"    </a>",
"    ]. This procedure also is helpful for differentiating the tapered tips of regrowing hairs from the blunt tips of broken or cut hairs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638534\">",
"    <span class=\"h3\">",
"     Hair pull test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hair pull test identifies active hair loss and should be performed on every patient who presents with a complaint of hair loss. To perform the test, 50 to 60 hair fibers are grasped close to the skin surface and tugged from the proximal to the distal end. The easy extraction of more than six hair fibers suggests the presence of active hair loss. The proximal ends of hairs obtained by the hair pull test can be microscopically examined to determine the type of hairs removed (eg, telogen, anagen, dystrophic, or broken hairs) (",
"    <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638390\">",
"    <span class=\"h2\">",
"     Examination of other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some hair loss disorders are associated with abnormalities in areas other than the scalp. Depending on the disorder, additional hair, nail, skin, tooth, or other abnormalities may be seen. Examining the entire skin surface, nails, and teeth at the time of the initial evaluation is useful for identifying additional sites of involvement and associated features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638397\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the cause of hair loss remains uncertain following the patient history and physical examination, additional tests may assist with diagnosis. Microscopic examination of hair shafts and scalp biopsies are commonly performed in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638543\">",
"    <span class=\"h2\">",
"     Microscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients present with diffuse hair shedding, microscopic evaluation of the proximal ends of shed hairs is useful for determining the type of hairs that are being shed (eg, telogen, anagen, or dystrophic anagen hairs). For patients with hair breakage, microscopic examination of the hair shaft may identify structural abnormalities that contribute to hair fragility (",
"    <a class=\"graphic graphic_picture graphicRef87473 graphicRef87475 graphicRef87478 graphicRef87480 graphicRef87483 \" href=\"UTD.htm?40/4/41034\">",
"     picture 20A-E",
"    </a>",
"    ). The use of 1 to 2 drops of a mounting medium (eg, Permount) when placing the hair shafts between a glass slide and a coverslip optimizes the examination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"     46",
"    </a>",
"    ]. Examinations for pili torti are an exception; the shadows and twists of pili torti are best visualized when the hair is examined dry, without a mounting medium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, microscopic examination under polarized light is necessary for visualization of the &ldquo;tiger-tail&rdquo; pattern seen in patients with trichothiodystrophy. (See",
"    <a class=\"local\" href=\"#H1871773\">",
"     'Inherited and acquired structural hair disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638551\">",
"    <span class=\"h2\">",
"     Scalp biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp biopsies can be a useful tool for the evaluation of hair loss when the diagnosis is uncertain. Scalp biopsies can distinguish scarring from nonscarring alopecia, and can provide information that further narrows the differential diagnosis. We perform scalp biopsies to confirm the diagnosis in all patients with cicatricial alopecia. Scalp biopsies are not usually performed for the diagnosis of hair shaft disorders due to the ability to diagnose these disorders with light microscopic examination of the hair shaft. However, in genetic structural hair disorders, abnormalities also may be evident when the intrafollicular portion of the hair shaft is seen on histological examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19632457\">",
"    <span class=\"h3\">",
"     Cicatricial alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected cicatricial alopecia, scalp biopsies for diagnosis should be performed in sites of active disease. Features that suggest sites of active disease include the presence of primary lesions, symptoms, or a positive pull test [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/14\">",
"     14",
"    </a>",
"    ]. The peripheral margin of an area of alopecia usually is the preferred site for a biopsy. Some hair should remain in the biopsy site; areas of end-stage, complete balding should be avoided.",
"   </p>",
"   <p>",
"    Many dermatopathologists prefer to receive two punch biopsy specimens, since this allows for evaluation of the tissue in both vertical and transverse sections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/14\">",
"     14",
"    </a>",
"    ]. We usually perform two 4 mm punch biopsies. If only one biopsy can be performed, transverse sections are preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The punch biopsies should be performed at an angle that mimics the direction of hair growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vascular nature of the scalp can lead to significant bleeding during surgical procedures. To decrease bleeding, we inject 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine for anesthesia and wait up to 10 minutes prior to performing scalp biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19632464\">",
"    <span class=\"h3\">",
"     Nonscarring alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp biopsies are less frequently performed in patients with nonscarring alopecias, since the clinical picture and patient history often provide the diagnosis. However, when the diagnosis remains uncertain, scalp biopsies can be useful for ruling in or ruling out certain diagnoses (",
"    <a class=\"graphic graphic_table graphicRef88347 graphicRef88346 \" href=\"UTD.htm?30/21/31071\">",
"     table 1A-B",
"    </a>",
"    ). Pathological assessment of the proportion of anagen, catagen, and telogen follicles; the proportion of terminal and vellus hairs; the follicular structure; and the degree of inflammation can aid in distinguishing between the different types of nonscarring alopecia and can provide important information for treatment selection and patient expectation. Scalp biopsies are particularly useful for distinguishing between the diffuse presentations of alopecia areata, telogen effluvium, and female pattern hair loss.",
"   </p>",
"   <p>",
"    A single scalp biopsy processed with transverse sections usually is sufficient for the evaluation of patients with clinical features suggestive of nonscarring alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93848306\">",
"    <span class=\"h2\">",
"     Trichograms and phototrichograms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichograms and phototrichograms are techniques for the evaluation of nonscarring hair loss that are primarily used in research studies and specialized hair centers. Trichograms and phototrichograms can be used to assist with diagnosis and following the response to treatment.",
"   </p>",
"   <p>",
"    To perform a trichogram, approximately 25 to 50 hairs are grasped close to the scalp with a needle holder. The hairs are then sharply plucked from the scalp. Following this, the proximal ends of the hairs are microscopically examined to evaluate the proportion of hairs in each stage of the hair cycle and to determine whether dystrophic hairs are present.",
"   </p>",
"   <p>",
"    A phototrichogram is a less traumatic procedure in which hairs in a defined area are clipped to a length of approximately 1 mm and photographed. This baseline photograph can be used to assess hair density and the proportion of vellus, intermediate, and terminal hairs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/51\">",
"     51",
"    </a>",
"    ]. The same site is photographed two to three days after the initial photograph to assess hair growth. Since only anagen hairs grow substantially, catagen hairs elongate only slightly, and telogen hairs remain stable, the proportion of anagen, catagen, and telogen (resting) hairs can be estimated by comparing the two photographs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phototrichogram technology has evolved to include contrast-enhanced phototrichograms. Contrast-enhanced phototrichograms involve the use of high resolution photography and hair dye that augments the contrast between hair color and skin color [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, a software-based system for performing phototrichograms (TrichoScan) has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/29/9690/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93848324\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the type of hair loss suspected, serological and microbiological studies may also be useful for obtaining information to support the diagnosis and to detect associated disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638404\">",
"    <span class=\"h1\">",
"     PATIENT SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the cosmetic value placed upon hair in many societies, hair loss can be a highly distressing condition. In addition to diagnosis and treatment of the hair loss disorder, the clinician must also address the emotional and psychological well-being of the patient. Organizations such as the National Alopecia Areata Foundation (",
"    <a class=\"external\" href=\"file://www.naaf.org/\">",
"     www.naaf.org",
"    </a>",
"    ) and the Cicatricial Alopecia Research Foundation (",
"    <a class=\"external\" href=\"file://www.carfintl.org/\">",
"     www.carfintl.org",
"    </a>",
"    ) can provide information and support for patients with hair loss. The North American Hair Research Society (",
"    <a class=\"external\" href=\"file://www.nahrs.org/\">",
"     www.nahrs.org",
"    </a>",
"    ) is an additional source for information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19632507\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throughout life, hair follicles undergo cycling characterized by periods of growth (anagen), involution (catagen), and rest (telogen). At any given time, 90 percent of hair follicles on the scalp are in anagen. The duration of the anagen phase determines maximum length of hair growth. (See",
"      <a class=\"local\" href=\"#H1871661\">",
"       'Hair cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hair loss disorders can be divided into cicatricial (scarring) alopecias, nonscarring alopecias, and structural hair disorders. Cicatricial alopecias are characterized by irreversible damage to the hair follicle that results in permanent hair loss. The primary cicatricial alopecias are subdivided into lymphocytic, neutrophilic, and mixed inflammatory disorders (",
"      <a class=\"graphic graphic_table graphicRef88347 \" href=\"UTD.htm?3/25/3486\">",
"       table 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H638327\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1871427\">",
"       'Cicatricial alopecia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonscarring alopecias are conditions in which the hair follicle is not destroyed; in many cases spontaneous or treatment-induced hair regrowth occurs. Recognition of the distribution of hair loss is useful for the diagnosis of nonscarring alopecias (",
"      <a class=\"graphic graphic_table graphicRef88346 \" href=\"UTD.htm?15/19/15678\">",
"       table 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1871434\">",
"       'Nonscarring alopecia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural hair disorders result in fragile hair and may be inherited or acquired. Damaging hair care techniques are a common cause of hair fragility. (See",
"      <a class=\"local\" href=\"#H1871773\">",
"       'Inherited and acquired structural hair disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of the patient with hair loss begins with obtaining a description of hair loss from the patient as well a medical history and family history. The physical examination incorporates inspection of the scalp, hair, and other body sites. (See",
"      <a class=\"local\" href=\"#H638334\">",
"       'Patient interview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H638362\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the diagnosis remains uncertain after the patient history and clinical examination have been performed, diagnostic techniques such as microscopic examination of hair and scalp biopsies may provide additional information that is helpful for diagnosis. Depending on the differential diagnosis, additional laboratory studies may be performed. (See",
"      <a class=\"local\" href=\"#H638397\">",
"       'Diagnostic techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Whiting DA. The structure of human hair follicle, Canfield Publishing, Fairfield, NJ 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/2\">",
"      Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/3\">",
"      Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/4\">",
"      Schweizer J, Langbein L, Rogers MA, Winter H. Hair follicle-specific keratins and their diseases. Exp Cell Res 2007; 313:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/5\">",
"      Myung P, Ito M. Dissecting the bulge in hair regeneration. J Clin Invest 2012; 122:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/6\">",
"      Mobini N, Tam S, Kamino H. Possible role of the bulge region in the pathogenesis of inflammatory scarring alopecia: lichen planopilaris as the prototype. J Cutan Pathol 2005; 32:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/7\">",
"      Ito M, Liu Y, Yang Z, et al. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med 2005; 11:1351.",
"     </a>",
"    </li>",
"    <li>",
"     Cotsarelis G, Botchkarev V. Biology of hair follicles. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, New York 2012. Vol 1, p.960.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/9\">",
"      Breitkopf T, Leung G, Yu M, et al. The basic science of hair biology: what are the causal mechanisms for the disordered hair follicle? Dermatol Clin 2013; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/10\">",
"      Miranda BH, Tobin DJ, Sharpe DT, Randall VA. Intermediate hair follicles: a new more clinically relevant model for hair growth investigations. Br J Dermatol 2010; 163:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/11\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/12\">",
"      Rebora A, Guarrera M. Kenogen. A new phase of the hair cycle? Dermatology 2002; 205:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/13\">",
"      Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol 2003; 48:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/14\">",
"      Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol 2005; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/15\">",
"      Zvulunov A, Shkalim V, Ben-Amitai D, Feinmesser M. Clinical and histopathologic spectrum of alopecia mucinosa/follicular mucinosis and its natural history in children. J Am Acad Dermatol 2012; 67:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/16\">",
"      Otberg N. Primary cicatricial alopecias. Dermatol Clin 2013; 31:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/17\">",
"      Aten E, Brasz LC, Bornholdt D, et al. Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2. Hum Mutat 2010; 31:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/18\">",
"      Castori M, Covaciu C, Paradisi M, Zambruno G. Clinical and genetic heterogeneity in keratosis follicularis spinulosa decalvans. Eur J Med Genet 2009; 52:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/19\">",
"      Bellet JS, Kaplan AL, Selim MA, Olsen EA. Keratosis follicularis spinulosa decalvans in a family. J Am Acad Dermatol 2008; 58:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/20\">",
"      Kang H, Alzolibani AA, Otberg N, Shapiro J. Lichen planopilaris. Dermatol Ther 2008; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/21\">",
"      MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol 2012; 67:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/22\">",
"      Donati A, Molina L, Doche I, et al. Facial papules in frontal fibrosing alopecia: evidence of vellus follicle involvement. Arch Dermatol 2011; 147:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/23\">",
"      RONCHESE F. Pseudopelade. Arch Dermatol 1960; 82:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/24\">",
"      Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J 2003; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/25\">",
"      Powell JJ, Dawber RP, Gatter K. Folliculitis decalvans including tufted folliculitis: clinical, histological and therapeutic findings. Br J Dermatol 1999; 140:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/26\">",
"      Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol 2001; 19:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/27\">",
"      STRITZLER C, FRIEDMAN R, LOVEMAN AB. Acne necrotica; relation to acne necrotica miliaris and response to penicillin and other antibiotics. AMA Arch Derm Syphilol 1951; 64:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/28\">",
"      Kossard S, Collins A, McCrossin I. Necrotizing lymphocytic folliculitis: the early lesion of acne necrotica (varioliformis). J Am Acad Dermatol 1987; 16:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/29\">",
"      Grattan CE, Peachey RD, Boon A. Evidence for a role of local trauma in the pathogenesis of erosive pustular dermatosis of the scalp. Clin Exp Dermatol 1988; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/30\">",
"      Wiles JC, Hansen RC. Postoperative (pressure) alopecia. J Am Acad Dermatol 1985; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/31\">",
"      Hanly AJ, Jorda M, Badiavas E, et al. Postoperative pressure-induced alopecia: report of a case and discussion of the role of apoptosis in non-scarring alopecia. J Cutan Pathol 1999; 26:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/32\">",
"      Trakimas C, Sperling LC, Skelton HG 3rd, et al. Clinical and histologic findings in temporal triangular alopecia. J Am Acad Dermatol 1994; 31:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/33\">",
"      Yamazaki M, Irisawa R, Tsuboi R. Temporal triangular alopecia and a review of 52 past cases. J Dermatol 2010; 37:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/34\">",
"      Chung J, Sim JH, Gye J, et al. Successful hair transplantation for treatment of acquired temporal triangular alopecia. Dermatol Surg 2012; 38:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/35\">",
"      Wu WY, Otberg N, Kang H, et al. Successful treatment of temporal triangular alopecia by hair restoration surgery using follicular unit transplantation. Dermatol Surg 2009; 35:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/36\">",
"      Sehgal VN, Srivastava G. Trichotillomania +/- trichobezoar: revisited. J Eur Acad Dermatol Venereol 2006; 20:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/37\">",
"      Cantatore-Francis JL, Orlow SJ. Practical guidelines for evaluation of loose anagen hair syndrome. Arch Dermatol 2009; 145:1123.",
"     </a>",
"    </li>",
"    <li>",
"     Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill, New York 2012. Vol 1, p.979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/39\">",
"      Michailidis E, Theos A, Zlotogorski A, et al. Atrichia with papular lesions resulting from novel compound heterozygous mutations in the human hairless gene. Pediatr Dermatol 2007; 24:E79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/40\">",
"      Pasternack SM, Refke M, Paknia E, et al. Mutations in SNRPE, which encodes a core protein of the spliceosome, cause autosomal-dominant hypotrichosis simplex. Am J Hum Genet 2013; 92:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/41\">",
"      Moghadam-Kia S, Franks AG Jr. Autoimmune disease and hair loss. Dermatol Clin 2013; 31:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/42\">",
"      T&uuml;mer Z, M&oslash;ller LB. Menkes disease. Eur J Hum Genet 2010; 18:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/43\">",
"      De Cruz R, Horev L, Green J, et al. A novel monilethrix mutation in coil 2A of KRT86 causing autosomal dominant monilethrix with incomplete penetrance. Br J Dermatol 2012; 166 Suppl 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/44\">",
"      Hashimoto S, Egly JM. Trichothiodystrophy view from the molecular basis of DNA repair/transcription factor TFIIH. Hum Mol Genet 2009; 18:R224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/45\">",
"      Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2006; 45:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/46\">",
"      Jackson AJ, Price VH. How to diagnose hair loss. Dermatol Clin 2013; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/47\">",
"      Rakowska A, Slowinska M, Kowalska-Oledzka E, et al. Trichoscopy of cicatricial alopecia. J Drugs Dermatol 2012; 11:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/48\">",
"      Karada K&ouml;se &Ouml;, G&uuml;le&ccedil; AT. Clinical evaluation of alopecias using a handheld dermatoscope. J Am Acad Dermatol 2012; 67:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/49\">",
"      Haliasos EC, Kerner M, Jaimes-Lopez N, et al. Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatr Dermatol 2013; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/50\">",
"      Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012; 67:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/51\">",
"      Olsen EA. Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. J Am Acad Dermatol 2003; 48:253.",
"     </a>",
"    </li>",
"    <li>",
"     Blume-Peytavi U, Hillmann K, Guarrera M. Hair growth assessment techniques. In: Hair Growth and Disorders, Blume-Peytavi U, Tosti A, Whiting DA, et al. (Eds), Springer, 2008. p.125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/29/9690/abstract/53\">",
"      Van Neste D, Tr&uuml;eb RM. Critical study of hair growth analysis with computer-assisted methods. J Eur Acad Dermatol Venereol 2006; 20:578.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15678 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9690=[""].join("\n");
var outline_f9_29_9690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19632507\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638313\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638320\">",
"      HAIR BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871668\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871675\">",
"      Hair types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871661\">",
"      Hair cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638327\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871427\">",
"      Cicatricial alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871434\">",
"      Nonscarring alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1871773\">",
"      Inherited and acquired structural hair disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638334\">",
"      PATIENT INTERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638341\">",
"      Description of hair loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638348\">",
"      Medical and family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638362\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638369\">",
"      Scalp and hair examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88147727\">",
"      - Visual inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H638534\">",
"      - Hair pull test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638390\">",
"      Examination of other sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638397\">",
"      DIAGNOSTIC TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638543\">",
"      Microscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638551\">",
"      Scalp biopsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19632457\">",
"      - Cicatricial alopecia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19632464\">",
"      - Nonscarring alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93848306\">",
"      Trichograms and phototrichograms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93848324\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H638404\">",
"      PATIENT SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19632507\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15678|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31332\" title=\"figure 1\">",
"      Hair follicle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2255\" title=\"figure 2\">",
"      Telogen and anagen hairs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15678|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23862\" title=\"picture 1\">",
"      Alopecia mucinosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38168\" title=\"picture 2\">",
"      Central centrifugal cicatricial alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/22/17766\" title=\"picture 3A\">",
"      Discoid lupus scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/14/40166\" title=\"picture 3B\">",
"      Discoid LE of the scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/60/28611\" title=\"picture 4A\">",
"      Keratosis follicularis spinulosa decalvans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/61/40917\" title=\"picture 4B\">",
"      Keratosis follicularis spinulosa decalvans face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/30/9703\" title=\"picture 5A\">",
"      Lichen planopilaris with erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/34/9767\" title=\"picture 5B\">",
"      Lichen planopilaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/38/21094\" title=\"picture 6A\">",
"      Dissecting cellulitis of the scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/7/38006\" title=\"picture 6B\">",
"      Dissecting cellulitis scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/13/6360\" title=\"picture 7A\">",
"      Folliculitis decalvans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/50/40744\" title=\"picture 7B\">",
"      Tufted folliculitis in folliculitis decalvans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/9/32921\" title=\"picture 8\">",
"      Acne keloidalis nuchae on posterior scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/60/40901\" title=\"picture 9\">",
"      Erosive pustular dermatosis of the scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/46/23271\" title=\"picture 10A\">",
"      Alopecia areata 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/23/36212\" title=\"picture 10B\">",
"      Alopecia areata severe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/57/33683\" title=\"picture 11\">",
"      Alopecia in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/8/33926\" title=\"picture 12\">",
"      Temporal triangular alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/36/38468\" title=\"picture 13\">",
"      Traction alopecia hairline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/50/6950\" title=\"picture 14A\">",
"      Androgenetic alopecia bitemporal recession",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/52/31559\" title=\"picture 14B\">",
"      Androgenetic alopecia vertex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40692\" title=\"picture 14C\">",
"      Androgenetic alopecia extensive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/22/15719\" title=\"picture 15A\">",
"      Female pattern hair loss 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/10/3238\" title=\"picture 15B\">",
"      Female pattern hair loss 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/30/2535\" title=\"picture 16\">",
"      Trichotillomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/25/4501\" title=\"picture 17\">",
"      Loose anagen syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/4/4162\" title=\"picture 18\">",
"      Normal anagen hair and loose anagen syndrome hair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/36/9792\" title=\"picture 19\">",
"      Telogen effluvium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/22/36195\" title=\"picture 20A\">",
"      Trichorrhexis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/22/24935\" title=\"picture 20B\">",
"      Trichoschisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/25/8592\" title=\"picture 20C\">",
"      Pili torti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/5/41040\" title=\"picture 20D\">",
"      Monilethrix hair shaft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/17/30992\" title=\"picture 20E\">",
"      Trichorrhexis invaginata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/18/43302\" title=\"picture 21\">",
"      Menkes disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/35/4663\" title=\"picture 22\">",
"      Monilethrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/6/37988\" title=\"picture 23\">",
"      Trichothiodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26056\" title=\"picture 24A\">",
"      Netherton syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/43/7860\" title=\"picture 24B\">",
"      Ichthyosis linearis circumflexa in Netherton syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/22/1384\" title=\"picture 25\">",
"      Uncombable hair syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/0/35844\" title=\"picture 26\">",
"      Exclamation point hairs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/25/3486\" title=\"table 1A\">",
"      Cicatricial alopecias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/19/15678\" title=\"table 1B\">",
"      Nonscarring alopecias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/47/15099\" title=\"table 2\">",
"      Examples of medications associated with hair loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=related_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31752?source=related_link\">",
"      Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_29_9691="Normal serum potassium levels in children";
var content_f9_29_9691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal serum potassium levels in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range (mEq/L or mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Premature infant",
"       </td>",
"       <td class=\"centered\">",
"        4.0 to 6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Newborn",
"       </td>",
"       <td class=\"centered\">",
"        3.7 to 5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Infant",
"       </td>",
"       <td class=\"centered\">",
"        4.1 to 5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Child &gt;1 year old",
"       </td>",
"       <td class=\"centered\">",
"        3.5 to 5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Local laboratory reference ranges for normal may vary depending on laboratory and assay technique. Clinical implications of variation from normal or reference range levels must be considered individually.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9691=[""].join("\n");
var outline_f9_29_9691=null;
var title_f9_29_9692="Brief fatigue inventory";
var content_f9_29_9692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of a Brief Fatigue Inventory (BFI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. Throughout our lives, most of us have times when we feel very tired or fatigued. Have you felt unusually tired or fatigued in the last week?",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes/No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        2. Please answer the following questions by rating your fatigue (weariness, tiredness) on a scale from 0 to 10, with 0 representing \"no fatigue\" and 10 representing \"the worst fatigue you can imagine\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A) Which number best represents your fatigue right",
"        <strong>",
"         now?",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B) Which number best describes your",
"        <strong>",
"         usual",
"        </strong>",
"        level of fatigue within the past 24 hours?",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C) Which number best describes your",
"        <strong>",
"         worst",
"        </strong>",
"        level of fatigue within the past 24 hours?",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        3. Please use a scale from 0 to 10 to answer the following questions that describe how, during the past 24 hours, your fatigue has interfered with aspects of your life. 0 represents \"no interference\" and 10 represents \"complete interference\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A) General activity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B) Mood",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C) Walking ability",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D) Normal work (including both work outside the home and daily chores)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E) Relations with other people",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        F) Enjoyment of life",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9692=[""].join("\n");
var outline_f9_29_9692=null;
var title_f9_29_9693="Gene polymorphism effects";
var content_f9_29_9693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gene polymorphism effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene/polymorphism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect/association",
"       </td>",
"       <td class=\"subtitle1\">",
"        Theoretical mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ref.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LTA + 80",
"       </td>",
"       <td>",
"        Parasitemia reduction",
"       </td>",
"       <td>",
"        Lymphotoxin production",
"       </td>",
"       <td>",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GNAS",
"       </td>",
"       <td>",
"        Severe malaria",
"       </td>",
"       <td>",
"        Red cell signaling; invasion inhibition",
"       </td>",
"       <td>",
"        [2]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INOS",
"       </td>",
"       <td>",
"        Severe malaria",
"       </td>",
"       <td>",
"        Decreased iNOS",
"       </td>",
"       <td>",
"        [3]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyruvate kinase",
"       </td>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        [4]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO glycosyltransferase",
"       </td>",
"       <td>",
"        Severe malaria anemia",
"       </td>",
"       <td>",
"        Decreased resetting of red blood cells",
"       </td>",
"       <td>",
"        [5]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toll-like Receptors (TLR-1, -6, and -9)",
"       </td>",
"       <td>",
"        Malaria and high parasitemia",
"       </td>",
"       <td>",
"        Innate immunity",
"       </td>",
"       <td>",
"        [6]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FLT1",
"       </td>",
"       <td>",
"        Placental malaria",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        [7]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TIM1",
"       </td>",
"       <td>",
"        Cerebral malaria",
"       </td>",
"       <td>",
"        Induction of Th2 anti-inflammatory responses",
"       </td>",
"       <td>",
"        [8]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-10",
"       </td>",
"       <td>",
"        Severe malaria anemia",
"       </td>",
"       <td>",
"        Anti-inflammatory activity of enhanced IL-10 production",
"       </td>",
"       <td>",
"        [9]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CR-1 (promoter)",
"       </td>",
"       <td>",
"        Cerebral malaria",
"       </td>",
"       <td>",
"        Increased clearance of infected cells",
"       </td>",
"       <td>",
"        [10,11]",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. &nbsp;Barbier, M, et al. Family-based association of a low producing lymphotoxin-alpha allele with reduced Plasmodium falciparum parasitemia. Microbes Infect 2008; 10:673.",
"     <br>",
"      2. &nbsp;Auburn, S, et al. Association of the GNAS locus with severe malaria. Human Genetics 2008; 124:499.",
"      <br>",
"       3. &nbsp;Dhangadamajhi, G, et al. The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection. Parasitology Research.",
"       <br>",
"        4. &nbsp;Durand, PM, Coetzer, TM. Pyruvate kinase deficiency protects against malaria in humans. Haematologica 2008; 93:939.",
"        <br>",
"         5. &nbsp;Fry, AE, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 2008; 17:567.",
"         <br>",
"          6. &nbsp;Leoratti, FM, et al. Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria. J Infect Dis 2008; 198:772.",
"          <br>",
"           7. &nbsp;Muehlenbachs, A, et al. Natural selection of FLT1 alleles and their association with malaria resistance in utero. Proc Natl Acad Sci U S A 2008; 105:14488.",
"           <br>",
"            8. &nbsp;Nuchnoi, P, et al. Significant Association Between TIM1 Promoter Polymorphisms and Protection Against Cerebral malaria in Thailand. Annals of Human Genetics 2008; 72:327.",
"            <br>",
"             9. &nbsp;Ouma, C, et al. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet 2008; 124:515.",
"             <br>",
"              10. Cockburn, IA, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A 2004; 101:272.",
"              <br>",
"               11. Teeranaipong, P, et al. A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. J Infect Dis 2008; 198:1880.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9693=[""].join("\n");
var outline_f9_29_9693=null;
var title_f9_29_9694="Older adult activity counseling";
var content_f9_29_9694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical activity counseling for older adults: An evidence-based quick guide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Recommendations:",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Aerobic:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <ul>",
"         <li>",
"          &ge;30 min or three bouts of &ge;10 min/day",
"         </li>",
"         <li>",
"          &ge;5 days/week",
"         </li>",
"         <li>",
"          Moderate intensity = 5 to 6 on a 10-point scale (where 0 = sitting, 5 to 6 = \"can talk,\" and 10 = all-out effort)",
"         </li>",
"         <li>",
"          In addition to routine ADL's",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Strength:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <ul>",
"         <li>",
"          8 to 10 exercises (major muscle groups), 10 to 15 repetitions",
"         </li>",
"         <li>",
"          &ge;2 nonconsecutive days/week",
"         </li>",
"         <li>",
"          Moderate to high intensity = 5 to 8 on a 10-point scale (where 5 to 6 = \"can talk\" and 7 to 8 = SOB)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Flexibility/balance:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <ul>",
"         <li>",
"          &ge;10 min &ge;2 days/week",
"         </li>",
"         <li>",
"          Flexibility to maintain/improve range of motion (ie, stretching of major muscle/tendon groups, yoga)",
"         </li>",
"         <li>",
"          Balance exercises for those at risk for falls (ie, tai chi, individualized balanced exercises)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"3\">",
"        Prevention:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <ul>",
"         <li>",
"          Create a single physical activity plan that integrates preventive and therapeutic treatment of chronic conditions",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Sample endurance (walking) and strength plan",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Weeks",
"       </td>",
"       <td class=\"subtitle2\">",
"        Walking",
"       </td>",
"       <td class=\"subtitle2\">",
"        Strength",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         <strong>",
"          Weeks 1 to 2:",
"         </strong>",
"        </p>",
"        Introduction and acclimatization",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Walk 10 min",
"         </li>",
"         <li>",
"          Three days/week",
"         </li>",
"         <li>",
"          Intensity level = 5 to 6 on a 10-point scale",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          4 to 5 exercises for major muscle groups using weight bearing calisthenics, elastic bands, free weights or weight machines",
"         </li>",
"         <li>",
"          One set of 10 to 15 repetitions on 2 nonconsecutive days/week",
"         </li>",
"         <li>",
"          Intensity level = 5 to 8 on a 10-point scale",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         <strong>",
"          Weeks 2 to 6:",
"         </strong>",
"        </p>",
"        Begin progression",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          First increase to five days/week",
"         </li>",
"         <li>",
"          Gradually increase time to either 20 min or two bouts of 10 min/day",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Gradually add 4 to 5 exercises, totaling 8 to 10 major muscle group exercises",
"         </li>",
"         <li>",
"          One set of 10 to 15 repetitions on two nonconsecutive days/week",
"         </li>",
"         <li>",
"          Intensity level = 5 to 8 on a 10-point scale",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        <p>",
"         <strong>",
"          Weeks 6+:",
"         </strong>",
"        </p>",
"        Continued progression and exercise routine refining",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Progress time to meet guideline of at least 30 min, in at least 10 min bouts",
"         </li>",
"         <li>",
"          Five or more days/week",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Add a third nonconsecutive day/week",
"         </li>",
"         <li>",
"          Increase resistance by 2 to 10 percent depending on patient's progress and comfort level",
"         </li>",
"         <li>",
"          Emphasize pain free exercising",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        <p>",
"         Recognize your role for PA advocacy",
"        </p>",
"        <em>",
"         Tips for physical activity counseling:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        If patient is:",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Planned approach:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not ready to change",
"       </td>",
"       <td colspan=\"2\">",
"        Educate on benefits of exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ready to change",
"       </td>",
"       <td colspan=\"2\">",
"        Develop a specific physical activity plan",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Active",
"       </td>",
"       <td colspan=\"2\">",
"        Support continued activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <ul>",
"         <li>",
"          Assess current physical activity (type, frequency, duration, intensity)",
"         </li>",
"         <li>",
"          Advise benefits relative to medical history",
"         </li>",
"         <li>",
"          Tailor realistic plan (consider chronic illness, current physical activity level, functional limits, and preferred activities)",
"         </li>",
"         <li>",
"          Specify",
"          <strong>",
"           what",
"          </strong>",
"          to do",
"          <strong>",
"           where",
"          </strong>",
"          and",
"          <strong>",
"           when",
"          </strong>",
"         </li>",
"         <li>",
"          Look for barriers and strategize solutions",
"         </li>",
"         <li>",
"          Encourage social support:",
"          <strong>",
"           who",
"          </strong>",
"          and",
"          <strong>",
"           how",
"          </strong>",
"         </li>",
"         <li>",
"          Confirm patient is",
"          <strong>",
"           \"very sure\"",
"          </strong>",
"          of physical activity success",
"         </li>",
"         <li>",
"          Chart plan and give written physical activity Rx to patient",
"         </li>",
"         <li>",
"          In follow-up, revise physical activity plan to enhance progress",
"         </li>",
"         <li>",
"          Reinforce positive behavior and activity documentation",
"         </li>",
"         <li>",
"          Reaffirm that more physical activity enhances benefits",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For more resources and handouts see:",
"    <br>",
"     <ul>",
"      <li>",
"       American College of Sports Medicine. Exercise is Medicine website. Available at:",
"       <a href=\"file://www.exerciseismedicine.org/resources.htm\" target=\"_blank\">",
"        www.exerciseismedicine.org/resources.htm",
"       </a>",
"       . (Accessed December 17, 2011).",
"      </li>",
"      <li>",
"       Veterans Health Administration Research and Development. Project LIFE Modules: Changing the PACE for Seniors. US Department of Veterans Affairs. Available at:",
"       <a href=\"file://www.research.va.gov/resources/pubs/LIFE-modules.cfm\" target=\"_blank\">",
"        www.research.va.gov/resources/pubs/LIFE-modules.cfm",
"       </a>",
"       . (Accessed December 17, 2011).",
"      </li>",
"      <li>",
"       National Center for Health Promotion and Disease Prevention (NCP). MOVE! Handouts. US Department of Veterans Affairs. Available at:",
"       <a href=\"file://www.move.va.gov/handouts.asp\" target=\"_blank\">",
"        www.move.va.gov/handouts.asp",
"       </a>",
"       . (Accessed December 17, 2011).",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"      ADL: activites of daily living; SOB: short of breath.",
"     </div>",
"     <div class=\"reference\">",
"      References:",
"      <ol>",
"       <li>",
"        Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116:1081.",
"       </li>",
"       <li>",
"        Morey MC. Celebrating 20 years of excellence in exercise for the older veteran. Federal Practitioner 2007; 24:38.",
"       </li>",
"      </ol>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9694=[""].join("\n");
var outline_f9_29_9694=null;
var title_f9_29_9695="Intra-graft stenosis";
var content_f9_29_9695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intra-graft stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intra-graft stenosis is shown on the left within a loop graft. Several lesions are present. On the right is the post therapy appearance after angioplasty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerald Beathard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_29_9695=[""].join("\n");
var outline_f9_29_9695=null;
